<?xml version="1.0" encoding="UTF-8"?>
<definitions publication-date="2025-01-01" publication-type="official">
<definition-item date-revised="2024-08-01"><classification-symbol scheme="cpc">A61K</classification-symbol><definition-title>PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES  (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms <class-ref scheme="cpc">A61J3/00</class-ref>; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles <class-ref scheme="cpc">A61L</class-ref>; soap compositions <class-ref scheme="cpc">C11D</class-ref>)</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Compositions which are:</paragraph-text><paragraph-text type="body">Used as preparations for dentistry, e.g. for artificial teeth, for filling or for capping teeth, or for taking dental impressions.</paragraph-text><paragraph-text type="body">Used for cosmetic purposes for treating the skin, hair, nails, teeth or oral cavity with a view to cleaning them, changing their appearance, correcting body odours, protecting them or keeping them in good condition.</paragraph-text><paragraph-text type="body">Used for medicinal purposes, e.g. drugs, biological compositions, when they are capable of:</paragraph-text><list><list-item><paragraph-text type="body">preventing, alleviating, treating or curing abnormal or pathological conditions of the living body by such means as destroying a parasitic organism or limiting the effect of the disease or abnormality by chemically altering the physiology of the host or parasite;</paragraph-text></list-item><list-item><paragraph-text type="body">maintaining, increasing, decreasing, limiting or destroying a physiological body function, e.g. vitamin compositions, sex sterilants, fertility inhibitors, growth promotors or the like;</paragraph-text></list-item><list-item><paragraph-text type="body">diagnosing a physiological condition or state by an in vivo test, e.g. X-ray contrast or skin patch test compositions.</paragraph-text></list-item></list><paragraph-text type="body">Processes:</paragraph-text><list><list-item><paragraph-text type="body">of preparing these compositions;</paragraph-text></list-item><list-item><paragraph-text type="body">of using these compositions or single compounds for medical, dental or toiletry purposes.</paragraph-text></list-item></list></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Subclass <class-ref scheme="cpc">A01N</class-ref> covers the preservation of bodies of humans or animals or plants or parts thereof; biocides, e.g. as disinfectants, as pesticides or as herbicides. The distinction between classification in subclass <class-ref scheme="cpc">A61K</class-ref> and subclass <class-ref scheme="cpc">A01N</class-ref> is probably best envisaged in terms of the purpose. Subject-matter classified in subclass <class-ref scheme="cpc">A61K</class-ref> imparts a direct benefit to the organism to which it is administered, e.g. curative. Subject-matter classified in subclass <class-ref scheme="cpc">A01N</class-ref> on the other hand has no benefit to the target organism even though there may well be a secondary benefit to another organism, e.g. pesticides in crop protection.</paragraph-text><paragraph-text type="body">Compounds per se are classified in classes <class-ref scheme="cpc">C01</class-ref>, <class-ref scheme="cpc">C07</class-ref> or <class-ref scheme="cpc">C08</class-ref>.</paragraph-text><paragraph-text type="body">Subclass <class-ref scheme="cpc">C08K</class-ref> covers the use of substances as compounding ingredients.</paragraph-text><paragraph-text type="body">Compositions per se containing polymers are classified in subclass <class-ref scheme="cpc">C08L</class-ref>.</paragraph-text><paragraph-text type="body">Microorganisms per se are classified in subclass <class-ref scheme="cpc">C12N</class-ref>.</paragraph-text><paragraph-text type="subheading">Multiple classification</paragraph-text><paragraph-text type="body">The therapeutic activity of medicinal preparations is further classified in subclass <class-ref scheme="cpc">A61P</class-ref>.</paragraph-text><paragraph-text type="body">The use of cosmetics or similar toiletry preparations is further classified in subclass <class-ref scheme="cpc">A61Q</class-ref>.</paragraph-text></section-body></relationship><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61J3/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Disinfection, sterilisation or deodorisation of air; Chemical aspects or use of materials for bandages, dressings, absorbent pads or surgical articles </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Detergent compositions</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C11D</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Sex sterilants for invertebrates per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A01N</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Biocides, pest repellents or attractants per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A01N25/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Wigs</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A41G3/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Hair pieces, inserts, rolls, pads or the like </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A41G5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Processes of waving, straightening or curling hair </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A45D7/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Artificial nails per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A45D31/00</class-ref> </paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Containers or accessories specially adapted for handling toiletry or cosmetic substances </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A45D34/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Diagnosis; Surgery; Identification</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61B</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dentistry</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Electrotherapy; Magnetotherapy; Radiation therapy; Ultrasound therapy </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Mixing, e.g. dissolving, emulsifying or dispersing</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">B01F</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Essential oils; Perfumes</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C11B9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Measuring or testing processes involving enzymes or microorganisms; Compositions or test papers therefore; Processes of preparing such compositions; Condition-responsive control in microbiological or enzymological processes </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12Q</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Investigating or analysing materials by determining their chemical or physical properties </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G01N</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Looping references between <class-ref scheme="cpc">A61L</class-ref> and <class-ref scheme="cpc">A61K</class-ref> have been identified. CPC will be updated/corrected once this inconsistency is resolved in IPC. The current classification practice in CPC is as follows: Both <class-ref scheme="cpc">A61L</class-ref> and <class-ref scheme="cpc">A61K</class-ref> will be considered as informative reference (classification in both subclasses is done when needed).</paragraph-text><paragraph-text type="body">Attention is drawn to the definitions of the groups of chemical elements following the title of section <class-ref scheme="cpc">C</class-ref>.</paragraph-text><paragraph-text type="body">In this subclass, with the exception of group <class-ref scheme="cpc">A61K8/00</class-ref>, in the absence of an indication to the contrary, classification is made in the last appropriate place.</paragraph-text><paragraph-text type="body">Attention is drawn to the Notes in class <class-ref scheme="cpc">C07</class-ref>, for example, the Notes following the title of the subclass <class-ref scheme="cpc">C07D</class-ref>, setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds of subclass <class-ref scheme="cpc">A61K</class-ref>.</paragraph-text><paragraph-text type="body">A composition, i.e. a mixture of two or more ingredients, is classified in the last of groups <class-ref scheme="cpc">A61K31/00</class-ref> - <class-ref scheme="cpc">A61K47/00</class-ref> that provides for at least one of these ingredients.</paragraph-text><paragraph-text type="body">Any part of a composition which is not identified by classification according to the last appropriate place of an active ingredient, which itself is determined to be novel and non-obvious, must also be classified. The part can be either a single ingredient or a composition in itself.</paragraph-text><paragraph-text type="body">Any part of a composition which is not identified by the classification according to the last appropriate place, which is considered to represent information of interest for search, may also be classified. This can for example be the case when it is considered of interest to enable searching of compositions using a combination of classification symbols. Such non-obligatory classification should be given as &quot;additional information&quot;.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/00</classification-symbol><definition-title>Preparations for dentistry</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Chemical compositions:</paragraph-text><list><list-item><paragraph-text type="body">for temporarily or permanently fixing teeth</paragraph-text></list-item><list-item><paragraph-text type="body">for artificial teeth</paragraph-text></list-item><list-item><paragraph-text type="body">for filling or capping teeth</paragraph-text></list-item><list-item><paragraph-text type="body">for dental root treatment</paragraph-text></list-item><list-item><paragraph-text type="body">for taking dental impressions</paragraph-text></list-item></list></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Apparatus, devices and methods per se for the application of the dental compositions are classified in the subclasses corresponding to their general function, e.g. impression cups or impression trays (<class-ref scheme="cpc">A61C9/00</class-ref> or <class-ref scheme="cpc">A61C9/0006</class-ref>); impression methods (<class-ref scheme="cpc">A61C9/00</class-ref>); computer assisted-sizing (<class-ref scheme="cpc">A61C13/0004</class-ref>).</paragraph-text><paragraph-text type="body">Chemical compounds/compositions per se without claimed use as dental composition are to be primarily classified in the subclasses corresponding to their chemical features (e.g. <class-ref scheme="cpc">C07C</class-ref>, <class-ref scheme="cpc">C07D</class-ref>, <class-ref scheme="cpc">C08L</class-ref>, <class-ref scheme="cpc">C04B</class-ref>, etc.), with a secondary classification in <class-ref scheme="cpc">A61K6/00</class-ref> if the use in a dental treatment is further claimed.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/90</class-ref> covers dental compositions for taking dental impressions. However analysis and determination, detecting (2D or 3D) by using computer imaging methods are classified <class-ref scheme="cpc">G06T19/00</class-ref>.</paragraph-text><paragraph-text type="body">Images-producing devices are classified in <class-ref scheme="cpc">A61B90/00</class-ref> .</paragraph-text><paragraph-text type="body">Surgical adhesives or cements are classified in <class-ref scheme="cpc">A61L24/00</class-ref> and ionomer cements, e.g. glass-ionomer cements are classified <class-ref scheme="cpc">A61L24/12</class-ref>.</paragraph-text></section-body></relationship><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Preparations for care of the teeth, of the oral cavity or of dentures </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/00</class-ref>, <class-ref scheme="cpc">A61Q11/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dentistry</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dental machines for boring or cutting</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C1/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dental tools or instruments</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C3/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Filling or capping teeth</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Orthodontics, e.g. brackets, arch wires, etc.</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C7/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dental implants, e.g. means to be fixed to the jawbone</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C8/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Means to be fixed to the jawbone for consolidating natural teeth or for fixing dental prostheses thereon characterised by the material or composition, e.g. ceramics, surface layer, or metal alloy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C8/0012</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Impression cups, impression methods</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dental prostheses</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C13/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Computer-assisted sizing</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C13/0004</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Tools for fastening artificial teeth</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C13/12</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Fastening dental prostheses in the mouth using adhesive foils or adhesive compositions</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C13/225</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Fastening of peg-teeth in the mouth</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C13/30</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Cements </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C04B</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Acyclic or carbocyclic compounds</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07C</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Heterocyclic compounds</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07D</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Inorganic or non-macromolecular organic substances as compounding ingredients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08K</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Resins compositions </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Alloys </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C22C</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">In the following groups the focus is on the intended use; the subgroups within a class are used to index further characteristics of the composition:</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/30</class-ref>: for temporarily or permanently fixing teeth</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/40</class-ref>: as primers</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/50</class-ref>: for dental root treatment</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/80</class-ref>: for artificial teeth, for filling or capping teeth</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/90</class-ref>: for taking dental impressions</paragraph-text><paragraph-text type="body">The following groups are used as an indexing scheme to classify further features of the chemical composition:</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/15</class-ref>: characterised by physical properties</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/60</class-ref> and <class-ref scheme="cpc">A61K6/70</class-ref>: characterised by the additives</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/802</class-ref>: use of ceramics</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/84</class-ref>: use of metals or alloys</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/849</class-ref>: use of inorganic cements</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/884</class-ref>: use of natural or synthetic resins</paragraph-text><paragraph-text type="body">In groups <class-ref scheme="cpc">A61K6/30</class-ref>-<class-ref scheme="cpc">A61K6/58</class-ref> and <class-ref scheme="cpc">A61K6/887</class-ref>-<class-ref scheme="cpc">A61K6/90</class-ref> the use of specific polymers is indicated by addition of classification symbols of the subclass <class-ref scheme="cpc">C08L</class-ref>, creating the correspondent Combination-set, e.g. compositions for taking dental impressions containing alginates are classified in (<class-ref scheme="cpc">A61K6/90</class-ref>, <class-ref scheme="cpc">C08L5/04</class-ref>).</paragraph-text><paragraph-text type="subheading">Further details of subgroups</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/887</class-ref>:</paragraph-text><paragraph-text type="body">Polymers obtained by reactions only involving carbon to carbon unsaturated bonds are classified in <class-ref scheme="cpc">A61K6/887</class-ref> in combination with the <class-ref scheme="cpc">C08L</class-ref> subclass identifying the specific monomer; if only the general polymerisation mechanism is characterising, and not a specific monomer, documents are to be classified in <class-ref scheme="cpc">A61K6/887</class-ref> without combination subclass.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/889</class-ref>:</paragraph-text><paragraph-text type="body">In the special case of glass ionomer cements, documents are to be classified in the groups <class-ref scheme="cpc">A61K6/889</class-ref> (Polycarboxylate cements).</paragraph-text><paragraph-text type="body">A glass ionomer cement is a dental cement mixture (CaF<sub>2</sub>-Al<sub>2</sub>O<sub>3</sub>-SiO<sub>2</sub> + polycarboxylate) of low strength and toughness produced by mixing a powder prepared from a calcium aluminosilicate glass and a liquid prepared from an aqueous solution of polycarboxylates.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K6/891</class-ref>:</paragraph-text><paragraph-text type="body">Polymers obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds are classified in <class-ref scheme="cpc">A61K6/891</class-ref> in combination with the <class-ref scheme="cpc">C08L</class-ref> subclass identifying the specific polymer; if a variety of polymers is mentioned, no particular type of polymer being characterising, documents are to be classified in <class-ref scheme="cpc">A61K6/891</class-ref> without combination subclass.</paragraph-text><paragraph-text type="body">In the special cases of polyurethanes (<class-ref scheme="cpc">A61K6/893</class-ref>), polyorganosilicon compounds (<class-ref scheme="cpc">A61K6/896</class-ref>), polysaccharides (<class-ref scheme="cpc">A61K6/898</class-ref>) documents are to be classified also in said groups.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/15</classification-symbol><definition-title>Compositions characterised by their physical properties</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Compositions characterised by physical properties and physical parameters in general. For example, a composition of a semi-crystalline resin and nanocluster with the physical property of being self-supporting. Furthermore the self-supporting structure has sufficient malleability to be reformed into a second shape, preferably at a temperature of about 15&#176;C to 38&#176;C, more preferably at a temperature of about 20&#176;C to 38&#176;C etc. </paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Image-producing devices</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61B90/36</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Acyclic or carbocyclic compounds</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07C</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Heterocyclic compounds</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07D</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Manipulating 3D models or images for computer graphics</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G06T19/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Documents are classified in&#160;<class-ref scheme="cpc">A61K6/15</class-ref>&#160;only if the characterising physical property is other than:</paragraph-text><list><list-item><paragraph-text type="body">refractive index (<class-ref scheme="cpc">A61K6/16</class-ref>)</paragraph-text></list-item><list-item><paragraph-text type="body">particle size (<class-ref scheme="cpc">A61K6/17</class-ref>)</paragraph-text></list-item><list-item><paragraph-text type="body">retraction (<class-ref scheme="cpc">A61K6/18</class-ref>: compositions causing retraction are able to widen the sulcus, for making dental impressions or removing teeth)</paragraph-text></list-item><list-item><paragraph-text type="body">self-expansion (<class-ref scheme="cpc">A61K6/19</class-ref>: compositions having self-expanding properties are able to overcome the effect of polymeric shrinkage)</paragraph-text></list-item></list></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/20</classification-symbol><definition-title>Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Protective coatings for natural or artificial teeth such as anti-abrasive coatings or remineralization coatings with particles, dye coatings for natural appearance, and temporary acid-resistant coatings during treatment as well as varnishes.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/25</classification-symbol><definition-title>Compositions for detecting or measuring, e.g. of irregularities on natural or artificial teeth</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Material used for assessing if the surface of a tooth is regular or not, for instance by determining the surface contact points.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/30</classification-symbol><definition-title>Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Chemical compositions for temporarily or permanently fixing teeth, palates or the like. For example, dental adhesives and primers for dental adhesives.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Surgical adhesive or cements are classified in <class-ref scheme="cpc">A61L24/00</class-ref>.</paragraph-text></section-body></relationship><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Preparations for care of the teeth, of the oral cavity or of dentures </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61Q11/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">If the type of polymer is characterized as an adhesive, the polymer should be classified in combination with the appropriate&#160;<class-ref scheme="cpc">C08L</class-ref>&#160;subclass for specifying the kind of polymer. For example, using hydroxy cellulose as adhesive: Combination-set (<class-ref scheme="cpc">A61K6/35</class-ref>,&#160;<class-ref scheme="cpc">C08L1/02</class-ref>). The specific use of stabilising dentures in the mouth are to be classified in&#160;<class-ref scheme="cpc">A61K6/35</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/40</classification-symbol><definition-title>Primers  (for dental adhesives <class-ref scheme="cpc">A61K6/30</class-ref>)</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Primer compositions used before applying a further material or layer thereon.</paragraph-text><paragraph-text type="body">A primer is a chemical composition for modifying and pre-treatment of (dental) surfaces, resulting in a preparatory surface modification on materials before further treatment, ensuring better adhesion, but not to be confused with dental adhesives, which are classified in&#160;<class-ref scheme="cpc">A61K6/30</class-ref>.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Chemical means for temporarily or permanently fixing teeth, palates or the like, including adhesive primers</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K6/30</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Primers are to be classified in combination with the appropriate&#160;<class-ref scheme="cpc">C08L</class-ref>&#160;subclass for specifying the kind of polymer, e.g. a primer composition based on homopolymers or copolymers of methyl methacrylate: Combination-set (<class-ref scheme="cpc">A61K6/40</class-ref>,&#160;<class-ref scheme="cpc">C08L33/12</class-ref>); if the kind of polymer is not characterizing, they are to be classified in the group&#160;<class-ref scheme="cpc">A61K6/40</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/50</classification-symbol><definition-title>Preparations specially adapted for dental root treatment</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Chemical compositions for the treatment of the root canal:</paragraph-text><list><list-item><paragraph-text type="body">for cleaning or disinfecting</paragraph-text></list-item><list-item><paragraph-text type="body">for filling or sealing</paragraph-text></list-item><list-item><paragraph-text type="body">for apical treatment</paragraph-text></list-item><list-item><paragraph-text type="body">and in combination with dental implants</paragraph-text></list-item></list></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Documents are to be classified in the group&#160;<class-ref scheme="cpc">A61K6/50</class-ref>&#160;only if the type of dental root treatment is other than:</paragraph-text><paragraph-text type="body">Cleaning, Disinfecting (<class-ref scheme="cpc">A61K6/52</class-ref>),</paragraph-text><paragraph-text type="body">Filling, Sealing (<class-ref scheme="cpc">A61K6/54</class-ref>),</paragraph-text><paragraph-text type="body">Apical treatment (<class-ref scheme="cpc">A61K6/56</class-ref>),</paragraph-text><paragraph-text type="body">Dental root treatment in combination with dental implants (<class-ref scheme="cpc">A61K6/58</class-ref>).</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/60</classification-symbol><definition-title>comprising organic or organo-metallic additives</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Chemical compositions for dental treatment characterised by the presence of organic or organo-metallic additives.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">According to their function, the additives are to be classified in the subgroups as:</paragraph-text><paragraph-text type="body">initiators:</paragraph-text><list><list-item><paragraph-text type="body">if cationic, anionic or redox:&#160;<class-ref scheme="cpc">A61K6/61</class-ref></paragraph-text></list-item><list-item><paragraph-text type="body">if photochemical:&#160;<class-ref scheme="cpc">A61K6/62</class-ref></paragraph-text></list-item><list-item><paragraph-text type="body">if thermal:&#160;<class-ref scheme="cpc">A61K6/64</class-ref></paragraph-text></list-item><list-item><paragraph-text type="body">if photochromic:&#160;<class-ref scheme="cpc">A61K6/66</class-ref></paragraph-text></list-item><list-item><paragraph-text type="body">if thermochromic&#160;<class-ref scheme="cpc">A61K6/68</class-ref></paragraph-text></list-item></list><paragraph-text type="body">dyes (<class-ref scheme="cpc">A61K6/65</class-ref>):</paragraph-text><paragraph-text type="body">medicaments or drugs (<class-ref scheme="cpc">A61K6/69</class-ref>)</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/70</classification-symbol><definition-title>comprising inorganic additives</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Chemical compositions for dental treatment characterised by the presence of inorganic additives.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">According to their function, the additives are to be classified in the subgroups as:</paragraph-text><list><list-item><paragraph-text type="body">fillers (<class-ref scheme="cpc">A61K6/71</class-ref>), further subdivided according to their chemical features in the subgroups&#160;<class-ref scheme="cpc">A61K6/72</class-ref> - <class-ref scheme="cpc">A61K6/77</class-ref></paragraph-text></list-item><list-item><paragraph-text type="body">pigments (<class-ref scheme="cpc">A61K6/78</class-ref>)</paragraph-text></list-item><list-item><paragraph-text type="body">Initiators (<class-ref scheme="cpc">A61K6/79</class-ref>)</paragraph-text></list-item></list></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/80</classification-symbol><definition-title>Preparations for artificial teeth, for filling teeth or for capping teeth</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Chemical compositions for artificial teeth, for filling or for capping teeth with respect to e.g. crowns, inlays, onlays, and filling material based on polymeric, metallic, ceramic, cement and composite materials.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Documents are to be classified in the group&#160;<class-ref scheme="cpc">A61K6/80</class-ref>&#160;only if no more appropriate class can be found according to the material used:</paragraph-text><list><list-item><paragraph-text type="body">Ceramics (<class-ref scheme="cpc">A61K6/802</class-ref>), further subdivided into different kinds of ceramics; based on the main metal used, documents are to be classified in the subgroups&#160;<class-ref scheme="cpc">A61K6/804</class-ref> - <class-ref scheme="cpc">A61K6/827</class-ref>.</paragraph-text></list-item><list-item><paragraph-text type="body">Cermets (Ceramics-Metal) composites (<class-ref scheme="cpc">A61K6/829</class-ref>).</paragraph-text></list-item><list-item><paragraph-text type="body">Materials comprising non-metallic elements or compounds thereof (<class-ref scheme="cpc">A61K6/831</class-ref>), further subdivided into: glass-ceramic composites (<class-ref scheme="cpc">A61K6/833</class-ref>); glasses (<class-ref scheme="cpc">A61K6/836</class-ref>); phosphorus compounds, e.g. apatite (<class-ref scheme="cpc">A61K6/838</class-ref>).</paragraph-text></list-item><list-item><paragraph-text type="body">Metals or alloys (<class-ref scheme="cpc">A61K6/84</class-ref>), further subdivided into: rare earth metals (<class-ref scheme="cpc">A61K6/842</class-ref>); noble metals (<class-ref scheme="cpc">A61K6/844</class-ref>), amalgams (<class-ref scheme="cpc">A61K6/847</class-ref>).</paragraph-text></list-item><list-item><paragraph-text type="body">Inorganic cements (<class-ref scheme="cpc">A61K6/849</class-ref>); based on the chemical features of the cement, documents are to be classified in subgroups&#160;<class-ref scheme="cpc">A61K6/851</class-ref> - <class-ref scheme="cpc">A61K6/882</class-ref>.</paragraph-text></list-item><list-item><paragraph-text type="body">Natural or synthetic resins (<class-ref scheme="cpc">A61K6/884</class-ref>).</paragraph-text></list-item></list><paragraph-text type="body">Specific resins are to be classified in the appropriate class (<class-ref scheme="cpc">A61K6/887</class-ref>&#160;or&#160;<class-ref scheme="cpc">A61K6/891</class-ref>, see below) in combination with a&#160;<class-ref scheme="cpc">C08L</class-ref>&#160;class for specifying the kind of polymer; only if the resin used is very general, documents are to be classified in the main group&#160;<class-ref scheme="cpc">A61K6/884</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K6/90</classification-symbol><definition-title>Compositions for taking dental impressions</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Chemical compositions for taking dental impressions.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Image-producing devices</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61B90/36</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Impression methods</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Impression cups or impression trays</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C9/0006</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Analysis and determination, detecting (2D or 3D) - computer assisted-sizing</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61C13/0004</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">The specific chemical compositions for taking dental impressions are to be classified in combination with the appropriate&#160;<class-ref scheme="cpc">C08L</class-ref>&#160;subclass for specifying the kind of polymer, e.g. containing alginates are classified in Combination set (<class-ref scheme="cpc">A61K6/90</class-ref>,&#160;<class-ref scheme="cpc">C08L5/04</class-ref>); for general polymer compositions, documents are to be classified in the main group&#160;<class-ref scheme="cpc">A61K6/90</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2021-05-01"><classification-symbol scheme="cpc">A61K8/00</classification-symbol><definition-title>Cosmetics or similar toiletry preparations</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Compositions for making-up the skin e.g. lipsticks, rouge, mascara, foundation or preparations for removing make-up, manicure and pedicure preparations e.g. nail polish and nail coating remover, hair care preparations e.g. Shampoo, preparations for permanent waving or straightening, bleaching, dying or conditioning the hair, preparations for affecting hair growth e.g. treatment of hair loss or for slowing hair grow, Preparations for removing hair e.g. shaving and depilatory preparations, oral care preparations e.g. dentifrices, formulations for perfume preparations, Anti-perspirants or body deodorant, barrier preparations e.g. insect repellents or sunscreens, preparations for care of the skin e.g. whitening, tanning, slimming, anti-aging or cleansing preparations.</paragraph-text><paragraph-text type="body">Processes of preparing and using the cosmetic or similar toilet preparations.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Use of cosmetics or similar toilet preparations should be further classified in subclass <class-ref scheme="cpc">A61Q</class-ref>.</paragraph-text><paragraph-text type="body">Soap bars (i.e. solid cleansing compositions) are classified in <class-ref scheme="cpc">C11D</class-ref>, even though general cleansing compositions which are usually liquid are classified in <class-ref scheme="cpc">A61Q</class-ref> and in <class-ref scheme="cpc">A61K8/00</class-ref>.</paragraph-text><paragraph-text type="body">Compositions which can be used in a therapeutic treatment should be classified in <class-ref scheme="cpc">A61K31/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K51/00</class-ref> and subgroups if they are defined by their ingredients or in <class-ref scheme="cpc">A61K9/00</class-ref> and subgroups, if they are defined by their physical form.</paragraph-text><paragraph-text type="body">Ingested compositions like food or dietary supplements having an external cosmetic effect are further classified in <class-ref scheme="cpc">A23L</class-ref>. Examples might be dietary supplements to strengthen nails or to act against skin aging, or drops or sweets affecting the oral cavity</paragraph-text></section-body></relationship><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Preparations for dentistry</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K6/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparation characterised by physical form</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/00</class-ref>, <class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparation characterised by chemical ingredients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/00</class-ref> -<class-ref scheme="cpc">A61K51/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Artificial eyelash or hair</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A41G5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Artificial nails </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A45D31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Casings or accessories for storing or handling of solid or pasty toilet or cosmetic substances</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A45D40/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Artificial skin</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F2/105</class-ref>, <class-ref scheme="cpc">A61L27/60</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Deodorisation of air</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Chemical compounds as such</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C01</class-ref> - <class-ref scheme="cpc">C09</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Essential oils or perfumes per-se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C11B9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Bar soap</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C11D17/0047</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dyeing of wool</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">D06P3/14</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">In each of groups <class-ref scheme="cpc">A61K8/02</class-ref> and <class-ref scheme="cpc">A61K8/18</class-ref>, in the absence of an indication of the contrary, classification is made in the last appropriate place.</paragraph-text><paragraph-text type="body">Each relevant compound (i.e. which belong to the core of the invention (see* in Glossary of terms)) is classified according to the last place rule in one of <class-ref scheme="cpc">A61K8/19</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K8/99</class-ref>.</paragraph-text><paragraph-text type="body">Only relevant compounds or pertinent physical form, i.e. compounds in the composition or specific form (example: emulsion, foam) linked to the effect aimed, i.e. &quot;core of the invention&quot; (see * in Glossary of terms). To classify a patent document, the claims, the description and the examples have to be checked to assess the core of the invention (see* in Glossary of terms).</paragraph-text><paragraph-text type="body">-&gt; example I</paragraph-text><paragraph-text type="body">Only specific compounds, i.e. those present in the exemplified compositions, are classified, not a general concept or a general formula.</paragraph-text><paragraph-text type="body">-&gt; example II</paragraph-text><paragraph-text type="body">Attention is drawn to the Notes in class <class-ref scheme="cpc">C07</class-ref>, for example the Notes following the title of subclass <class-ref scheme="cpc">C07D</class-ref>, setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds in group <class-ref scheme="cpc">A61K8/00</class-ref>.</paragraph-text><paragraph-text type="body">Salts or complexes of organic compounds are classified according to the base compounds. If a complex is formed between two or more compounds, classification is made in both places.</paragraph-text><paragraph-text type="body">Further &quot;properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects&quot; are further classified in <class-ref scheme="cpc">A61K2800/00</class-ref> and subgroups.</paragraph-text><paragraph-text type="body">Class combinations</paragraph-text><paragraph-text type="body">This group is always combined with the subclass <class-ref scheme="cpc">A61Q</class-ref> (i.e. principal uses (see** in Glossary of terms)) and can be further classified in <class-ref scheme="cpc">A61K2800/00</class-ref> and/or <class-ref scheme="cpc">A61Q</class-ref>.</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K2800/00</class-ref> e.g. <class-ref scheme="cpc">A61K2800/522</class-ref> (Antioxidants)</paragraph-text></table-column></table-row></table><paragraph-text type="body">The Indexing Codes of this scheme are to be used mainly with classification <class-ref scheme="cpc">A61K8/00</class-ref> and <class-ref scheme="cpc">A61Q</class-ref> and is considered to be obligatory supplementary classification of subject matter already classified in <class-ref scheme="cpc">A61K8/00</class-ref> and <class-ref scheme="cpc">A61Q</class-ref> if applicable.</paragraph-text><table>
<table-row><table-column preferred-width="7.52cm"><paragraph-text type="body">Compositions or compounds characterised by specific properties</paragraph-text></table-column><table-column preferred-width="7.52cm"><paragraph-text type="body"><class-ref scheme="cpc">A61Q</class-ref></paragraph-text></table-column></table-row></table><paragraph-text type="body"><class-ref scheme="cpc">A61Q</class-ref> is considered as additional information (see** in Glossary of terms), i.e. obligatory supplementary classification of subject matter already classified in&#160;<class-ref scheme="cpc">A61K8/00</class-ref>&#160;and&#160;<class-ref scheme="cpc">A61Q</class-ref>&#160;if applicable. This subclass concerns cosmetic uses that are indicated as eventual application(s) for the composition.</paragraph-text><paragraph-text type="body">-&gt;Example III</paragraph-text><paragraph-text type="body">Reference is further made to annotations in subclasses where it has been considered relevant and helpful.</paragraph-text><paragraph-text type="body">Example I: &quot;classify only relevant compounds&quot;</paragraph-text><paragraph-text type="body">A sunscreen composition stabilised with a specific compound will be classified as follow: <class-ref scheme="cpc">A61Q17/04</class-ref> and under <class-ref scheme="cpc">A61K8/00</class-ref> for the compound; no class is attributed for the sunscreen agent used in the example, i.e. redundant information. In case where the technical problem of the patent document is linked to a specific compound, the compound is classified!</paragraph-text><paragraph-text type="body">The same can be observed for compositions containing hair oxidative or direct dyes or skin tanning agent and dealing with an other technical problem, i.e. viscosity, cosmetic properties where the type of cosmetic agent is not pertinent.</paragraph-text><paragraph-text type="body">Example II: &quot;General formula /specific compound&quot;</paragraph-text><paragraph-text type="body">A patent document claims the use of an amino acid (group title of <class-ref scheme="cpc">A61K8/44</class-ref>) but the single compound used in the examples is Histidine (i.e. <class-ref scheme="cpc">A61K8/4946</class-ref>) or Cysteine (<class-ref scheme="cpc">A61K8/447</class-ref>). Classes are made only for the concrete compounds explicitly disclosed or present in exemplified compositions in the patent document.</paragraph-text><paragraph-text type="body">The same is applicable for ingredients described by a general formula (i.e. &quot;Markush formula&quot;), only the concrete compounds are classified, not the common chemical concept.</paragraph-text><paragraph-text type="body">Example III: principal or additional use(s)</paragraph-text><paragraph-text type="body">A skin moisturising composition which is further used in a anti-ageing preparation or as lip cream, would be classified in <class-ref scheme="cpc">A61Q19/00</class-ref>, <class-ref scheme="cpc">A61Q19/08</class-ref> and <class-ref scheme="cpc">A61Q19/001</class-ref>.</paragraph-text><paragraph-text type="body">If the active is a new sunscreen and an anti-ageing preparation which contains this new compound is exemplified, it should be classified in <class-ref scheme="cpc">A61Q17/04</class-ref> and <class-ref scheme="cpc">A61Q19/08</class-ref>.</paragraph-text><paragraph-text type="body">If the active is a compound to condition the hair and a shampoo or a colouring composition (non-permanent hair dyeing containing direct dyes) is exemplified, it should be classified in <class-ref scheme="cpc">A61Q5/12</class-ref>, <class-ref scheme="cpc">A61Q5/02</class-ref> and <class-ref scheme="cpc">A61Q5/065</class-ref></paragraph-text></section-body></special-rules><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">(*) Core of the invention</paragraph-text></table-column><table-column><paragraph-text type="body">Compounds in the composition or specific form (example: emulsion, foam) linked to the effect aimed. This means that not all compounds present in a composition are classified. To classify a document, the claims, the description and the examples have to be checked. Only specific components, i.e. those present in the exemplified compositions, are classified not a general concept or a general formula.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">(**) Principal use vs. additional use</paragraph-text></table-column><table-column><paragraph-text type="body">The principal use is linked to the effect intended in the document and is classified in <class-ref scheme="cpc">A61Q</class-ref>. In the claims or examples further uses or types of compositions are often described which should be classified in <class-ref scheme="cpc">A61Q</class-ref>. For example: a mixture of compounds is directed to an anti-aging purpose ( <class-ref scheme="cpc">A61Q19/08</class-ref>) which is further introduced in sunscreen composition ( <class-ref scheme="cpc">A61Q17/04</class-ref> ). </paragraph-text></table-column></table-row></table></section-body></glossary-of-terms></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K8/02</classification-symbol><definition-title>characterised by special physical form</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Films; injections; cotton-swab applicators (Q-tip); paracrystaline or</paragraph-text><paragraph-text type="body">multiphases; Oral administration</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Hexagonal or cubic phases being liquid crystals</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/0295</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Medicinal preparations characterized by special physical form</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Cosmetic equipment</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A45D</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Compositions characterized by special physical form should be classified in group <class-ref scheme="cpc">A61K8/02</class-ref> together with the appropriate Indexing Code under <class-ref scheme="cpc">A61K2800/00</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/0208</classification-symbol><definition-title>{Tissues; Wipes; Patches}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Towelettes; impregnated napkins; impregnated sponges; impregnated</paragraph-text><paragraph-text type="body">non-woven fabrics.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body"> Medicinal preparations characterized by special physical form: Web, sheet or filament bases</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/70</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Sanitary equipment not otherwise provided for</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A47K</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Making textile fabrics</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Layered products</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">B32B</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Containers Op packages with special means for dispensing contents</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">B65D83/08</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Detergent compositions</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C11D</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/0212</classification-symbol><definition-title>{Face masks}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Packs</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Masks for cosmetics treatment of the face</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A45D44/002</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/0291</classification-symbol><definition-title>{Micelles}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Rod-like micelles; globular micelles.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">On a phase diagram, a multiple emulsion (classified in <class-ref scheme="cpc">A61K8/066</class-ref>), liquid crystals (classified in <class-ref scheme="cpc">A61K8/0295</class-ref>) and micelles can coexist.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2015-03-01"><classification-symbol scheme="cpc">A61K8/0295</classification-symbol><definition-title>{Liquid crystals}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Lyotropic phases; mesophases; mesomorphic phases; lamellar, cubic</paragraph-text><paragraph-text type="body">(isotropic) or hexagonal phases; nematic, smectic or cholesteric phases;</paragraph-text><paragraph-text type="body">bilayer lamellar gel network (WO0119343).</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Liquid crystals in medicinal preparations</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/1274</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2022-01-01"><classification-symbol scheme="cpc">A61K8/04</classification-symbol><definition-title>Dispersions; Emulsions</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body"> Use of substances as emulsifying, wetting, dispersing or foam-producing agent</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C09K23/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/042</classification-symbol><definition-title>{Gels}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Dispersions of a macromolecular compound in colloidal form in a liquid dispersing phase.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/044</classification-symbol><definition-title>{Suspensions}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Wax microdispersions.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K8/046</classification-symbol><definition-title>{Aerosols; Foams}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Foamable compositions; self foaming (CO<sub>2</sub> releasing) compositions;</paragraph-text><paragraph-text type="body">sprays; post-foaming compositions.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Effervescent compositions should be classified in subclass <class-ref scheme="cpc">A61K8/046</class-ref> together with the appropriate Indexing Code under <class-ref scheme="cpc">A61K2800/00</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/06</classification-symbol><definition-title>Emulsions</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Direct emulsions (O/W); inverse emulsions (W/O); Pickering emulsions.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/068</classification-symbol><definition-title>{Microemulsions}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Transparent emulsions; o/w nanogel (US2003012759).</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/11</classification-symbol><definition-title>Encapsulated compositions</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Encapsulated compositions having a particle size bigger than 100</paragraph-text><paragraph-text type="body">micrometers.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K8/14</classification-symbol><definition-title>Liposomes; Vesicles</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Nanosomes; nanovesicles.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Nanosomes and nanovesicles should be classified in subclass <class-ref scheme="cpc">A61K8/14</class-ref> together with the appropriate Indexing Code under <class-ref scheme="cpc">A61K2800/00</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/19</classification-symbol><definition-title>containing inorganic ingredients</definition-title><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Complexes e.g. zinc hyaluronic acid, should be classified in the subclass <class-ref scheme="cpc">A61K8/19</class-ref> and subgroups according to the inorganic part together with the appropriate classification according to the organic part in <class-ref scheme="cpc">A61K8/30</class-ref> and subgroups.</paragraph-text></section-body></relationship></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/22</classification-symbol><definition-title>Peroxides; Oxygen; Ozone</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Perborates; persalts; H 2O 2.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/23</classification-symbol><definition-title>Sulfur; Selenium; Tellurium; Compounds thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Persulphates; thiosulphates.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/24</classification-symbol><definition-title>Phosphorous; Compounds thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Tripolyphosphates; Fluorophosphates (NaMFP).</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/25</classification-symbol><definition-title>Silicon; Compounds thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Glass beads; sand; talc (Mg silicate); Chrysotile (Mg silicate).</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/26</classification-symbol><definition-title>Aluminium; Compounds thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Clays in general (aluminosilicates): Bentonite, hectorite, montmorillonite, kaolin; mica; zeolites.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Quaternary ammonium clays should be classified in subclass <class-ref scheme="cpc">A61K8/26</class-ref> together with subclass <class-ref scheme="cpc">A61K8/416</class-ref>.</paragraph-text></section-body></relationship></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/27</classification-symbol><definition-title>Zinc; Compounds thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Zinc oxides; Zinc peroxides.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/28</classification-symbol><definition-title>Zirconium; Compounds thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Aluminium-zirconium compounds.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/29</classification-symbol><definition-title>Titanium; Compounds thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Titanium oxides.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/31</classification-symbol><definition-title>Hydrocarbons</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Paraffins, e.g. Permethyl 99A (isododecane) or Isopar E (mixture of C 8-C 9 aliphatic hydrocarbons); Squalane; Patrolatum (Vaseline); Carotenes, e.g. lycopene.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/315</classification-symbol><definition-title>{Halogenated hydrocarbons}</definition-title><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Chlorofluorocarbons (Freons)</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/69</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Polymeric Chlorofluorocarbons (polymeric Freons)</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/8123</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/33</classification-symbol><definition-title>containing oxygen</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Aldehydes; Ethers.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/355</classification-symbol><definition-title>{Quinones}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Hydroquinone</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/347</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2016-08-01"><classification-symbol scheme="cpc">A61K8/362</classification-symbol><definition-title>Polycarboxylic acids</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Salts and anhydrides thereof; Dicarboxylic acids.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/365</classification-symbol><definition-title>Hydroxycarboxylic acids; Ketocarboxylic acids</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Salts and anhydrides thereof; Gluconic acids.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/368</classification-symbol><definition-title>with carboxyl groups directly bound to carbon atoms of aromatic rings</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Salts and anhydrides thereof.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/37</classification-symbol><definition-title>Esters of carboxylic acids</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Carbonic acid ester, e.g. dialkyl carbonates.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/39</classification-symbol><definition-title>Derivatives containing from 2 to 10 oxyalkylene groups</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Polyglycerins containing from 2 to 10 repeating units in the same chain.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body"> Alkoxylated derivatives containing 11 or more oxyalkylene groups in thesame chain</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/86</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Polyglycerins containing 11 or more repeating units in the same chain</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/86</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/40</classification-symbol><definition-title>containing nitrogen  (quinones containing nitrogen <class-ref scheme="cpc">A61K8/355</class-ref>)</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Imine R=N-H; Oximes R-CH=N-OH; Hydrazones R-CH=N-NH 2; Azines</paragraph-text><paragraph-text type="body">R-CH=N-N=C; Nitriles R-CN; Isocyanates R-N=C=O; Cyanates R-O-CN;</paragraph-text><paragraph-text type="body">Amine oxides; Quinoneimines; Azo compounds; imides RR&apos;C=NH.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/41</classification-symbol><definition-title>Amines</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Alkanolamines; Cyanamides NC=NH 2; Sphingosines.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/415</classification-symbol><definition-title>{Aminophenols}</definition-title><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Anthraquinones</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/355</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/42</classification-symbol><definition-title>Amides</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Urea (H 2N-C(=O)-NH 2 ) is also included in this group</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/44</classification-symbol><definition-title>Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Betaines; Carbamates.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Asparagine</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/442</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Glutamine</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/442</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Proline</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/4913</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Tryptophan</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/492</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Histidine</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/4946</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Peptides, i.e. polymers of 2 or more aminoacids</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/64</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/442</classification-symbol><definition-title>{substituted by amido group(s)}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Amidobetaines; Cocoamphoacetates; Aspargine; Glutamine.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/45</classification-symbol><definition-title>Derivatives containing from 2 to 10 oxyalkylene groups</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body"> Alkoxylated derivatives containing 11 or more oxyalkylene groups in thesame chain</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/86</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/46</classification-symbol><definition-title>containing sulfur  (<class-ref scheme="cpc">A61K8/44</class-ref> takes precedence)</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Thiocyanates R-S-CN; Sulfamic acids N-SO 3H.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/466</classification-symbol><definition-title>{containing sulfonic acid derivatives; Salts}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Sulfonamides; Sulfosuccinates; Sultaines, e.g. Cocoamidopropylhydroxysultaine; Taurine; Isethionates.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/49</classification-symbol><definition-title>containing heterocyclic compounds</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Thiazole, pyrrole-oxazole, morpholine; Heterocyclic compounds containing having at least two different hetero atoms in the same or</paragraph-text><paragraph-text type="body">different hetero ring, condensed or not and/or in the same or different ring system.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/4906</classification-symbol><definition-title>{with one nitrogen as the only hetero atom}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Heterocyclic compounds containing one or several hetero rings, condensed or not, in the same or different ring system, each hetero ring</paragraph-text><paragraph-text type="body">having only one nitrogen as the only hetero atom.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/4913</classification-symbol><definition-title>{having five membered rings, e.g. pyrrolidone carboxylic acid}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Pyrrole; Pyrrolidine; Proline; Heterocyclic compounds containing one or several not condensed hetero rings, in the same or different ring system, each hetero ring having only one nitrogen as the only hetero atom and having five membered hetero rings.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/492</classification-symbol><definition-title>{having condensed rings, e.g. indol}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Phthalimides; Pyrrocoline; Isatin; Trytophan; Heterocyclic compounds containing one or several condensed hetero rings, in the same or different ring system, each hetero ring having only one nitrogen as the only hetero atom and having five membered hetero rings.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/4926</classification-symbol><definition-title>{having six membered rings}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Piperidine; Pyridine; Acridine; Quinoline; Heterocyclic compounds containing one or several condensed or not hetero rings, in the same or different ring system, each hetero ring having only one nitrogen as the only hetero atom and having six-membered hetero rings.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Nicotinic acid</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/675</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/4933</classification-symbol><definition-title>{having sulfur as an exocyclic substituent, e.g. pyridinethione}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Heterocyclic compounds containing one or several hetero rings, condensed or not, in the same or different rings systems, each hetero ring having only one nitrogen as the only hetero atom and having sulphur as an exocyclic substituent of the hetero ring.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/494</classification-symbol><definition-title>{with more than one nitrogen as the only hetero atom}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Pyrazole; Piperazine; Pyridazine; Pyrazine; Heterocyclic compounds containing one or several hetero rings, condensed or not, in the same or different rings systems, and at least one hetero ring having more than one nitrogen as the only hetero atom.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/4946</classification-symbol><definition-title>{Imidazoles or their condensed derivatives, e.g. benzimidazoles}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Allantoin (imidazolidinyl urea derivative); Histidine.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/4953</classification-symbol><definition-title>{containing pyrimidine ring derivatives, e.g. minoxidil}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Condensed derivatives of the pyrimidine ring; Purines; Orotic acid;</paragraph-text><paragraph-text type="body">Adenine; Guanine.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Folic acid</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/67</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/4973</classification-symbol><definition-title>{with oxygen as the only hetero atom}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Oxetane; sorbitan esters; Heterocyclic compounds containing one or several hetero rings, condensed or not, in the same or different rings systems, each hetero ring having oxygen as the only hetero atom.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/498</classification-symbol><definition-title>{having 6-membered rings or their condensed derivatives, e.g. coumarin}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Genistein; Heterocyclic compounds containing one or several hetero rings, condensed or not, in the same or different rings systems, each hetero ring having oxygen as the only hetero atom and having six membered hetero rings.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/4986</classification-symbol><definition-title>{with sulfur as the only hetero atom}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Thiophene; Lipoic acid; Compounds containing one or several hetero rings, condensed or not, in the same or different rings systems, each hetero ring having sulphur as the only hetero atom.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/4993</classification-symbol><definition-title>{Derivatives containing from 2 to 10 oxyalkylene groups}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Condensed derivatives; Polysorbates.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body"> Alkoxylated derivatives containing 11 or more oxyalkylene groups in thesame chain</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/86</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/58</classification-symbol><definition-title>containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Organometallic compounds.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/585</classification-symbol><definition-title>{Organosilicon compounds}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Silanes; Silisesquioxanes; Cyclomethicones, e.g. Hexamethylcyclotrisiloxane, Octamethylcyclotetrasiloxane, Decamethylcyclopentasiloxane; Linear volatile siloxanes; Chlorophyll.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Polysiloxanes </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/89</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/60</classification-symbol><definition-title>Sugars; Derivatives thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Oligosaccharides up to 5 monomeric units; Aminosugars, e.g. glucosamine; Uronic acids, e.g. glucuronic acid; Erythrulose.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Reduced sugar derivatives, e.g. erythritol, glucitol or xylitol</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/345</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Straight-chain acids, e.g. gluconic acid</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/365</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Ethers of disaccharides and a steroid</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/63</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2016-08-01"><classification-symbol scheme="cpc">A61K8/602</classification-symbol><definition-title>{Glycosides, e.g. rutin}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Glucosides; Galactosides.</paragraph-text></section-body></definition-statement><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Glycoside </paragraph-text></table-column><table-column><paragraph-text type="body"> acetal derivative of a sugar.</paragraph-text></table-column></table-row></table></section-body></glossary-of-terms></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/604</classification-symbol><definition-title>{Alkylpolyglycosides; Derivatives thereof, e.g. esters}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Alkylmonoglycosides, oligoglycosides and -polyglycosides.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/608</classification-symbol><definition-title>{Derivatives containing from 2 to 10 oxyalkylene groups}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body"> Alkoxylated derivatives containing 11 or more oxyalkylene groups in thesame chain</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/86</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2016-08-01"><classification-symbol scheme="cpc">A61K8/64</classification-symbol><definition-title>Proteins; Peptides; Derivatives or degradation products thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Cytochromes; glycoproteines; antibodies.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Polyaminoacids formed from one up to three repeating aminoacid units</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/88</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing peptides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K38/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing antigens or antibodies</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Peptide </paragraph-text></table-column><table-column><paragraph-text type="body"> Compounds containing at least two aminoacids units which are bound through at least one normal peptide link.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Normal peptide link </paragraph-text></table-column><table-column><paragraph-text type="body"> The link between an alpha-amino group of an amino acid and the carboxyl group - in position 1 - of an other alphaaminoacid.</paragraph-text></table-column></table-row></table></section-body></glossary-of-terms></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/645</classification-symbol><definition-title>{Proteins of vegetable origin; Derivatives or degradation products thereof}</definition-title><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Cyclosporins should be classified according to their structures.</paragraph-text></section-body></special-rules></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/66</classification-symbol><definition-title>Enzymes</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing enzymes</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2016-08-01"><classification-symbol scheme="cpc">A61K8/67</classification-symbol><definition-title>Vitamins</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Folic acid.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/676</classification-symbol><definition-title>{Ascorbic acid, i.e. vitamin C}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Derivatives of ascorbic acid.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/678</classification-symbol><definition-title>{Tocopherol, i.e. vitamin E}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Derivatives of tocopherol.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/68</classification-symbol><definition-title>Sphingolipids, e.g. ceramides, cerebrosides, gangliosides</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Synthetized pseudoceramide derivatives which are characterized by structures having both amide or nitrogen bonds and hydroxyl groups as hydrophilic units, as well as two long chains; Alkanolamides from sphingosine and a fatty acid; Glycoceramides.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/69</classification-symbol><definition-title>containing fluorine</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Organic fluorides and Chlorofluorocarbons (Freons).</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2015-03-01"><classification-symbol scheme="cpc">A61K8/72</classification-symbol><definition-title>containing organic macromolecular compounds</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Natural rubber; Latex; Melanins; Dendrimers; Supra-molecular polymers.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Alkylpolyglycosides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/604</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Nucleic acids</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/606</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Proteins</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/64</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/73</classification-symbol><definition-title>Polysaccharides</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Polymers of 6 or more saccharide units, e.g. dextran.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/732</classification-symbol><definition-title>{Starch; Amylose; Amylopectin; Derivatives thereof}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">(Malto) dextrin.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Cyclodextrins </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/738</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/737</classification-symbol><definition-title>{Galactomannans, e.g. guar; Derivatives thereof}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Locust bean gum; Tara; Ceratonia siliqua.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/738</classification-symbol><definition-title>{Cyclodextrins}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Cyclodextrins in medicinal preparations </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/40</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2016-08-01"><classification-symbol scheme="cpc">A61K8/81</classification-symbol><definition-title>obtained by reactions involving only carbon-to-carbon unsaturated bonds</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Unless otherwise specified in this classification, these group and its subgroups cover the polymers as defined in <class-ref scheme="cpc">C08L23/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">C08L49/00</class-ref>.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8105</classification-symbol><definition-title>{Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Compositions of such homopolymers or copolymers per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L23/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8111</classification-symbol><definition-title>{Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Polydecene.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8117</classification-symbol><definition-title>{Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Sodium polystyrene sulfonate; Polymers obtained from divinylbenzene.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8123</classification-symbol><definition-title>{Compositions of homopolymers or copolymers of compounds having one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers, e.g. PVC, PTFE}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Compositions of such homopolymers or copolymers per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L27/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8129</classification-symbol><definition-title>{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Compositions of such homopolymers or copolymers per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L29/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8135</classification-symbol><definition-title>{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid; Compositions of derivatives of such polymers, e.g. vinyl esters (polyvinylacetate)}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Compositions of such homopolymers or copolymers per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L31/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8141</classification-symbol><definition-title>{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Compositions of such homopolymers or copolymers per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L33/00</class-ref>.</paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8147</classification-symbol><definition-title>{Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Compositions of such homopolymers or copolymers per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L33/02</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8152</classification-symbol><definition-title>{Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L33/04</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8158</classification-symbol><definition-title>{Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Polymers obtained from polyacrylamidomethylpropane sulphonic acid</paragraph-text><paragraph-text type="body">(AMPS).</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body"> Such homopolymers or copolymers of amides or imides per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L33/24</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8164</classification-symbol><definition-title>{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Compositions of such homopolymers or copolymers per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L35/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/817</classification-symbol><definition-title>{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Compositions of such homopolymers or copolymers per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L39/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">This class is given only if the nitrogen atom or the nitrogen containing heterocycle ring is directly linked to the polymer forming double bond.</paragraph-text></section-body></special-rules></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8188</classification-symbol><definition-title>{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bonds, and at least one being terminated by a bond to sulfur or by a hertocyclic ring containing sulfur; Compositions of derivatives of such polymers}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Polyvinylsulfonates; Polythiophenes.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Polystyrene sulphonic acid</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/8117</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> AMPS polymers</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/8158</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Polyquaternium-44</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/8182</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Compositions of such homopolymers or copolymers per se </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L41/00</class-ref>.</paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">This class is given only if the sulphur atom or the sulphur containing heterocycle ring is directly linked to the polymer forming double bond.</paragraph-text></section-body></special-rules></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/8194</classification-symbol><definition-title>{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds; Compositions of derivatives of such polymers}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Polymers obtained from monomers having conjugated double bonds, e.g. butadiene, isoprene and chloroprene.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Polydecene</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/8111</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Divinylbenzene</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/8117</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Allylmethacrylate</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/8152</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Diallylamines, e.g. Polyquaternium-6, Polyquaternium-7, Polyquaternium-22 and Polyquaternium-39</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/817</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Compositions of such homopolymers or copolymers per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08L47/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2016-08-01"><classification-symbol scheme="cpc">A61K8/84</classification-symbol><definition-title>obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Unless otherwise specified in this classification, these group and its subgroups cover the polymers as defined in <class-ref scheme="cpc">C08L59/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">C08L87/00</class-ref>;</paragraph-text><paragraph-text type="body">Polyureas; Polyurilene resin.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/86</classification-symbol><definition-title>Polyethers</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Alkoxylated derivatives containing 11 or more oxyalkylene groups in the same chain.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Alkoxylated derivatives, i.e. derivatives containing from 2 to 10 groups</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/39</class-ref>, <class-ref scheme="cpc">A61K8/45</class-ref>, <class-ref scheme="cpc">A61K8/4993</class-ref>, <class-ref scheme="cpc">A61K8/556</class-ref>, <class-ref scheme="cpc">A61K8/608</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/88</classification-symbol><definition-title>Polyamides</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Polyaminoacids formed from one up to three repeating aminoacid units; Polyimides; Polyaminoamides.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Proteins and peptides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/64</class-ref>.</paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/89</classification-symbol><definition-title>Polysiloxanes</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Organo silicon compounds not being polymers</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/585</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/891</classification-symbol><definition-title>saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone</definition-title><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Saturated </paragraph-text></table-column><table-column><paragraph-text type="body"> polysiloxanes containing silicone atoms bound to saturated or aromatic group.</paragraph-text></table-column></table-row></table></section-body></glossary-of-terms></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/893</classification-symbol><definition-title>modified by an alkoxy or aryloxy group, e.g. behenoxy dimethicone or stearoxy dimethicone</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Polysiloxanes derivatives containing from 2 to 10 alkoxy or aryloxy groups; Dimethicone PEG-8 benzoate.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/894</classification-symbol><definition-title>modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Polysiloxanes derivatives containing 11 or more oxyalkylene groups.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/895</classification-symbol><definition-title>containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Crosspolymers obtained from vinyl dimethicone.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/92</classification-symbol><definition-title>Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Mixtures of several compounds of different nature and being oils, fats or waxes.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/922</classification-symbol><definition-title>{of vegetable origin}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Essential oils.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/965</classification-symbol><definition-title>{of inanimate origin}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Mud; Sea water; mineral water.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K8/97</classification-symbol><definition-title>from algae, fungi, lichens or plants; from derivatives thereof</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Humus; Tar; Charcoal; Saponins; Tannins with no specific chemical structure.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Condensed tannins, e.g. proanthocyanidines</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/498</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Hydrolysable tannins, e.g. glycosides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/602</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/98</classification-symbol><definition-title>of animal origin</definition-title><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">No document should be classified in this subgroup. Every document concerning material or animal origin should be classified in <class-ref scheme="cpc">A61K8/981</class-ref> and subgroups or in <class-ref scheme="cpc">A61K8/987</class-ref> and subgroups.</paragraph-text></section-body></special-rules></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K8/987</classification-symbol><definition-title>{of species other than mammals or birds}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Material from fish or insects; Silk; Natural sponges; Pearls from oysters;</paragraph-text><paragraph-text type="body">Mother-of-pearl (nacre).</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K8/99</classification-symbol><definition-title>from microorganisms other than algae or fungi, e.g. protozoa or bacteria</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Cell cultures; Yeasts; Plankton; Lower fungi; Bacteria; Krill; Lichens;</paragraph-text><paragraph-text type="body">Undifferentiated plant seed cells.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Fermentated products should be classified according to their origin together with an Indexing Code, e.g. <class-ref scheme="cpc">A61K2800/85</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K9/00</classification-symbol><definition-title>Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations&#160;<class-ref scheme="cpc">A61K49/18</class-ref>; preparations containing radioactive substances&#160;<class-ref scheme="cpc">A61K51/12</class-ref>)}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Pharmaceutical compositions which are characterised by the following galenical aspects:</paragraph-text><list><list-item><paragraph-text type="body">The form (e.g. tablets) (see also &quot;Special rules&quot; section)</paragraph-text></list-item><list-item><paragraph-text type="body">The site of application, i.e. the body location where they are administered (e.g. oral, nasal, rectal compositions)</paragraph-text></list-item><list-item><paragraph-text type="body">The drug release technique (e.g. effervescent compositions, osmotic delivery systems)</paragraph-text></list-item></list><paragraph-text type="body">In addition, the following is also classified:</paragraph-text><list><list-item><paragraph-text type="body">Processes of making such compositions</paragraph-text></list-item><list-item><paragraph-text type="body">Medical uses characterised by any of the above galenical aspects (dosage form, site of application, release technique)</paragraph-text></list-item><list-item><paragraph-text type="body">Excipients for use in a specific dosage form (e.g. tableting excipients)</paragraph-text></list-item></list><paragraph-text type="body">In <class-ref scheme="cpc">A61K</class-ref> &quot;Galenic&quot; form&quot; relates to pharmaceutical (drug delivery) compositions in general. &quot;Galenical&quot; aspects relate to aspects of pharmaceutical technology of pharmaceutical compositions. (i.e. aspects of pharmaceutical compositions other than the active ingredient per se, e.g. physical form, excipients, dosage etc.</paragraph-text><paragraph-text type="body">It is sufficient to say pill, capsule, particle etc. for classification. The pill or the like does not require further elaboration to warrant classification in <class-ref scheme="cpc">A61K9/00</class-ref>. Any concrete, well-defined pharmaceutical composition disclosed in the examples is considered to be characterized by a physical form. Also classified are independent claims defining galenical aspects of a pharmaceutical composition or a medical use. For example the following forms are considered to be characterized by a physical form:- a suppository, ointment, solution, dispersion, emulsion, aerosol, foam, liposome, powder, granulate, micro/nanosphere, pill, tablet, capsule, micro/nanocapsule, web, sheet, filament, etc. This list is not exhaustive. A borderline case is an animal test where the galenical aspect of the composition is not further defined (e.g. intravenous injection, per os administration), unless it is absolutely clear that the test represents the intended mode of administration.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Galenical aspects of pharmaceutical compositions are usually classified by giving a combination of classes in <class-ref scheme="cpc">A61K9/00</class-ref> and <class-ref scheme="cpc">A61K47/00</class-ref>. The last place rule does not apply between <class-ref scheme="cpc">A61K9/00</class-ref> and <class-ref scheme="cpc">A61K47/00</class-ref> - <class-ref scheme="cpc">A61K47/46</class-ref>. Excipients can be classified in <class-ref scheme="cpc">A61K47/00</class-ref> or in <class-ref scheme="cpc">A61K9/00</class-ref>, depending on the situation: <class-ref scheme="cpc">A61K47/00</class-ref> is used to classify excipients in compositions for which <class-ref scheme="cpc">A61K9/00</class-ref> does not provide information on excipients. No <class-ref scheme="cpc">A61K47/00</class-ref> is given if <class-ref scheme="cpc">A61K9/00</class-ref> already provides information on excipients (e.g. tablet excipients are only classified in <class-ref scheme="cpc">A61K9/20</class-ref>...). New excipients per se are (in addition) classified in <class-ref scheme="cpc">A61K47/00</class-ref>.</paragraph-text><paragraph-text type="body">Conjugates, i.e. compounds comprising a non-active ingredient bound to the active ingredient, are classified in <class-ref scheme="cpc">A61K47/50</class-ref>. Pharmaceutical compositions comprising conjugates may in addition be classified in <class-ref scheme="cpc">A61K9/00</class-ref>.</paragraph-text><paragraph-text type="body">The active ingredients in pharmaceutical compositions are classified in <class-ref scheme="cpc">A61K31/00</class-ref> - <class-ref scheme="cpc">A61K45/00</class-ref>, or <class-ref scheme="cpc">A61K48/00</class-ref> - <class-ref scheme="cpc">A61K51/00</class-ref>.</paragraph-text><paragraph-text type="body">Bandages for treatment of wounds are classified in <class-ref scheme="cpc">A61L</class-ref>. These bandages may comprise active agents, e.g. anti-inflammatory, antibacterial agents to enhance the action of the bandage. Compositions comprising an active agent for wound healing which are neither bandages, nor form bandages (e.g. spray-on bandages) are classified in <class-ref scheme="cpc">A61K9/00</class-ref>. These compositions, e.g. lotions, are classified according to the site of application, <class-ref scheme="cpc">A61K9/0014</class-ref> and, where relevant, according to the form e.g. <class-ref scheme="cpc">A61K9/06</class-ref>, <class-ref scheme="cpc">A61K9/08</class-ref> and/or excipients used (<class-ref scheme="cpc">A61K47/00</class-ref>). Bandages for wound treatment should not be confused with transdermal patches, the main function of which is (usually systemic) drug delivery rather than the treatment of wounds. Transdermal patches are classified in <class-ref scheme="cpc">A61K9/7023</class-ref> and subgroups. Bandages also should not be confused with medicated film (forming) compositions that are not for wound healing; these are classified in <class-ref scheme="cpc">A61K9/7007</class-ref> (and <class-ref scheme="cpc">A61K9/7015</class-ref>)</paragraph-text></section-body></relationship><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/18</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Preparations containing radioactive substances</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K51/12</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Classified are concrete, well-defined pharmaceutical compositions disclosed in the examples. Also classified are independent claims defining galenical aspects of a pharmaceutical composition or a medical use.</paragraph-text><paragraph-text type="body">All relevant galenical aspects must be classified.</paragraph-text><paragraph-text type="body">The one dot groups of <class-ref scheme="cpc">A61K9/00</class-ref> do not follow the last place rule</paragraph-text><paragraph-text type="body">In principle all examples are classified, also &apos;standard&apos; examples in documents describing e.g. a new medical use.</paragraph-text><paragraph-text type="body">However, systematically classifying all excipients in the examples is not necessary, and often undesirable. In any case classified are excipients which are described as being important for the invention, or which the reader can identify as having an important function, e.g. for sustained release. For &apos;standard&apos; compositions the examiner should choose one or a few excipients to classify. (Note: A &apos;standard&apos; example is an example that is simple and does not appear to be part of the invention. For instance in a document relating to the new medical use of a (new) chemical compound, often some compositions are given which are &apos;standard&apos; (if not hypothetical): a tablet with e.g. lactose, microcrystalline cellulose and magnesium stearate, an injection solution with NaCl, etc.</paragraph-text><paragraph-text type="body">In any case such examples should be classified, whether considered &apos;standard&apos; or not. In how far all excipients in such compositions are classified is left to the classifier&apos;s discretion).</paragraph-text><paragraph-text type="body">When there are too many examples, they can sometimes be covered by a more general class. However, head groups should not be used for this. </paragraph-text><paragraph-text type="body">( A &quot;head&quot; group does not have the same meaning as a main group. With &quot;head group&quot; is meant a group which is further subdivided in such a way that classification can always be made in one of the lower groups. For instance <class-ref scheme="cpc">A61K9/2004</class-ref> is a head group, <class-ref scheme="cpc">A61K9/0012</class-ref> is a head group, as well as <class-ref scheme="cpc">A61K9/0002</class-ref>. In principle such head groups should be empty.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K9/0002</class-ref> is the head group for the drug release techniques (see Definition statement). Only its subgroups are used for classification, when relevant. <class-ref scheme="cpc">A61K9/0002</class-ref> is empty; there is no general sustained release group.</paragraph-text><paragraph-text type="body">Animal tests to study pharmacokinetic properties of a drug are not classified, unless it is absolutely clear that they represent the intended mode of administration. (Note: What is meant here, are pharmacokinetic tests in animals, e.g. by injection or gavage. Such tests usually say nothing about the final intended dosage forms, but are necessary e.g. for regulatory purposes. The value of their pharmaceutical/galenical information is therefore very low. Exceptions are perhaps inhalation tests in animals, as these are normally only done with drugs intended to be inhaled).</paragraph-text><paragraph-text type="body">Processes for preparing a composition, even when claimed, are only classified if they appear of interest.</paragraph-text><paragraph-text type="body">The description and dependent claims are not classified. However, if the document as a whole focuses on one clearly preferred embodiment, this embodiment may be classified, even in the absence of relevant examples or independent claims. The intention here is primarily to avoid that all lists in the dependent claims are fully classified (e.g. all tablet excipients for sustained release, while only one is used in the examples).</paragraph-text><paragraph-text type="body">If a specific subcombination is claimed, such a subcombination will usually be reflected in the examples, which should in any case be classified. And if this subcombination is not reflected in examples, but clearly forms the invention (following e.g. the description), then it also should be classified. In all other cases, the specific subcombination is probably not inventive, so no need to classify.</paragraph-text><paragraph-text type="body">In general, information relating to the invention is classified using invention information symbols, while additional information is classified using additional information symbols. This is largely up to the discretion of the examiner. Please note however the following special situations:</paragraph-text><list><list-item><paragraph-text type="body">Normally only final compositions are classified, not intermediates. However, it may be useful to classify intermediates as additional information (e.g. a tablet comprising microcapsules; a multicoated microparticle). If the intermediates are claimed separately, they must be classified as invention information.</paragraph-text></list-item><list-item><paragraph-text type="body">If, in the classification scheme, a group refers out to another group, an additional information symbol may still be given for the first group (e.g. oral mucoadhesive film).</paragraph-text></list-item></list></section-body></special-rules><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Microemulsion</paragraph-text></table-column><table-column><paragraph-text type="body">any emulsion with a particle size below 1 &#956;m</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Microparticle</paragraph-text></table-column><table-column><paragraph-text type="body">particle having a size between 1 &#956;m and about 3 mm</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Microsphere</paragraph-text></table-column><table-column><paragraph-text type="body"> homogenous or multi-nuclear particle having a size between 1 &#956;m and about 3 mm</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Microcapsule</paragraph-text></table-column><table-column><paragraph-text type="body">capsule or coated particle having a size between 1 &#956;m and about 3 mm</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Nanoparticle, nanocapsule</paragraph-text></table-column><table-column><paragraph-text type="body">(coated) particle or capsule having a size below 1 &#956;m</paragraph-text></table-column></table-row></table></section-body></glossary-of-terms></definition-item>
<definition-item date-revised="2021-05-01"><classification-symbol scheme="cpc">A61K9/70</classification-symbol><definition-title>Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug  (hollow drug-filled fibres <class-ref scheme="cpc">A61K9/0092</class-ref>)}</definition-title><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Hollow drug-filled fibres</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/0092</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Bandages, dressings or absorbent pads</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F13/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Chemical aspects thereof</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L15/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2019-08-01"><classification-symbol scheme="cpc">A61K31/00</classification-symbol><definition-title>Medicinal preparations containing organic active ingredients</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Medicinal formulations or compositions per se containing organic therapeutically active ingredients.</paragraph-text><paragraph-text type="body">Organic active compounds for use in any first or further medical application.</paragraph-text><paragraph-text type="body">Use of an organic active ingredient for the manufacture of a medicament for the treatment of a pathological condition.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">When a compound is only and exclusively defined in the description and claims by means of a functional definition, and no specific examples at all are provided, and it is unclear whether the functionally defined compound would be a compound according to any of <class-ref scheme="cpc">A61K31/00</class-ref>, <class-ref scheme="cpc">A61K33/00</class-ref>, <class-ref scheme="cpc">A61K35/00</class-ref>, <class-ref scheme="cpc">A61K36/00</class-ref>, <class-ref scheme="cpc">A61K38/00</class-ref> or <class-ref scheme="cpc">A61K39/00</class-ref>, the main group <class-ref scheme="cpc">A61K45/00</class-ref> is to be assigned.</paragraph-text><paragraph-text type="body">For mixtures containing one or more active ingredients without chemical characterisation (i.e. only expressed in term of a functional feature, e.g. antihistamines, PDE4 inhibitors, neuroprotectors, serotonin receptor agonists, etc.), the symbol <class-ref scheme="cpc">A61K45/06</class-ref> is also to be given in addition to the <class-ref scheme="cpc">A61K31/00</class-ref> subgroup corresponding to the well defined component(s) of the mixture.</paragraph-text><paragraph-text type="body">In the case of peptidic enzyme inhibitors wherein the chemical structure is well defined and can be classified under an <class-ref scheme="cpc">A61K31/00</class-ref> subgroup (e.g. apicidin), that <class-ref scheme="cpc">A61K31/00</class-ref> subgroup is assigned in addition to the appropriate <class-ref scheme="cpc">A61K38/00</class-ref> symbol. This applies in the rare cases where a compound could be classified in both groups and thus could be retrieved either via the <class-ref scheme="cpc">A61K31/00</class-ref> classification scheme or the <class-ref scheme="cpc">A61K38/00</class-ref> classification scheme, bearing in mind that no information should be lost during the classification process.</paragraph-text><paragraph-text type="body">Cosmetic preparations which can be used for cosmetic as well as therapeutic indications are classified in both <class-ref scheme="cpc">A61K8/00</class-ref> and <class-ref scheme="cpc">A61K31/00</class-ref>.</paragraph-text><paragraph-text type="body">Compositions with a therapeutic application in the form of food, beverages or dietary supplements are further classified in <class-ref scheme="cpc">A23L</class-ref>.</paragraph-text><paragraph-text type="body">Organic active compounds containing non-radioactive isotopes, e.g. deuterium, N15 or C13, are to be classified in <class-ref scheme="cpc">A61K31/00</class-ref> and not in <class-ref scheme="cpc">A61K51/00</class-ref>.</paragraph-text><paragraph-text type="body">Contrary to IPC , no <class-ref scheme="cpc">A61K31/00</class-ref> symbol is given for novel compounds, i.e. compounds claimed per se (including polymorphs and highly pure compounds) falling under subclasses <class-ref scheme="cpc">C07C</class-ref>&#160;-&#160;<class-ref scheme="cpc">C07J</class-ref>, even when the set of claims further contains claims relating to their medical use. For those compounds, classification is only made in the relevant subclasses <class-ref scheme="cpc">C07C</class-ref>&#160;-&#160;<class-ref scheme="cpc">C07J</class-ref> according to the structure. This exception does not apply to novel compounds falling outside <class-ref scheme="cpc">C07C</class-ref>&#160;-&#160;<class-ref scheme="cpc">C07J</class-ref>. Thus, novel polymers also claimed for their therapeutic use will be classified under <class-ref scheme="cpc">C08</class-ref> as well as the corresponding symbol under <class-ref scheme="cpc">A61K31/00</class-ref>.</paragraph-text><paragraph-text type="body">However, when the invention also discloses medicinal preparations containing said novel compounds, falling under <class-ref scheme="cpc">C07C</class-ref>&#160;-&#160;<class-ref scheme="cpc">C07J</class-ref>, in admixture with one or more active organic ingredients, then said novel compounds are also classified in the appropriate <class-ref scheme="cpc">A61K31/00</class-ref> subgroup followed by symbol <class-ref scheme="cpc">A61K2300/00</class-ref> to create the corresponding Combination-set, e.g. (<class-ref scheme="cpc">A61K31/60</class-ref>, <class-ref scheme="cpc">A61K2300/00</class-ref>), in addition to the <class-ref scheme="cpc">C07</class-ref> classification.</paragraph-text><paragraph-text type="body">When a document discloses materials or extracts from algae, lichens, fungi or plants as well as the active component which has been isolated from said material or extract, and said active component has a well defined chemical structure falling under <class-ref scheme="cpc">A61K31/00</class-ref>, a class under <class-ref scheme="cpc">A61K36/00</class-ref> together with the appropriate <class-ref scheme="cpc">A61K31/00</class-ref> class is given. This applies unless the isolated active compound is a novel compound falling under <class-ref scheme="cpc">C07C</class-ref>&#160;-&#160;<class-ref scheme="cpc">C07J</class-ref>.</paragraph-text></section-body></relationship><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Empty galenic formulations, i.e. only comprising carriers, additives, excipients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/00</class-ref>, <class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Organic active compounds forming salts with heavy metals (unless otherwise specified) </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K33/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Organic compounds claimed per se, i.e. allegedly novel organic compounds</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">General methods in organic chemistry</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07B</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Acyclic and carbocyclic compounds per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07C</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Heterocyclic compounds per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07D</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Sugars per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07H</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Steroids per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07J</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><paragraph-text type="body">In addition to the classification in <class-ref scheme="cpc">A61K31/00</class-ref>, a document has to be forwarded for classification in the following fields if (also) relating to:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Preparations for dentistry</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K6/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Cosmetics, unless a therapeutic effect is also implied</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Galenic formulations characterized by special physical form</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicaments containing inorganic active ingredients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K33/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicaments containing active ingredients of undetermined constitution</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K35/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicaments containing active ingredients from algae, lichens, fungi or plants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K36/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicaments containing peptides or proteins</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K38/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicaments containing antigens or antibodies, vaccines, adjuvants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Homeopathy, thermotherapy, photodynamic therapy, photoactivable drugs</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Mixtures of active ingredients without chemical characterization</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K45/06</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Galenic formulations characterized by the non-active ingredients used</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Conjugates of active ingredients with a non-active ingredient</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/50</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing genetic material, gene therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K48/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Preparations for testing in vivo, e.g. screening, contrast agents, ultrasound</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Preparations containing radioactive substances</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K51/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Biocides, pest repellants or attractants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A01N</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Animal feeding-stuffs</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23K10/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Food or functional food (nutraceuticals)</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23L</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Prosthese; orthopedic, nursing or contraceptive devices; protections of eyes or ears; bandages, dressing or absorbent pads, first-aid kits</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Biomaterials</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Electrotherapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N1/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Magnetotherapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N2/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Radiation therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Organic compounds claimed per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">General methods in organic chemistry</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07B</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Acyclic and carbocyclic compounds per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07C</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Heterocyclic compounds per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07D</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Sugars per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07H</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Steroids per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07J</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Antibodies</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="not-mapped">C07K/16</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Detergent compositions</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C11D</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Undifferentiate human, animal or plant cells, e.g. cell lines; Tissues; Culture media</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Coding and non-coding nucleic acids, e.g. ribozymes, antisenses</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N15/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">In vitro diagnosis</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G01N</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">General rules</paragraph-text><list><list-item><paragraph-text type="body">In the absence of an indication to the contrary, a compound is classified in the last appropriate place (last place rule), i.e. by identifying the portion of molecule which is identified in the lowest possible place in the classification scheme (i.e. the lowest place in print order), and assigning the corresponding subgroup.</paragraph-text></list-item><list-item><paragraph-text type="body">In this group no distinction is made between Invention information and Additional information</paragraph-text></list-item></list><paragraph-text type="body">What is classified?</paragraph-text><list><list-item><paragraph-text type="body">Classified are the concrete, well-defined organic pharmaceutically active compounds disclosed in the claims and/or in the examples. In the absence of specific compounds, generic formulae (Markush formulae) are to be classified.</paragraph-text></list-item><list-item><paragraph-text type="body">In principle all specific compounds mentioned in the claims are classified. However, when there are too many compounds, as in the case of lengthy lists, classification is to be limited to a reasonable number of assignments, i.e. 10-15 compounds, covering e.g. the compounds tested, or the more significant compounds. Any generalisation to the next hierarchically higher level is to be avoided.</paragraph-text></list-item></list><paragraph-text type="body">How are compounds classified?</paragraph-text><paragraph-text type="body">When a compound is only and exclusively defined in the application by means of functional definitions, and no specific examples at all are provided, the main group <class-ref scheme="cpc">A61K31/00</class-ref> will be assigned provided it is clear that the intended compound is an organic compound falling under <class-ref scheme="cpc">A61K31/00</class-ref>. However, should the application refer to said functionally defined compounds as being e.g. inorganic compounds, peptides, proteins, antigens or antibodies, then <class-ref scheme="cpc">A61K31/00</class-ref> is not to be assigned.</paragraph-text><paragraph-text type="body">Combinations or mixtures of pharmaceutically active compounds are classified in the appropriate <class-ref scheme="cpc">A61K31/00</class-ref> subgroup followed by <class-ref scheme="cpc">A61K2300/00</class-ref> in the corresponding Combination-set for each active ingredient. This also applies to mixtures comprising novel compounds receiving <class-ref scheme="cpc">C07</class-ref> classification. However, the combination of an organic therapeutically active compound with a specified excipient (e.g. crospovidone and mannitol) is not to be considered as a mixture of two therapeutically active ingredients and therefore no Combination-set is to be created. In this case, the assignment of the appropriate symbol in <class-ref scheme="cpc">A61K47/00</class-ref> for the excipient(s) may be required.</paragraph-text><paragraph-text type="body">Salts or complexes of organic active compounds are classified according to the corresponding free compounds. However, salts or complexes formed between two or more organic active compounds are classified according to all compounds forming the salts or complexes followed by with <class-ref scheme="cpc">A61K2300/00</class-ref> to create the corresponding Combination-set (i.e. as a mixture of active organic compounds).</paragraph-text><paragraph-text type="body">According to the last place rule, salts formed between an organic active compound and heavy metals should be classified in <class-ref scheme="cpc">A61K33/24</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K33/38</class-ref> and not in subgroups <class-ref scheme="cpc">A61K31/28</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K31/32</class-ref>, <class-ref scheme="cpc">A61K31/555</class-ref> or <class-ref scheme="cpc">A61K31/714</class-ref>. This does not apply to complexes with heavy metals, as apparent from the <class-ref scheme="cpc">A61K31/00</class-ref> scheme, wherein the complexes hemin and hematin are classified in <class-ref scheme="cpc">A61K31/555</class-ref> and cyanocobalamin in <class-ref scheme="cpc">A61K31/714</class-ref>.</paragraph-text><paragraph-text type="body">If a subgroup title is the name of a specific compound or a group of specific compounds (e.g. <class-ref scheme="cpc">A61K31/203</class-ref> &quot;Retinoic acid&quot;, <class-ref scheme="cpc">A61K31/375</class-ref> &quot;Ascorbic acid&quot;, <class-ref scheme="cpc">A61K31/4415</class-ref> &quot;Pyridoxine&quot;) only exactly the compounds named are classified in this group (not derivatives thereof). For instance <class-ref scheme="cpc">A61K31/203</class-ref> covers retinoic acid, but not derivatives thereof. However, salts of retinoic acid or ascorbic acid still fall under the respective subgroup for the acid.</paragraph-text><paragraph-text type="body">On the other hand, when a compound is mentioned in the group title only as an example (&quot;e.g.&quot;), such as in <class-ref scheme="cpc">A61K31/5375</class-ref> &quot;1,4-oxazines, e.g. morpholine&quot;, the scope is not limited to this example.</paragraph-text><paragraph-text type="body">A fusion heteroatom, i.e. a heteroatom which is shared by two (or more) rings in a fused ring system is to be counted for all adjacent rings. Example: indolizine is correctly classified in <class-ref scheme="cpc">A61K31/437</class-ref>.</paragraph-text><paragraph-text type="body"><media id="media0.png" file-name="cpc-def-A61K-0000.png" type="png" preferred-width="2.56cm" preferred-height="1.58cm"/></paragraph-text><paragraph-text type="body">Unless otherwise specified (e.g. when distinguishing between non-condensed pyridines in <class-ref scheme="cpc">A61K31/44</class-ref> and non-condensed piperidines in <class-ref scheme="cpc">A61K31/445</class-ref>), a class definition using a ring name encompasses all hydrogenated, (partially) dehydrogenated, oxidized (i.e. carrying a keto-group) and/or substituted derivatives. Examples: <class-ref scheme="cpc">A61K31/404</class-ref> &quot;Indoles&quot; also covers fully hydrogenated derivatives, e.g. trandalopril</paragraph-text><paragraph-text type="body"><media id="media1.png" file-name="cpc-def-A61K-0001.png" type="png" preferred-width="5.02cm" preferred-height="3.17cm"/></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/4709</class-ref> &quot;Non condensed quinolines and containing further heterocyclic rings&quot; covers e.g. clinafloxacin</paragraph-text><paragraph-text type="body"><media id="media2.png" file-name="cpc-def-A61K-0002.png" type="png" preferred-width="5.02cm" preferred-height="2.65cm"/></paragraph-text></section-body></special-rules><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><paragraph-text type="body">Unless explicitly defined otherwise, all chemical terms have their universally accepted meaning as understood by a chemist, e.g. as defined in the IUPAC Gold Book.</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Alkyl</paragraph-text></table-column><table-column><paragraph-text type="body">does not encompass alkenyl, alkynyl or cycloalkyl</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Arylalkylamine (<class-ref scheme="cpc">A61K31/137</class-ref>)</paragraph-text></table-column><table-column><paragraph-text type="body"> - does not encompass arylcycloalkyl-amine; - does not encompass arylalkenyl-amine; - does not encompass N-aryl,N-alkylamine; - encompasses hydroxy-substituted, keto-substituted or halo-substituted arylalkylamine as well as bis-arylalkylamine.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Aryloxyalkylamine (<class-ref scheme="cpc">A61K31/138</class-ref>)</paragraph-text></table-column><table-column><paragraph-text type="body">indicates the sequence Ar-O-Alk-N- and as above, allows substitutions on the Ar and Alk portion.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Steroids</paragraph-text></table-column><table-column><paragraph-text type="body">see definition given in the Note following the title of <class-ref scheme="cpc">C07J</class-ref>.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Carbohydrates and sugars</paragraph-text></table-column><table-column><paragraph-text type="body">see definitions given in the Notefollowing the title of <class-ref scheme="cpc">C07H</class-ref>.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Condensed ring system</paragraph-text></table-column><table-column><paragraph-text type="body">Two rings are &quot;condensed&quot; if they share at least one ring member, i.e. not only ortho- and peri-, but also &quot;bridged&quot; and &quot;spiro&quot; are considered as condensed, as for example irbesartan, which is correctly classified in <class-ref scheme="cpc">A61K31/4184</class-ref><media id="media3.png" file-name="cpc-def-A61K-0003.png" type="png" preferred-width="5.0cm" preferred-height="2.48cm"/> A &quot;condensed ring system&quot; is a ring system in which all rings are condensed among themselves.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Attached to </paragraph-text></table-column><table-column><paragraph-text type="body">directly attached, not via a linker, thus for example cyclopentolate is to be classified in <class-ref scheme="cpc">A61K31/216</class-ref> and not <class-ref scheme="cpc">A61K31/235</class-ref><media id="media4.png" file-name="cpc-def-A61K-0004.png" type="png" preferred-width="3.58cm" preferred-height="1.78cm"/></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Bridged ring system </paragraph-text></table-column><table-column><paragraph-text type="body"> a system which contains interlocking rings, i.e. a ring system where some of the rings constitute a fused ring system with ortho- and/or peri-condensation, and the remaining rings are created by one or more bridges, e.g. amantadine and hexamine<media id="media5.png" file-name="cpc-def-A61K-0005.png" type="png" preferred-width="2.65cm" preferred-height="2.65cm"/><media id="media6.png" file-name="cpc-def-A61K-0006.png" type="png" preferred-width="2.65cm" preferred-height="2.65cm"/></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">&quot; Containing carbocyclic rings&quot;, or &quot;containing heterocyclic rings&quot;</paragraph-text></table-column><table-column><paragraph-text type="body">the plural form does not require the presence of more than one such ring, as for example in trilostane, which is correctly classified in <class-ref scheme="cpc">A61K31/58</class-ref><media id="media7.png" file-name="cpc-def-A61K-0007.png" type="png" preferred-width="4.15cm" preferred-height="2.37cm"/></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">&quot; Containing heterocyclic rings&quot; [(for compounds classified according to the presence of a specific carbocyclic ring (system)], or&quot;containing further heterocyclic rings&quot; [for compounds classified according to the presence of a specific heterocyclic ring (system)] </paragraph-text></table-column><table-column><paragraph-text type="body">does not require these further rings to be part of the specific ring (system) used as primary criterion for classification. Thus for example vecuronium bromide is to be classified in <class-ref scheme="cpc">A61K31/58</class-ref><media id="media8.png" file-name="cpc-def-A61K-0008.png" type="png" preferred-width="5.06cm" preferred-height="3.17cm"/></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Condensed with heterocyclic ring system</paragraph-text></table-column><table-column><paragraph-text type="body">allows the condensation to occur via the non-heterocyclic ring of the heterocyclic ring system. </paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">&quot; containing further heterocyclic rings&quot; and &quot;condensed with heterocyclic rings&quot; </paragraph-text></table-column><table-column><paragraph-text type="body">also cover compounds having two or more identical heterocyclic rings, e.g. the compounds wherein the further heterocyclic ring is the same as the primary ring.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">&quot;containing&quot; vs. &quot;having&quot;</paragraph-text></table-column><table-column><paragraph-text type="body">in the definitions for all heterocyclic compounds, the term &quot;having&quot; requires that the feature indicated in the subgroup is possessed by or is on the heterocycle, whereas the term &quot;containing&quot; relates to an additional feature which can be in any part of the molecule.</paragraph-text></table-column></table-row></table><paragraph-text type="body">Further details of the subgroups</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/137</class-ref></paragraph-text><paragraph-text type="body">The term &quot;Arylalkylamines&quot; in <class-ref scheme="cpc">A61K31/137</class-ref>:</paragraph-text><list><list-item><paragraph-text type="body">- encompasses bis-arylalkylamine; for example methadone</paragraph-text></list-item></list><paragraph-text type="body"><media id="media9.png" file-name="cpc-def-A61K-0009.png" type="png" preferred-width="3.1cm" preferred-height="3.35cm"/></paragraph-text><list><list-item><paragraph-text type="body">- encompasses hydroxy-substituted, keto-substituted or halo-substituted arylalkylamine; for example clenbuterol and bupropion</paragraph-text></list-item></list><paragraph-text type="body"><media id="media10.png" file-name="cpc-def-A61K-0010.png" type="png" preferred-width="4.71cm" preferred-height="2.34cm"/><media id="media11.png" file-name="cpc-def-A61K-0011.png" type="png" preferred-width="4.96cm" preferred-height="1.82cm"/></paragraph-text><paragraph-text type="body">are to be classified in <class-ref scheme="cpc">A61K31/137</class-ref>.</paragraph-text><paragraph-text type="body">However, if the keto-substitution is adjacent to the amino-group to give an amide, e.g. as in guanfacine</paragraph-text><paragraph-text type="body"><media id="media12.png" file-name="cpc-def-A61K-0012.png" type="png" preferred-width="4.27cm" preferred-height="1.87cm"/>,</paragraph-text><paragraph-text type="body">then the amido group would take precedence, thus the compound is not to be classified in <class-ref scheme="cpc">A61K31/137</class-ref> nor in <class-ref scheme="cpc">A61K31/155</class-ref> (guanidine), but in <class-ref scheme="cpc">A61K31/165</class-ref> according to the last place rule.</paragraph-text><list><list-item><paragraph-text type="body">- does not encompass arylcycloalkylamine;</paragraph-text></list-item></list><paragraph-text type="body">for example ketamine and tranylcypromine</paragraph-text><paragraph-text type="body"><media id="media13.png" file-name="cpc-def-A61K-0013.png" type="png" preferred-width="3.45cm" preferred-height="1.89cm"/><media id="media14.png" file-name="cpc-def-A61K-0014.png" type="png" preferred-width="3.76cm" preferred-height="1.65cm"/></paragraph-text><paragraph-text type="body">are to be classified in <class-ref scheme="cpc">A61K31/135</class-ref> not in <class-ref scheme="cpc">A61K31/137</class-ref>.</paragraph-text><list><list-item><paragraph-text type="body">- does not encompass arylalkenylamine; for example notriptyline</paragraph-text></list-item></list><paragraph-text type="body"><media id="media15.png" file-name="cpc-def-A61K-0015.png" type="png" preferred-width="4.08cm" preferred-height="2.48cm"/></paragraph-text><paragraph-text type="body">is to be classified in <class-ref scheme="cpc">A61K31/135</class-ref> not in <class-ref scheme="cpc">A61K31/137</class-ref>.</paragraph-text><paragraph-text type="body">does not encompass N-aryl,N-alkylamine; for example aprindine</paragraph-text><paragraph-text type="body"><media id="media16.png" file-name="cpc-def-A61K-0016.png" type="png" preferred-width="5.35cm" preferred-height="2.12cm"/></paragraph-text><paragraph-text type="body">is to be classified in <class-ref scheme="cpc">A61K31/136</class-ref> not in <class-ref scheme="cpc">A61K31/137</class-ref>.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/198</class-ref></paragraph-text><paragraph-text type="body">This subgroup also encompasses amino acid derivatives such as e.g. carbidopa, which is seen as an N-amino-substituted amino acid.</paragraph-text><paragraph-text type="body"><media id="media17.png" file-name="cpc-def-A61K-0017.png" type="png" preferred-width="3.98cm" preferred-height="2.17cm"/></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/33</class-ref></paragraph-text><paragraph-text type="body">Heterocyclic compounds having e.g. &quot;sulfur as a ring heteroatom&quot; and &quot;having five-membered rings&quot; (<class-ref scheme="cpc">A61K31/381</class-ref>), means that the sulfur containing ring must be a five-membered one. For example zileuton, which contains a carbocyclic six-membered ring, is to be classified in <class-ref scheme="cpc">A61K31/381</class-ref> and not in <class-ref scheme="cpc">A61K31/382</class-ref>.</paragraph-text><paragraph-text type="body"><media id="media18.png" file-name="cpc-def-A61K-0018.png" type="png" preferred-width="4.11cm" preferred-height="1.61cm"/></paragraph-text><paragraph-text type="body">The same applies to all subclasses relating to heterocyclic compounds.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/48</class-ref></paragraph-text><paragraph-text type="body">Ergoline derivatives include a class of compounds characterized by the ring system</paragraph-text><paragraph-text type="body"><media id="media19.png" file-name="cpc-def-A61K-0019.png" type="png" preferred-width="2.07cm" preferred-height="2.64cm"/></paragraph-text><paragraph-text type="body">As explicitly mentioned in the scheme, the subclass for the ergoline ring system <class-ref scheme="cpc">A61K31/48</class-ref> takes precedence over <class-ref scheme="cpc">A61K31/495</class-ref> &quot;six membered rings with two nitrogen atoms as the only ring heteroatoms&quot; and corresponding subclasses. For example bromocriptine is to be classified in <class-ref scheme="cpc">A61K31/48</class-ref> and not in <class-ref scheme="cpc">A61K31/495</class-ref>.</paragraph-text><paragraph-text type="body"><media id="media20.png" file-name="cpc-def-A61K-0020.png" type="png" preferred-width="5.1cm" preferred-height="3.29cm"/></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/485</class-ref></paragraph-text><paragraph-text type="body">Morphinan derivatives include a class of compounds characterized by the ring system below (with or without an oxygen bridge)</paragraph-text><paragraph-text type="body"><media id="media21.png" file-name="cpc-def-A61K-0021.png" type="png" preferred-width="2.49cm" preferred-height="2.67cm"/></paragraph-text><paragraph-text type="body">e.g. butorphanol</paragraph-text><paragraph-text type="body"><media id="media22.png" file-name="cpc-def-A61K-0022.png" type="png" preferred-width="5.01cm" preferred-height="3.62cm"/>;</paragraph-text><paragraph-text type="body">; dihydrocodeine</paragraph-text><paragraph-text type="body"><media id="media23.png" file-name="cpc-def-A61K-0023.png" type="png" preferred-width="5.12cm" preferred-height="3.69cm"/></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/49</class-ref></paragraph-text><paragraph-text type="body">Chinconane derivatives are characterized by the ring system</paragraph-text><paragraph-text type="body"><media id="media24.png" file-name="cpc-def-A61K-0024.png" type="png" preferred-width="2.48cm" preferred-height="3.15cm"/></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/495</class-ref></paragraph-text><paragraph-text type="body">This subgroup also covers compounds having six-membered rings with four nitrogens as the only ring heteroatoms, i.e. tetrazine and tetrazine-containing compounds. For example temozolomide is to be classified in this subgroup.</paragraph-text><paragraph-text type="body"><media id="media25.png" file-name="cpc-def-A61K-0025.png" type="png" preferred-width="4.32cm" preferred-height="2.63cm"/></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/515</class-ref></paragraph-text><paragraph-text type="body">Barbituric acid derivatives share the structure below</paragraph-text><paragraph-text type="body"><media id="media26.png" file-name="cpc-def-A61K-0026.png" type="png" preferred-width="2.88cm" preferred-height="2.47cm"/></paragraph-text><paragraph-text type="body">Therefore, primidone is not to be considered a barbituric acid derivative since it is missing a carbonyl group (primidone is to be correctly classified in <class-ref scheme="cpc">A61K31/513</class-ref>).</paragraph-text><paragraph-text type="body"><media id="media27.png" file-name="cpc-def-A61K-0027.png" type="png" preferred-width="3.68cm" preferred-height="2.05cm"/></paragraph-text><paragraph-text type="body">Moreover, the presence of the core structure of barbituric acid may not be sufficient per se in order to identify a compound as a barbituric acid derivative. In this subgroup, the classifier will not only take into account the extent of modification but also whether the compound shares the same pharmacological effect of barbituric acid, i.e. any of sedative, anaesthetic, anxolytic, hypnotic and anticonvulsant effect.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/555</class-ref></paragraph-text><paragraph-text type="body">In addition to the examples explicitly referred to in the scheme, other examples e.g. carboplatin, oxaliplatin and sodium stibogluconate are also to be classified here (not in <class-ref scheme="cpc">A61K33/00</class-ref> nor in <class-ref scheme="cpc">A61K31/282</class-ref> or <class-ref scheme="cpc">A61K31/29</class-ref>), since they are heterocyclic active compounds forming a complex with a heavy metal.</paragraph-text><paragraph-text type="body"><media id="media28.png" file-name="cpc-def-A61K-0028.png" type="png" preferred-width="4.71cm" preferred-height="2.47cm"/><media id="media29.png" file-name="cpc-def-A61K-0029.png" type="png" preferred-width="4.63cm" preferred-height="2.37cm"/><media id="media30.png" file-name="cpc-def-A61K-0030.png" type="png" preferred-width="5.08cm" preferred-height="3.57cm"/></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/56</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K31/585</class-ref></paragraph-text><paragraph-text type="body">The compounds in these subgroups have the following skeleton</paragraph-text><paragraph-text type="body"><media id="media31.png" file-name="cpc-def-A61K-0031.png" type="png" preferred-width="3.77cm" preferred-height="2.44cm"/></paragraph-text><paragraph-text type="body">and are further subdivided according to the structure of</paragraph-text><paragraph-text type="body">estranes</paragraph-text><paragraph-text type="body"><media id="media32.png" file-name="cpc-def-A61K-0032.png" type="png" preferred-width="3.77cm" preferred-height="3.13cm"/></paragraph-text><paragraph-text type="body">gonanes</paragraph-text><paragraph-text type="body"><media id="media33.png" file-name="cpc-def-A61K-0033.png" type="png" preferred-width="3.96cm" preferred-height="2.94cm"/></paragraph-text><paragraph-text type="body">androstanes</paragraph-text><paragraph-text type="body"><media id="media34.png" file-name="cpc-def-A61K-0034.png" type="png" preferred-width="4.11cm" preferred-height="3.22cm"/></paragraph-text><paragraph-text type="body">pregnanes</paragraph-text><paragraph-text type="body"><media id="media35.png" file-name="cpc-def-A61K-0035.png" type="png" preferred-width="4.11cm" preferred-height="3.59cm"/></paragraph-text><paragraph-text type="body">cholanes</paragraph-text><paragraph-text type="body"><media id="media36.png" file-name="cpc-def-A61K-0036.png" type="png" preferred-width="5.25cm" preferred-height="3.72cm"/></paragraph-text><paragraph-text type="body">as well as according to the presence or absence of substitutions in position 10, 13, 17 and/or 21.</paragraph-text><paragraph-text type="body">In subgroups <class-ref scheme="cpc">A61K31/58</class-ref> and <class-ref scheme="cpc">A61K31/585</class-ref>, the additional ring can be isolated or condensed to the cyclopentanoperhydrophenantrene ring system.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/59</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K31/593</class-ref></paragraph-text><paragraph-text type="body">The compounds in these subgroups have the following skeleton</paragraph-text><paragraph-text type="body"><media id="media37.png" file-name="cpc-def-A61K-0037.png" type="png" preferred-width="2.76cm" preferred-height="4.32cm"/></paragraph-text><paragraph-text type="body">the difference between 9,10-secoergostane derivatives and 9,10-secocholestane derivatives being a double bond in the side chain.</paragraph-text><paragraph-text type="body">ergocalciferol</paragraph-text><paragraph-text type="body"><media id="media38.png" file-name="cpc-def-A61K-0038.png" type="png" preferred-width="6.16cm" preferred-height="4.02cm"/></paragraph-text><paragraph-text type="body">cholecalciferol</paragraph-text><paragraph-text type="body"><media id="media39.png" file-name="cpc-def-A61K-0039.png" type="png" preferred-width="4.84cm" preferred-height="3.47cm"/></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/60</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K31/625</class-ref></paragraph-text><paragraph-text type="body">These subgroups cover salicylic acid and derivatives thereof.</paragraph-text><paragraph-text type="body">The presence of the core structure of the 2-hydroxybenzoic acid, i.e.</paragraph-text><paragraph-text type="body"><media id="media40.png" file-name="cpc-def-A61K-0040.png" type="png" preferred-width="2.82cm" preferred-height="2.28cm"/></paragraph-text><paragraph-text type="body">may not be sufficient per se in order to identify a compound as a salicylic acid derivative. In this subgroup, the classifier will not only take into account the extent of modification but also whether the compound shares the same pharmacological effect of salicylic acid, i.e. any of analgesic, antipyretic and antiinflammatory effect. Derivatives with a substitution on the benzene ring are also included in this group (e.g. diflunisal).</paragraph-text><paragraph-text type="body">For instance, certain compounds are not to be considered salicylic acid derivative due to the extent of the modification and because they do not possess the pharmacological profile of salicylates, e.g. for example the compounds labetalol (<class-ref scheme="cpc">A61K31/166</class-ref>), cisapride (<class-ref scheme="cpc">A61K31/4468</class-ref>), flecainide (<class-ref scheme="cpc">A61K31/4458</class-ref>), metoclopramide (<class-ref scheme="cpc">A61K31/166</class-ref>) and remoxipride (<class-ref scheme="cpc">A61K31/40</class-ref>).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/65</class-ref></paragraph-text><paragraph-text type="body">The compounds in this subgroup share the core structure of tetracycline</paragraph-text><paragraph-text type="body"><media id="media41.png" file-name="cpc-def-A61K-0041.png" type="png" preferred-width="5.67cm" preferred-height="3.18cm"/></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/7105</class-ref></paragraph-text><paragraph-text type="body">This subgroup also includes non-modified miRNA and snRNA; shRNA and ribozymes.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K31/713</class-ref></paragraph-text><paragraph-text type="body">This subgroup also includes siRNA, pRNA, sd-rxRNA, recombinant nucleic acids, as well as modified miRNA and snRNA.</paragraph-text><paragraph-text type="body">Antisense nucleotides and non-coding nucleic acids are classified in <class-ref scheme="cpc">C12N15/00</class-ref>.</paragraph-text></section-body></glossary-of-terms></definition-item>
<definition-item date-revised="2018-01-01"><classification-symbol scheme="cpc">A61K33/00</classification-symbol><definition-title>Medicinal preparations containing inorganic active ingredients</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Medicinal preparations containing inorganic active ingredients either alone or in a mixture with other active ingredients. Organic active compounds forming salts or complexes with heavy metals are also classified in <class-ref scheme="cpc">A61K33/00</class-ref> according to the last place rule, unless explicit reference to the contrary is made in the <class-ref scheme="cpc">A61K31/00</class-ref> scheme (see below)</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Empty galenic formulations, i.e. only comprising carriers, additives, excipients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/00</class-ref>, <class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Hemin and hematin</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/555</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Cyanocobalamin</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/714</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Biomaterials</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Disinfecting or sterilising contact lenses</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L12/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">For bandages, dressings or absorbent pads</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L15/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Surgical sutures</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L17/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Surgical adhesives or cements</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L24/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">For wound dressings, bandages, also liquid, gel, powder</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L26/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">For (coating of) grafts, prostheses</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L27/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">For other surgical articles, e.g. stents, embolization</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Detergent compositions</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C11D</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N5/00</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Pharmaceuticals </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Organic active ingredients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Active ingredients of undetermined constitution (i.e. natural products) </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K35/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Active ingredients from algae, lichens, fungi or plants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K36/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Peptides, proteins</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K38/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Antigens or antibodies, vaccines, adjuvants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Homeopathy, thermotherapy, photodynamic therapy, photoactivable drugs</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Mixtures of active ingredients without chemical characterisation</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K45/06</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Characterized by non-active ingredients e.g. carriers, inert additives, excipients...</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Conjugates; targeted drugs</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/50</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Gene therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K48/00</class-ref></paragraph-text></table-column></table-row></table><paragraph-text type="subheading">Diagnosis</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Testing in vivo, e.g. screening, contrast agents, ultrasound</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Radioactive substances</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K51/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Medicine/pharmacy - mechanical aspects</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F</class-ref>, <class-ref scheme="cpc">A61M</class-ref>, <class-ref scheme="cpc">A61N</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Stents</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F2/07</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Contraceptive devices </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F6/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Ophthalmic implants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F9/0017</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Bandages, dressings, absorbent pads </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F13/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Making transdermal patches</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F2013/0296</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Tampons (also medicated)</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F13/20</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Electrotherapy </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N1/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Iontophoresis</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N1/30</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Magnetotherapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N2/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">In vitro diagnosis</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G01N</class-ref></paragraph-text></table-column></table-row></table><paragraph-text type="subheading">Other medical</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Dentistry</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K6/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Sterilization methods</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L2/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Contact lenses</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G02C7/04</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Healthcare informatics</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G16H</class-ref></paragraph-text></table-column></table-row></table><paragraph-text type="subheading"> Other human necessities</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Cosmetics</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Biocides, pest repellants or attractants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A01N</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Animal feeding-stuffs</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23K10/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Food or functional food i.e food containing ingredients performing an additional function e.g. disease prevention (neutraceuticals)</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23L</class-ref></paragraph-text></table-column></table-row></table><paragraph-text type="subheading">General chemistry</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Quaternary ammonium compounds</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07C211/62</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Phosphatides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07F9/10</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dendrimers</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08G83/002</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Macromolecular gels</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08J3/075</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">In this group classification is according to the last place priority rule.</paragraph-text><paragraph-text type="body">In this group no distinction is made between Invention and Additional information.</paragraph-text><paragraph-text type="body">In other words all information, whether it be invention or additional, is classified in as far as it relates to material which the classifier considers likely to be of importance for future reference. Trivial or general state-of-the-art disclosure is not classified.</paragraph-text><paragraph-text type="body">Therapeutic use: an <class-ref scheme="cpc">A61K33/00</class-ref> classification symbol is given only if the inorganic ingredient has a physiological, pharmacological or biological effect.</paragraph-text><paragraph-text type="body">Combinations/mixtures: Give a classification symbol followed by <class-ref scheme="cpc">A61K2300/00</class-ref> for each active ingredient in the mixture. For each mixture containing at least one active ingredient without chemical characterisation (e.g. functional feature), <class-ref scheme="cpc">A61K45/06</class-ref> is additionally to be given.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2018-01-01"><classification-symbol scheme="cpc">A61K35/00</classification-symbol><definition-title>Medicinal preparations containing materials or reaction products thereof with undetermined constitution</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Medicinal preparations containing various tissues, cells, organisms, materials or reaction products thereof, also with undetermined constitution, as well as their first or further medical use.</paragraph-text><paragraph-text type="body">An <class-ref scheme="cpc">A61K35/00</class-ref> symbol is given only if the therapeutic effect is clearly attributed to the &quot;active substance&quot; of the medicinal preparation, and is an essential part of the disclosure.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">The main group <class-ref scheme="cpc">A61K35/00</class-ref> may overlap with many other subclasses or main groups relating to medicinal preparations, or preparations comprising the tissues, cells organisms or materials, where the effect is neither mainly nor only pharmaceutical. The most relevant areas are genetically modified cells, viral or cellular vaccines, and antibodies.</paragraph-text><list><list-item><paragraph-text type="body">Documents relating to microorganisms and cells used for vaccination where there is no other therapeutic use or therapeutic effect are not classified in <class-ref scheme="cpc">A61K35/00</class-ref> class.</paragraph-text></list-item><list-item><paragraph-text type="body">Genetically modified cells and documents relating to gene therapy: </paragraph-text></list-item></list><paragraph-text type="body">Gene therapy: <class-ref scheme="cpc">A61K48/00</class-ref>. Genetically modified cells: <class-ref scheme="cpc">C12N5/10</class-ref>.</paragraph-text><list><list-item><paragraph-text type="body">Isolated cells: If cells are used as hosts or vectors (no therapeutic activity), no <class-ref scheme="cpc">A61K35/00</class-ref> class is given. Cells that are transplanted after a culturing step are classified in <class-ref scheme="cpc">A61K35/00</class-ref> and <class-ref scheme="cpc">C12N5/00</class-ref>.</paragraph-text></list-item><list-item><paragraph-text type="body">Lymphocytes: Overlap with vaccines: Compositions comprising cells of the myeloid line and lymphocytes, when activated by a specific antigen (for example antibodies), are classified in <class-ref scheme="cpc">A61K39/00</class-ref>, since this represents a vaccine. However, therapeutic combinations of antibodies (or fragments thereof) and blood derived cells that have no vaccine effect are classified in <class-ref scheme="cpc">A61K35/00</class-ref>, <class-ref scheme="cpc">A61K39/395</class-ref> and <class-ref scheme="cpc">C07K16/00</class-ref> because this is a combination of a vaccine and a therapeutically used cell.</paragraph-text></list-item></list><paragraph-text type="body">Example of where an <class-ref scheme="cpc">A61K35/17</class-ref> class is given in regard to lymphocytes: A method of enhancing normal healing in individuals comprising administering to a site in need thereof an effective amount of autologous B cells immediately before, at the time of or immediately after tissue injury.</paragraph-text><list><list-item><paragraph-text type="body">Viruses: Pharmaceutical compositions comprising a virus (and its medical use) are classified in <class-ref scheme="cpc">A61K35/00</class-ref> if it is not a viral vaccine. If the therapeutic effect is clearly and exclusively a vaccine effect, no <class-ref scheme="cpc">A61K35/00</class-ref> class is given.</paragraph-text></list-item></list><paragraph-text type="body">Documents relating to viruses per se (without medical use) are classified in <class-ref scheme="cpc">C12N7/00</class-ref>; viral proteins per se <class-ref scheme="cpc">C07K14/005</class-ref>; use of virus as a vector <class-ref scheme="cpc">C12N15/86</class-ref>; use of virus or part thereof as vaccine <class-ref scheme="cpc">A61K39/12</class-ref>; therapeutic use of a viral protein <class-ref scheme="cpc">A61K38/16</class-ref>.</paragraph-text><paragraph-text type="body">Preparations comprising a modified virus are classified in <class-ref scheme="cpc">C12N7/00</class-ref>; the ICO code <class-ref scheme="cpc">A61K35/13</class-ref> is given if a therapeutic activity (not vaccine) is suggested. If a therapeutic activity (not vaccine) is disclosed for the modified virus, it is also classified in <class-ref scheme="cpc">A61K35/00</class-ref>.</paragraph-text><list><list-item><paragraph-text type="body">Bacteria: If bacteria are claimed per se, they are classified in <class-ref scheme="cpc">C12N1/00</class-ref> and the CPC symbol <class-ref scheme="cpc">A61K2035/11</class-ref> is given.</paragraph-text></list-item><list-item><paragraph-text type="body">Toxins of bacteria, snakes, scorpions, fish etc: documents related to protein toxins of these animals only are classified in <class-ref scheme="cpc">A61K38/00</class-ref>. No <class-ref scheme="cpc">A61K35/00</class-ref> class is given unless the animal or part thereof is also part of the therapeutic composition or use.</paragraph-text></list-item><list-item><paragraph-text type="body">When the composition comprises a special galenic form, it is also classified in <class-ref scheme="cpc">A61K9/00</class-ref>.</paragraph-text></list-item><list-item><paragraph-text type="body">Combinations with other substances: are classified in all appropriate subgroups. For example, combination of lactobacillus and a protein: give <class-ref scheme="cpc">A61K35/74</class-ref> symbol and also classify in <class-ref scheme="cpc">A61K38/00</class-ref>.</paragraph-text></list-item><list-item><paragraph-text type="body">For each mixture containing at least one ingredient without chemical characterization (e.g. functional feature), <class-ref scheme="cpc">A61K45/06</class-ref> is to be given.</paragraph-text></list-item><list-item><paragraph-text type="body">When a compound is only and exclusively defined in the application by means of a functional definition, and no specific examples at all are provided, and it is unclear whether the functionally defined compound would be a compound according to any of <class-ref scheme="cpc">A61K31/00</class-ref>, <class-ref scheme="cpc">A61K33/00</class-ref>, <class-ref scheme="cpc">A61K35/00</class-ref>, <class-ref scheme="cpc">A61K36/00</class-ref>, <class-ref scheme="cpc">A61K38/00</class-ref> or <class-ref scheme="cpc">A61K39/00</class-ref>, the main group <class-ref scheme="cpc">A61K45/00</class-ref> is to be assigned.</paragraph-text></list-item></list></section-body></relationship><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Medical use of chemical compounds </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Plants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K36/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Algae, Fungi, e.g. yeast</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K36/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medical use of peptides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K38/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Microorganisms used for vaccination</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Vaccines</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref>; <class-ref scheme="cpc">C12N7/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Viruses per se, purification; virus vaccines</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref>; <class-ref scheme="cpc">C12N7/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations obtained by treating materials with wave energy or particle radiation</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Compound defined by means of a functional definition </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K45/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Drug delivery systems</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Transgenic animals</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A01K67/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Food</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23L5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Orthopaedic methods for treatment for bones or joints</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Bandages, dressings, surgical articles</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L15/00</class-ref>; <class-ref scheme="cpc">A61L27/00</class-ref>; <class-ref scheme="cpc">A61L29/00</class-ref>, <class-ref scheme="cpc">A61L31/00</class-ref>; <class-ref scheme="cpc">A61L33/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Chemical compounds as such</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C01</class-ref>- <class-ref scheme="cpc">C09</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Bacteria claimed per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N1/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Genetic engineering of cells, cell lines per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Screening methods</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G01N33/00</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><paragraph-text type="body"> Furthermore, a class in addition to a <class-ref scheme="cpc">A61K35/00</class-ref> from the list below might be necessary depending on the subject-matter to be classified:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Cosmetic preparations </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparation characterised by physical, galenic form</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing inorganic active ingredients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K33/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medical use of peptides originating from organisms falling under <class-ref scheme="cpc">A61K35/00</class-ref></paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K38/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Food or &quot;functional&quot; food, e.g. probiotic bacterial where a medical use and a food is claimed. </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23L5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Therapeutic activity of chemical compounds </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61P</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Modified cells with medical use</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Modified virus with medical use (not vaccine)</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N7/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><list><list-item><paragraph-text type="body">Relevant subject-matter that is exemplified, but not claimed, should also be classified. For very long, exhaustive lists of actives claimed for a therapeutic use, if it appears from the dependent claims/description/examples that only few actives are preferred/well described, only these substances will be classified.</paragraph-text></list-item></list><paragraph-text type="body">The last place rule does not apply in <class-ref scheme="cpc">A61K35/00</class-ref>. Each component of a pharmaceutical composition (if an active ingredient and not a vaccine) that is falling under the definitions of <class-ref scheme="cpc">A61K35/00</class-ref> is classified</paragraph-text><list><list-item><paragraph-text type="body">Mixtures/Combinations comprising several actives classified in <class-ref scheme="cpc">A61K35/00</class-ref>:</paragraph-text></list-item></list><paragraph-text type="body">A classification symbol is given for each active ingredient in the mixture followed by <class-ref scheme="cpc">A61K2300/00</class-ref> to create the corresponding Combination-set.</paragraph-text><paragraph-text type="body">For example, a composition comprising lactobacilli and propolis extract will be allocated the symbols <class-ref scheme="cpc">A61K35/74</class-ref> and <class-ref scheme="cpc">A61K35/644</class-ref>, each followed by the symbol <class-ref scheme="cpc">A61K2300/00</class-ref>.</paragraph-text><paragraph-text type="body">For each mixture containing at least one ingredient without chemical characterisation (e.g. functional feature), <class-ref scheme="cpc">A61K45/06</class-ref> is to be given.</paragraph-text><list><list-item><paragraph-text type="body">Compositions comprising cells or non-embryonic stem cells: if the cells are characterized, give the symbol of the corresponding tissue, i.e. Pancreatic stem cells are classified in <class-ref scheme="cpc">A61K35/39</class-ref>, Pancreas. The most relevant types of stem cells relating to different tissues are specifically indicated by the respective symbols.</paragraph-text></list-item><list-item><paragraph-text type="body">Isolated cells that are transplanted without a culturing step, in order to obtain a therapeutic effect are classified in <class-ref scheme="cpc">A61K35/12</class-ref> if the cell type is not specified. Otherwise classify under the respective tissue.</paragraph-text></list-item><list-item><paragraph-text type="body">Mesenchymal stem cells are always classified in <class-ref scheme="cpc">A61K35/28</class-ref>, irrespective of the origin.</paragraph-text></list-item><list-item><paragraph-text type="body">Important aspects of the invention mentioned only in the description deserve classification as well.</paragraph-text></list-item></list></section-body></special-rules><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Blue algae</paragraph-text></table-column><table-column><paragraph-text type="body"> cyanobacteriae</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Bacteriophage</paragraph-text></table-column><table-column><paragraph-text type="body"> virus</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Protozoa</paragraph-text></table-column><table-column><paragraph-text type="body"> single cell animal-like eukaryotic organisms, e.g. flagellates (Giardia), amoeboids, sporozoans (Plasmodium)</paragraph-text></table-column></table-row></table><paragraph-text type="body">Indexing codes used in <class-ref scheme="cpc">A61K35/00</class-ref>:</paragraph-text><paragraph-text type="body">For additional information purposes:</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K35/00</class-ref> Medicinal preparations comprising living biological materials, e.g. virus, cells, tissue, organs</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K2035/11</class-ref> Medicinal preparations comprising living procariotic cells</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K2035/115</class-ref>: Probiotics (used in cases of nutritional compositions with probiotics, where a medical use is not clearly shown but implied, or where the probiotic bacteria are not disclosed and a specific <class-ref scheme="cpc">A61K35/74</class-ref> class cannot be assigned. </paragraph-text><paragraph-text type="body">With respect to materials from mammals:</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K35/12</class-ref> Medicinal preparations comprising living eukaryotic cells</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K2035/122</class-ref>..for inducing tolerance or suppression of immune responses</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K2035/124</class-ref>.. the cells being haematopoietic, bone marrow derived or blood cells</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K2035/126</class-ref>.. immunoprotecting barriers, e.g. jackets, diffusion chambers</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K2035/128</class-ref>&#8230; capsules, e.g. microcapsules</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K35/13</class-ref> Medicinal preparations comprising living viruses</paragraph-text></section-body></glossary-of-terms></definition-item>
<definition-item date-revised="2016-08-01"><classification-symbol scheme="cpc">A61K36/00</classification-symbol><definition-title>Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines {(antigens from pollen <class-ref scheme="cpc">A61K39/36</class-ref>)}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Medicinal preparations containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines, also of undetermined constitution.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K36/00</class-ref> is given only if a therapeutic effect is clearly attributed to the &quot;active substance&quot; of the medicinal preparation, and is an essential part of the disclosure. In particular:</paragraph-text><paragraph-text type="body">Medicinal formulations or compositions per se containing therapeutically active material from algae, lichens, fungi or plants</paragraph-text><paragraph-text type="body">Material from algae, lichens, fungi or plants for use in any first or further medical application</paragraph-text><paragraph-text type="body">Use of a material from algae, lichens, fungi or plants for the manufacture of a medicament for the treatment of a pathological condition</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Purified active components: if the active component has been isolated from material from algae, lichens, fungi or plants and the chemical structure is well-defined and can be classified under <class-ref scheme="cpc">A61K31/00</class-ref>, a class under <class-ref scheme="cpc">A61K36/00</class-ref> together with the appropriate <class-ref scheme="cpc">A61K31/00</class-ref> class is given.</paragraph-text><paragraph-text type="body">Purified proteins, peptides or lectins: documents related to isolated plant peptides or proteins are classified in <class-ref scheme="cpc">A61K38/00</class-ref>. An additional <class-ref scheme="cpc">A61K36/00</class-ref> class is given if the source of the purified compound can be clearly attributed to a specific material from algae, lichens, fungi or plants.</paragraph-text><paragraph-text type="body">Claims to a new galenic formulation of a known material for use in therapy are classified in <class-ref scheme="cpc">A61K9/00</class-ref>. An additional <class-ref scheme="cpc">A61K36/00</class-ref> class is given for the material only in case of a specific material from algae, lichens, fungi or plants. No <class-ref scheme="cpc">A61K36/00</class-ref> class is given if only unspecific material (for example &quot;plant extracts&quot;, &quot;essential oil&quot;) is mentioned.</paragraph-text><paragraph-text type="body">Cosmetic preparations containing material from algae, lichens, fungi or plants are classified in <class-ref scheme="cpc">A61K8/00</class-ref>. An additional <class-ref scheme="cpc">A61K36/00</class-ref> class is given for the material only in case of a therapeutic effect.</paragraph-text><paragraph-text type="body">Food containing material from algae, lichens, fungi or plants is classified in <class-ref scheme="cpc">A23L5/00</class-ref>. An additional <class-ref scheme="cpc">A61K36/00</class-ref> class is given for the material only in case of a therapeutic effect (functional food).</paragraph-text><paragraph-text type="body">Bacteria: If bacteria are claimed per se, they are classified in <class-ref scheme="cpc">C12N1/00</class-ref>, medicinal preparations with bacteria are classified in <class-ref scheme="cpc">A61K35/74</class-ref>.</paragraph-text><paragraph-text type="body">Blue algae (Spirulina) are cyanobacteriae and classified in <class-ref scheme="cpc">A61K35/74</class-ref>.</paragraph-text><paragraph-text type="body">Honey, beeswax, propolis: <class-ref scheme="cpc">A61K35/644</class-ref></paragraph-text><paragraph-text type="body">Genetically modified cells: Compositions comprising genetically modified cells are classified in <class-ref scheme="cpc">A61K48/00</class-ref> (Gene therapy), or <class-ref scheme="cpc">C12N5/10</class-ref> (Genetically modified cells).</paragraph-text><paragraph-text type="body">Separation procedures as such, not relating to a medicinal preparation or a therapeutic use, are classified in <class-ref scheme="cpc">B01D</class-ref>.</paragraph-text><list><list-item><paragraph-text type="body">When a compound is only and exclusively defined in the application by means of a functional definition, and no specific examples at all are provided, and it is unclear whether the functionally defined compound would be a compound according to any of <class-ref scheme="cpc">A61K31/00</class-ref>, <class-ref scheme="cpc">A61K33/00</class-ref>, <class-ref scheme="cpc">A61K35/00</class-ref>, <class-ref scheme="cpc">A61K36/00</class-ref>, <class-ref scheme="cpc">A61K38/00</class-ref> or <class-ref scheme="cpc">A61K39/00</class-ref>, the main group <class-ref scheme="cpc">A61K45/00</class-ref> is to be assigned.</paragraph-text></list-item></list></section-body></relationship><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Cosmetic preparations containing material from algae, lichens, fungi or plants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medical use of chemical compounds </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing material of undetermined constitution</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K35/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medical use of peptides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K38/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Microorganisms used for vaccination</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Vaccines</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref>; <class-ref scheme="cpc">C12N7/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Viruses per se, purification; virus vaccines</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref>; <class-ref scheme="cpc">C12N7/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations obtained by treating materials with wave energy or particle radiation</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Compound defined by means of a functional definition </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K45/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Drug delivery systems</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Food</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23L5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Bandages, dressings, absorbent pads containing material from algae, lichens, fungi or plants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L15/40</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Separation or extraction processes as such</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">B01D</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Chemical compounds as such</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C01</class-ref>- <class-ref scheme="cpc">C09</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Bacteria claimed per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N1/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Genetic engineering of cells, cell lines per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Screening methods</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G01N33/00</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Cosmetic preparations e.g. plant material or extracts where a medical and a cosmetic use is claimed</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparation characterised by physical, galenic form</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing inorganic active ingredients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K33/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medical use of peptides originating from organisms falling under <class-ref scheme="cpc">A61K36/00</class-ref></paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K38/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Food or &quot;functional&quot; food, e.g. plant material or extracts where a medical use and a food is claimed</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23L5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Modified cells with medical use</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N5/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Each specific active component is classified according to its systematic name in <class-ref scheme="cpc">A61K36/00</class-ref>. The last place rule does not apply.</paragraph-text><paragraph-text type="body">A class within this group is only given for the use of specific compounds, i.e. those present in the claims or exemplified in the description, and therapeutically active agents (which is not always the case, e.g. essential oils used as perfume or taste masking compounds).</paragraph-text><paragraph-text type="body">Relevant subject-matter that is exemplified, but not claimed, should also be classified. Important aspects of the invention mentioned only in the description deserve a class as well.</paragraph-text><paragraph-text type="body">Classification should be restricted to the relevant or essential part of the disclosure. For very long lists (10 and more) of material claimed for a therapeutic use, and if it appears from the dependent claims/description/examples that only few plants are preferred/well described, classification should be limited to the compounds tested, or the more significant compounds.</paragraph-text><paragraph-text type="body">A general concept (e.g. &quot;Compound X for use in treating disease Y, wherein X is a plant, an antibody or a chemical compound&quot; with no specific compounds given) does not get any <class-ref scheme="cpc">A61K36/00</class-ref> class.</paragraph-text><paragraph-text type="body">The medicinal preparation can also be in the form of a product by process claim, reflecting a specific extraction process.</paragraph-text><paragraph-text type="body">If the extraction process is claimed and considered relevant or an essential part of the disclosure, at least one additional Indexing Code in <class-ref scheme="cpc">A61K2236/00</class-ref> is given.</paragraph-text><paragraph-text type="body">Combinations/mixtures: a Combination-set is generated having after &quot;,&quot; the symbol <class-ref scheme="cpc">A61K2300/00</class-ref> for each active ingredient in the mixture, for example (<class-ref scheme="cpc">A61K31/60</class-ref>, <class-ref scheme="cpc">A61K2300/00</class-ref>)</paragraph-text><paragraph-text type="body">For each mixture containing at least one ingredient without chemical characterisation (e.g. functional feature), <class-ref scheme="cpc">A61K45/06</class-ref> is to be given.</paragraph-text><paragraph-text type="body">For fermented preparations the Indexing Code <class-ref scheme="cpc">A61K2236/19</class-ref> is to be added:</paragraph-text><paragraph-text type="body">A medical preparation with red fermented rice will get <class-ref scheme="cpc">A61K36/899</class-ref> (rice), <class-ref scheme="cpc">A61K36/062</class-ref> (Monascus) and <class-ref scheme="cpc">A61K2236/19</class-ref> (fermentation process)</paragraph-text><paragraph-text type="body">Pollen (not further specified): <class-ref scheme="cpc">A61K36/00</class-ref></paragraph-text><paragraph-text type="body">Wood tar, sap or resin (not further specified): <class-ref scheme="cpc">A61K36/00</class-ref></paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K38/00</classification-symbol><definition-title>Medicinal preparations containing peptides  (peptides containing beta-lactam rings <class-ref scheme="cpc">A61K31/00</class-ref>; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, <class-ref scheme="cpc">A61K31/00</class-ref>; ergot alkaloids of the cyclic peptide type <class-ref scheme="cpc">A61K31/48</class-ref>; containing macromolecular compounds having statistically distributed amino acid units <class-ref scheme="cpc">A61K31/74</class-ref>; medicinal preparations containing antigens or antibodies <class-ref scheme="cpc">A61K39/00</class-ref>; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, <class-ref scheme="cpc">A61K47/00</class-ref>)</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Peptides, proteins or their fragments (from dipeptides onwards), or the corresponding nucleic acids encoding these peptides/proteins, when claimed for use in the therapy of humans or animals, i.e. when claimed as therapeutically active components.</paragraph-text><paragraph-text type="body">In particular:</paragraph-text><paragraph-text type="body">Medicinal formulations or compositions per se containing therapeutically active peptides or proteins.</paragraph-text><paragraph-text type="body">Peptides or proteins for use in any first or further medical applications.</paragraph-text><paragraph-text type="body">Use of a peptide or protein for the manufacture of a medicament for the treatment of a pathological condition.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Proteins or peptides claimed per se, are classified under the proper <class-ref scheme="cpc">C07K</class-ref> subgroup; within the same document, further claims to their use in therapy are given the additional information symbol <class-ref scheme="cpc">A61K38/00</class-ref>. An invention information classification should be given in <class-ref scheme="cpc">A61K38/00</class-ref>+ only for documents claiming the further medical use of proteins or peptides without claiming the proteins or peptides per se (Note: The <class-ref scheme="cpc">A61K38/00</class-ref> scheme is mostly (with exceptions) aligned with the <class-ref scheme="cpc">C07K2/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">C07K14/00</class-ref> schemes, however with less subdivisions. Hence to find the appropriate <class-ref scheme="cpc">A61K38/00</class-ref> classification subgroup to be given to a protein used in therapy, the procedure consists of checking the place of said protein in the <class-ref scheme="cpc">C07K</class-ref> scheme and apply the corresponding place, if correct and justified, in the <class-ref scheme="cpc">A61K38/00</class-ref> scheme, for the sake of consistency between schemes).</paragraph-text><paragraph-text type="body">The use of proteins or peptides of known source in therapy, or therapeutic compositions, is classified as additional information in the <class-ref scheme="cpc">A61K35/00</class-ref> or <class-ref scheme="cpc">A61K36/00</class-ref> subgroups if the source is considered an important aspect of the invention, as well as in the appropriate <class-ref scheme="cpc">A61K38/00</class-ref> subgroup for known sequences or <class-ref scheme="cpc">A61K38/02</class-ref> for unknown sequence. If the source is not known, only a classification in <class-ref scheme="cpc">A61K38/00</class-ref>+ is needed.</paragraph-text><paragraph-text type="body">When a protein or peptide mixture for use in therapy contains at least one active ingredient without chemical characterisation (e.g. functional feature such as antiphlogistics, anti-cancer agent), invention information classifications should be given in <class-ref scheme="cpc">A61K38/00</class-ref>+ and <class-ref scheme="cpc">A61K45/06</class-ref>.</paragraph-text><paragraph-text type="body">When a compound is only and exclusively defined in the description and claims by means of a functional definition, no specific examples are provided, and it is unclear whether the functionally defined compound is a compound according to any of <class-ref scheme="cpc">A61K31/00</class-ref>, <class-ref scheme="cpc">A61K33/00</class-ref>, <class-ref scheme="cpc">A61K35/00</class-ref>, <class-ref scheme="cpc">A61K36/00</class-ref>, <class-ref scheme="cpc">A61K38/00</class-ref> or <class-ref scheme="cpc">A61K39/00</class-ref>, then invention information classification in <class-ref scheme="cpc">A61K45/00</class-ref> is assigned. For example a general concept (e.g. &quot;Compound X for use in treating disease Y, wherein X is a protein, an antibody or a chemical compound&quot; with no specific compounds given, i.e. the document does not give a single, concrete example of peptidic or proteic compounds) is not classified under <class-ref scheme="cpc">A61K38/00</class-ref> but under <class-ref scheme="cpc">A61K45/00</class-ref>.</paragraph-text><paragraph-text type="body">Preparations comprising enzymes are classified under <class-ref scheme="cpc">A61K38/43</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K38/54</class-ref>, followed by a <class-ref scheme="cpc">C12Y</class-ref> invention information symbol for the specified enzyme(s). For example, a preparation comprising alpha-galactosidase is classified under <class-ref scheme="cpc">A61K38/47</class-ref> (i.e. Hydrolases acting on glycosyl compounds) and <class-ref scheme="cpc">C12Y302/01022</class-ref> (i.e. alpha-galactosidase EC 3.2.1.22).</paragraph-text><paragraph-text type="body">Claims to &quot;enzyme inhibitors&quot; for use in therapy, without any specific example or without an identified peptidic structure, i.e. &quot;reach-through&quot; claims, are not covered by <class-ref scheme="cpc">A61K38/00</class-ref> but are classified in <class-ref scheme="cpc">C12Q1/00</class-ref> or <class-ref scheme="cpc">G01N33/00</class-ref> as appropriate. At first glance this may appear somewhat of an anomaly however claims of this type are usually a result of a screening process e.g. A compound identified by the method of claim 1 for treatment of disease X. Claim 1 would typically be something like A method for identifying an inhibitor for cholesterol esterase comprising ...etc. As the method for identification of such a compound would be classified in <class-ref scheme="cpc">C12Q</class-ref> and no provision is made in <class-ref scheme="cpc">A61K38/00</class-ref> for classification of compounds without an identified peptidic structure, classification in <class-ref scheme="cpc">C12Q</class-ref> alone is deemed sufficient. The same applies to documents classified in <class-ref scheme="cpc">G01N</class-ref> for screening purposes. (Note: A &quot;reach-through&quot; claim is defined as a claim attempting to obtain protection for a chemical products&apos; uses, compositions thereof, etc. by defining that product by its functionality in terms of its action e.g. an agonist, antagonist, inhibitor of a biological target such as an enzyme or receptor).</paragraph-text><paragraph-text type="body">Stabilisation of a specific active protein or peptide with an inert additive (i.e. inactive carrier, targeting agent, potentiator, adjuvant) for use in therapy is classified under the appropriate <class-ref scheme="cpc">A61K38/00</class-ref> symbol for the therapeutically active protein or peptide and under <class-ref scheme="cpc">A61K47/00</class-ref>. For example, a therapeutic composition comprising growth hormone together with albumin or collagen, the latter being present in the composition for its function as stabiliser of the hormone, will be classified under <class-ref scheme="cpc">A61K38/27</class-ref> (growth hormone) as well as <class-ref scheme="cpc">A61K47/42</class-ref> (albumin, collagen) but not under <class-ref scheme="cpc">A61K38/38</class-ref> (albumin used as therapeutically active agent) nor <class-ref scheme="cpc">A61K38/39</class-ref> (collagen used as therapeutically active agent).</paragraph-text><paragraph-text type="body">Proteins or peptides for use in therapy, characterised by the special physical form (i.e. new galenic formulation of a known protein or peptide for use in therapy) may require classification under <class-ref scheme="cpc">A61K9/00</class-ref>. An <class-ref scheme="cpc">A61K38/00</class-ref> classification is given for the protein or peptide only in case of a specified protein or family of proteins. No <class-ref scheme="cpc">A61K38/00</class-ref> classification is given as invention information to an exhaustive list of unrelated and unspecific proteins. Instead <class-ref scheme="cpc">A61K38/00</class-ref> is given as additional information.</paragraph-text><paragraph-text type="body">For gene therapy, an appropriate <class-ref scheme="cpc">A61K38/00</class-ref> classification is given for the protein or peptide used in the gene therapy method, together with an <class-ref scheme="cpc">A61K48/00</class-ref> symbol. The same applies for the use of a nucleic acid encoding a specific protein, or of cells modified to produce a specific protein, for use in gene therapy: an invention information is given both in <class-ref scheme="cpc">A61K38/00</class-ref>+ and <class-ref scheme="cpc">A61K48/00</class-ref>+.</paragraph-text><paragraph-text type="body">For vaccines comprising peptides or fragments thereof, if the therapeutic effect is clearly and exclusively a vaccine effect, no <class-ref scheme="cpc">A61K38/00</class-ref> classification is given. The vaccine is classified in <class-ref scheme="cpc">A61K39/00</class-ref> or one of its subgroups as appropriate.</paragraph-text></section-body></relationship><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Single amino acids or single nucleic acids for use in therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medical use of non-coding nucleic acids, e.g. ribozymes, antisenses</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/7084</class-ref> - <class-ref scheme="cpc">A61K31/713</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Vaccines</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Stabilisation of proteins in general</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/50</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Peptides forming the non active part of a conjugate</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/62</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">NMR contrast preparations containing peptides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/14</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Preparations containing radioactive peptides for use in therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K51/08</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Antibodies</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K16/00</class-ref>, <class-ref scheme="cpc">A61K2039/505</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Enzymes per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Non-coding nucleic acids, e.g. ribozymes, antisenses</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N15/113</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Cosmetic preparations containing proteins orpeptides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/64</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations characterised by physical form</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing material of undetermined constitution</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K35/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Proteins or peptides used in food</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23L</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Proteins or peptides involved in bandages, dressings</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L15/32</class-ref>, <class-ref scheme="cpc">A61L26/0028</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Proteins or peptides involved in surgical articles</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L24/10</class-ref>, <class-ref scheme="cpc">A61L31/043</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Proteins or peptides involved in prostheses or coatings </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L27/22</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Proteins or peptides involved in catheters </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L29/044</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Proteins or peptides involved in antithrombogenic treatment of surgical articles</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L33/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Proteins or peptides per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Methods for the preparation of peptides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K1/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Enzymes per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12Y</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Each specific active component in a medical use claim is classified according to the last place rule.</paragraph-text><paragraph-text type="body">Classification within this group is only given for the use of peptides or proteins (i.e. those present in the claims or exemplified in the description) as active agents.</paragraph-text><paragraph-text type="body">The sole symbol for additional information classification is <class-ref scheme="cpc">A61K38/00</class-ref>, without subdivisions. An invention information classification with the head symbol <class-ref scheme="cpc">A61K38/00</class-ref> should be avoided.</paragraph-text><paragraph-text type="body">A fragment of a protein in a medical claim is classified with its parent, if known. If the protein from which the fragment derives is not identified in the document to be classified, the fragment will be classified according to its length. Protein fragments less than 5 amino acids long are additionally classified under <class-ref scheme="cpc">A61K38/043</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K38/07</class-ref>.</paragraph-text><paragraph-text type="body">A nucleic acid encoding a protein in a medical use claim is classified under the protein it encodes.</paragraph-text><paragraph-text type="body">In principle all specific compounds mentioned in the claims are classified. However, when there are too many compounds, as in the case of lengthy, exhaustive lists of proteins or peptides claimed for a therapeutic use, classification should be limited to a reasonable number of assignments covering e.g. the compounds tested or exemplified. Any generalisation which would lead to the next hierarchically higher level should be avoided. The therapeutic use of undefined proteins or peptides (no peptidic structure described) is not classified under <class-ref scheme="cpc">A61K38/02</class-ref> which is for the medical use of compounds of peptidic or proteic nature but of undefined length, e.g. polymers of repeated motifs of aminoacids of undefined length, but nevertheless disclosed in the document.</paragraph-text><paragraph-text type="body">Enzyme inhibitors in a medical use claim are classified within the <class-ref scheme="cpc">A61K38/005</class-ref> (enzyme inhibitors) or <class-ref scheme="cpc">A61K38/55</class-ref> (protease inhibitors) groups only if they are of peptidic structure. <class-ref scheme="cpc">A61K38/005</class-ref> or <class-ref scheme="cpc">A61K38/55</class-ref> should be assigned with another, more informative classification symbol: if the inhibitor is directly derived from the enzyme sequence itself, like for example an inhibitory enzyme fragment, it is also classified under the enzyme from which it is derived (<class-ref scheme="cpc">A61K38/43</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K38/54</class-ref>); if the inhibitor is not disclosed in the document as being derived from a known enzyme, for example the inhibitor is synthetically produced and is clearly constituted of a sequence of amino acids (defined or not), it is classified under its length. The concept &quot;enzyme inhibitors&quot; without any specific example or given peptidic structure does not require classification within this group.</paragraph-text><paragraph-text type="body">For mixtures or combinations: a classification symbol is given for each active ingredient in a medical use claim, followed by <class-ref scheme="cpc">A61K2300/00</class-ref> (Additional Information Symbol for mixtures) to create the corresponding Combination-set. This applies also if one mixture component is claimed per se.</paragraph-text><paragraph-text type="body">Fusion peptides in a medical use claim are classified under <class-ref scheme="cpc">A61K38/00</class-ref> with the symbols of their components.</paragraph-text><paragraph-text type="body">Important aspects of the invention mentioned only in the description should also be classified.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2024-08-01"><classification-symbol scheme="cpc">A61K39/00</classification-symbol><definition-title>Medicinal preparations containing antigens or antibodies  (materials for immunoassay <class-ref scheme="cpc">G01N33/53</class-ref>)</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">The use of antigens or antibodies in medicinal preparations for immunization..</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Gene therapy: An appropriate <class-ref scheme="cpc">A61K39/00</class-ref> symbol is given when the in vivo expression of a protein arising from the delivery of a nucleic acid encoding the protein, and the generation of an immune response against the encoded protein results in a prophylactic or therapeutic effect. The same applies for the use of cells modified to produce a specific antigen/antibody, for use in gene therapy. An <class-ref scheme="cpc">A61K48/00</class-ref> symbol may also be given, if applicable, as specified under the <class-ref scheme="cpc">A61K48/00</class-ref> section definitions</paragraph-text></section-body></relationship><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Gene therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K48/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Material for immunoassay</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G01N33/53</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Viral peptides having more than 20 amino acids</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K14/005</class-ref> and/or <class-ref scheme="cpc">C12N</class-ref>7xx/xxxx22 defining the origin of the viral peptide </paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Bacterial peptides having more than 20 amino acids</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K14/195</class-ref> and subgroups further defining the origin of the bacterial peptide</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Fungal peptides having more than 20 amino acids</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K14/37</class-ref> and subgroups further defining the origin of the fungal peptide</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Animal/human peptides having more than 20 amino acids</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K14/435</class-ref> and subgroups further defining the origin of the animal/human peptide</paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">In CPC, an important limitation for the classification in <class-ref scheme="cpc">A61K39/00</class-ref> has been introduced, in comparison with the IPC:</paragraph-text><paragraph-text type="body">The medicinal use of proteinaceous antigens hypothetically useful for vaccination is classified only in <class-ref scheme="cpc">C07K14/00</class-ref> or <class-ref scheme="cpc">C12N9/00</class-ref>, according to the origin of the protein, with addition of the Indexing Code <class-ref scheme="cpc">A61K39/00</class-ref>.</paragraph-text><paragraph-text type="body">Guidance for the classification of medicinal preparations containing antibodies (<class-ref scheme="cpc">A61K39/395</class-ref> and subgroups) as active ingredients is given in a separate definition concerning antibodies (<class-ref scheme="cpc">C07K16/00</class-ref>).</paragraph-text><paragraph-text type="body">What follows below is the classification strategy for the medicinal use of antigens for which vaccination has been sufficiently disclosed.</paragraph-text><paragraph-text type="body">Documents relating to the medicinal use of antigens are classified in <class-ref scheme="cpc">A61K39/00</class-ref>, mainly according to the origin of the antigen.</paragraph-text><paragraph-text type="body">Indexing Codes (<class-ref scheme="cpc">A61K2039/51</class-ref> - <class-ref scheme="cpc">A61K2039/64</class-ref>) are used for classifying further relevant and sufficiently disclosed aspects of the immunogenic compositions.</paragraph-text><paragraph-text type="body">Preparations containing archeal antigens for vaccination: <class-ref scheme="cpc">A61K39/0001</class-ref></paragraph-text><paragraph-text type="body">Preparations containing fungal antigens for vaccination: <class-ref scheme="cpc">A61K39/0002</class-ref></paragraph-text><paragraph-text type="body">Preparations containing invertebrate antigens for vaccination: <class-ref scheme="cpc">A61K39/0003</class-ref></paragraph-text><paragraph-text type="body">Preparations containing vertebrate antigens for vaccination:</paragraph-text><paragraph-text type="body">from <class-ref scheme="cpc">A61K39/0005</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K39/0012</class-ref></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0006</class-ref> :contraceptive vaccins, vaccins against sex hormones</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0007</class-ref> : preparations containing nervous system antigens or prions</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0008</class-ref> : preparations containing antigens related to auto-immune diseases and preparations to induce self-tolerance</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/001</class-ref> : preparations to induce tolerance to non-self, e.g. prior to transplantation</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0011</class-ref> : preparations containing cancer antigens</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0012</class-ref> : preparations containing lipid or lipoprotein antigens</paragraph-text><paragraph-text type="body">Preparations containing protozoa antigens: from <class-ref scheme="cpc">A61K39/002</class-ref> - <class-ref scheme="cpc">A61K39/018</class-ref> according to the origin of the antigen</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/005</class-ref> : preparations containing Trypanosoma antigens</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/008</class-ref> : preparations containing Leishmania antigens</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/012</class-ref> : preparations containing Coccidia antigens</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/015</class-ref> : preparations containing Hemosporidia antigens e.g. Plasmodium antigens</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/018</class-ref> : preparations containing Babesia antigens e.g. Theileria antigens</paragraph-text><paragraph-text type="body">Preparations containing bacterial antigens: from <class-ref scheme="cpc">A61K39/02</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K39/118</class-ref> according to the origin of the antigen</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0208</class-ref> : preparations containing antigens from specific bacteria, which cannot be classified in <class-ref scheme="cpc">A61K39/0216</class-ref> - <class-ref scheme="cpc">A61K39/118</class-ref></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0216</class-ref> : preparations containing antigens from Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0225</class-ref> : preparations containing antigens from Spirochetes, e.g. Treponema, Leptospira, Borrelia</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0233</class-ref> : preparations containing antigens from Rickettsiales, e.g. Anaplasma</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0241</class-ref> : preparations containing antigens from Mollicutes, e.g. Mycoplasma, Erysipelothrix</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/025</class-ref> : preparations containing antigens from Enterobacteriales, e.g. Enterobacter, Yersinia</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0258</class-ref> : preparations containing antigens from Escherichia</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0266</class-ref> : preparations containing antigens from Klebsiella</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0275</class-ref> : preparations containing antigens from Salmonella</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/0283</class-ref> : preparations containing antigens from Shigella</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/04</class-ref> : preparations containing antigens from Mycobacterium, e.g. Mycobacterium tuberculosis</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/05</class-ref> : preparations containing antigens from Actinobacteria (e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium,Gardnerella), Corynebacteria, Propionibacteria. Preparations containing antigens from Mycobacterium are classified in <class-ref scheme="cpc">A61K39/04</class-ref></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/07</class-ref> : preparations containing antigens from Bacillus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/08</class-ref> : preparations containing antigens from Clostridium, e.g. Clostridium tetanus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/085</class-ref> : preparations containing antigens from Staphylococcus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/09</class-ref> : preparations containing antigens from Lactobacillales, e.g. Aerococcus, Enterococcus, Lactobacillus, Lactococcus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/092</class-ref> : preparations containing antigens from Streptococcus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/095</class-ref> : preparations containing antigens from Neisseria</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K2039/10</class-ref> : not used</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/098</class-ref> : preparations containing antigens from Brucella</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/099</class-ref> : preparations containing antigens from Bordetella, e.g. Bordetella pertussis</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/102</class-ref> : preparations containing antigens from Pasteurellales, e.g. Actinobacillus, Pasteurella, Haemophilus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/104</class-ref> : preparations containing antigens from Pseudomonadales, e.g. Pseudomonas</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/1045</class-ref> : preparations containing antigens from Moraxella</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K2039/106</class-ref> : not used</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/098</class-ref> : preparations containing antigens from Delta proteobacteriales, e.g. Lawsonia, from Epsilon proteobacteriales, e.g. campylobacter, Helicobacter</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/114</class-ref> : preparations containing antigens from Fusobacterium</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/116</class-ref> : preparations containing antigens from more than one bacteria; preparation containing a mixture of bacterial and viral antigens are classified in <class-ref scheme="cpc">A61K39/295</class-ref></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/118</class-ref> : preparations containing antigens from Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci</paragraph-text><paragraph-text type="body">Preparations containing viral antigens: <class-ref scheme="cpc">A61K39/12</class-ref> AND <class-ref scheme="cpc">C12N7/00</class-ref> in combination with an Indexing Code in the <class-ref scheme="cpc">C12N2710/00</class-ref> - <class-ref scheme="cpc">C12N2796/00</class-ref> series according to the origin of the viral antigen.</paragraph-text><paragraph-text type="body">The specific Indexing Codes have the format <class-ref scheme="cpc">C12N</class-ref>7xx/xxxx34</paragraph-text><paragraph-text type="body">The first part (xxx/xxxx)of the code indicates the specific virus from which the antigen has been derived. The first four digits after the &quot;/&quot; represent the taxonomic location of the virus and the last place rule applies.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2710/00</class-ref> double stranded DNA virus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2720/00</class-ref> double stranded RNA virus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2730/00</class-ref> reverse transcribing DNA virus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2740/00</class-ref> reverse transcribing RNA virus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2750/00</class-ref> single stranded DNA virus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2760/00</class-ref> single stranded RNA virus negative-sense</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2770/00</class-ref> single stranded RNA virus positive-sense</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2780/00</class-ref> viroids and subviral agents</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2790/00</class-ref> naked RNA Virus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2792/00</class-ref> archaeabacteria virus</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">C12N2795/00</class-ref> bacteriophage</paragraph-text><paragraph-text type="body">The second part of the Indexing Code(34) indicates the use, namely that the virus or viral component is used as vaccine</paragraph-text><paragraph-text type="body">Preparations containing multiple antigens of which at least one is a viral antigen: <class-ref scheme="cpc">A61K39/295</class-ref> AND <class-ref scheme="cpc">C12N7/00</class-ref> in combination with an Indexing Code in the <class-ref scheme="cpc">C12N2710/00</class-ref> - <class-ref scheme="cpc">C12N2796/00</class-ref> series according to the origin of the viral antigen(s).</paragraph-text><paragraph-text type="body">Preparations containing allergens for vaccination: from <class-ref scheme="cpc">A61K39/35</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K39/36</class-ref></paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/36</class-ref> : preparations containing allergens</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K39/36</class-ref> : preparations containing allergens from pollen</paragraph-text><paragraph-text type="body">Preparations containing antigens from snakes for vaccination: <class-ref scheme="cpc">A61K39/38</class-ref></paragraph-text><paragraph-text type="body">Preparations characterized by haptens or antigens bound to a carrier: <class-ref scheme="cpc">A61K39/385</class-ref></paragraph-text><paragraph-text type="body">Documents disclosing a new carrier will be classified within <class-ref scheme="cpc">A61K39/385</class-ref>. In addition, specific examples will also be classified according to the nature of the antigen with the addition of an Indexing Code from the <class-ref scheme="cpc">A61K2039/60</class-ref> series to characterise the carrier.</paragraph-text><paragraph-text type="body">Documents relating to compositions containing specific antigens bound to a carrier are preferably classified according to the nature of the antigen in groups <class-ref scheme="cpc">A61K39/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K39/38</class-ref> with the addition of an Indexing Code from the <class-ref scheme="cpc">A61K2039/60</class-ref> series to characterise the carrier and possibly also an Indexing Code from the <class-ref scheme="cpc">A61K2039/62</class-ref> series to characterise the link between the carrier and the antigen and an Indexing Code from the <class-ref scheme="cpc">A61K2039/64</class-ref> series to characterise the architecture of the carrier-antigen complex.</paragraph-text><paragraph-text type="body">Preparations characterized by the immunostimulating additive or adjuvant: <class-ref scheme="cpc">A61K39/39</class-ref></paragraph-text><paragraph-text type="body">Documents disclosing a new adjuvant will be classified within <class-ref scheme="cpc">A61K39/39</class-ref> and the specific examples will also be classified according to the nature of the antigen with the addition of an Indexing Code from the <class-ref scheme="cpc">A61K2039/555</class-ref> series to characterise the adjuvant.</paragraph-text><paragraph-text type="body">Documents relating to compositions containing specific antigens in the presence of an immunostimulating additive/adjuvant are classified according to the nature of the antigen in groups <class-ref scheme="cpc">A61K39/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K39/38</class-ref> with the addition of an Indexing Code from the <class-ref scheme="cpc">A61K2039/555</class-ref> series to characterise the adjuvant.</paragraph-text><paragraph-text type="body">Preparations containing DNA encoding an antigen for vaccination</paragraph-text><paragraph-text type="body">Documents disclosing a DNA vaccine will be classified according to the nature of the antigen in groups <class-ref scheme="cpc">A61K39/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K39/38</class-ref> with the addition of the Indexing Code <class-ref scheme="cpc">A61K2039/53</class-ref>.</paragraph-text><paragraph-text type="body">Preparations containing an antigen for vaccination in combination with another/other active ingredient(s) are classified in the corresponding <class-ref scheme="cpc">A61K39/00</class-ref> class with the addition of the Indexing Code <class-ref scheme="cpc">A61K2300/00</class-ref></paragraph-text><paragraph-text type="body">The following relevant and sufficiently disclosed aspects of the vaccines are further classified using Indexing Codes:</paragraph-text><paragraph-text type="body">vaccines comprising whole cells, animal cells, bacterial cells or viruses: <class-ref scheme="cpc">A61K2039/51</class-ref> and subgroups thereof</paragraph-text><paragraph-text type="body">vaccines characterised by the route of administration: <class-ref scheme="cpc">A61K2039/54</class-ref> and subgroups thereof</paragraph-text><paragraph-text type="body">vaccines characterised by the dose, timing or administration schedule: <class-ref scheme="cpc">A61K2039/545</class-ref></paragraph-text><paragraph-text type="body">vaccines characterised by the host/recipient: <class-ref scheme="cpc">A61K2039/55</class-ref> and subgroup <class-ref scheme="cpc">A61K2039/552</class-ref></paragraph-text><paragraph-text type="body">vaccines characterised by a specific combination antigen/adjuvant: <class-ref scheme="cpc">A61K2039/555</class-ref> and subgroups thereof for characterising the adjuvant</paragraph-text><paragraph-text type="body">vaccines characterised by the type of immune response: <class-ref scheme="cpc">A61K2039/57</class-ref></paragraph-text><paragraph-text type="body">vaccines characterised by the carrier linked to the antigen: <class-ref scheme="cpc">A61K2039/60</class-ref> and subgroups thereof</paragraph-text><paragraph-text type="body">vaccines characterised by the link between antigen and carrier: <class-ref scheme="cpc">A61K2039/62</class-ref> and subgroups thereof</paragraph-text><paragraph-text type="body">vaccines characterised by the architecture of the carrier-antigen complex: <class-ref scheme="cpc">A61K2039/64</class-ref> and subgroup <class-ref scheme="cpc">A61K2039/645</class-ref></paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2024-08-01"><classification-symbol scheme="cpc">A61K2039/544</classification-symbol><definition-title>{to the airways}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Mucosal route or intranasal</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K2039/543</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2024-08-01"><classification-symbol scheme="cpc">A61K2039/6006</classification-symbol><definition-title>{Cells}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing animal cells expressing foreign proteins</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K2039/5156</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing bacterial, fungal or protozoal cells expressing foreign proteins</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K2039/523</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2025-01-01"><classification-symbol scheme="cpc">A61K40/00</classification-symbol><definition-title>Cellular immunotherapy  (medicinal preparations containing antigens or antibodies <class-ref scheme="cpc">A61K39/00</class-ref>)</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Isolated cells of the immune system presenting or targeting a specific antigen or a mix of antigens for use in therapy against, e.g. cancer, infectious diseases or auto-immune diseases.</paragraph-text><paragraph-text type="body">The antigen presented/targeted may be a single epitope or a mix of epitopes or antigens.</paragraph-text><paragraph-text type="body">Antigens may also be undefined like in the case of TILs or LAKs derived lymphocytes which will target several unidentified antigens.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Due to their structure, cells used in cellular immunotherapy may warrant classification of subject-matter in various main groups, beyond the allocation in&#160;<class-ref scheme="cpc">A61K40/00</class-ref>&#160;and subgroups.&#160;</paragraph-text><paragraph-text type="body">If the structure of the antibody portion of the construct is an important aspect, then classification in&#160;<class-ref scheme="cpc">C07K16/00</class-ref>&#160;and subgroups should be considered. The same applies to the type of protein expressed (TCR, CAR, cytokine&#8230;), which can be classified in&#160;<class-ref scheme="cpc">C07K14/00</class-ref>&#160;and subgroups.</paragraph-text><paragraph-text type="body">Genetically modified cells or T lymphocytes for immunotherapy may be classified in&#160;<class-ref scheme="cpc">C12N5/0634</class-ref>&#160;-&#160;<class-ref scheme="cpc">C12N5/064</class-ref>&#160;with added classification in&#160;<class-ref scheme="cpc">A61K40/00</class-ref>&#160;and subgroups, and indexing codes&#160;<class-ref scheme="cpc">A61K2239/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K2239/59</class-ref>. Documents relating to the in vitro cell culture/expansion methods or to specific types/subtypes of immune cells may also be classified in&#160;<class-ref scheme="cpc">C12N5/00</class-ref>&#160;and subgroups.</paragraph-text><paragraph-text type="body">Cells for cellular immunotherapy may be given symbols in <class-ref scheme="cpc">A61K35/15</class-ref> (e.g. dendritic cells) and/or <class-ref scheme="cpc">A61K35/17</class-ref> (e.g. lymphocytes; B-cells; T-cells; natural killer cells; interferon-activated or cytokine-activated lymphocytes) for the cell and <class-ref scheme="cpc">A61K39/00</class-ref> and subgroups for the therapeutic aspect of the antigen/antibody, as well as in <class-ref scheme="cpc">C07K14/00</class-ref> (when a novel peptide is claimed and exemplified) and/or <class-ref scheme="cpc">C07K16/00</class-ref> and subgroups (for further, specific classification of the antibody and/or when the antibody is novel).</paragraph-text><paragraph-text type="body">Classification in&#160;<class-ref scheme="cpc">A61K35/17</class-ref>&#160;should be considered if the effect of the lymphocyte is not due to its antigen specificity (e.g. the administration of B cells to treat tissue injury).&#160;<class-ref scheme="cpc">A61K35/15</class-ref>&#160;or&#160;<class-ref scheme="cpc">A61K35/17</class-ref>&#160;need not be given by default to immune cells directed to a given antigen (or to a mixture of antigens).</paragraph-text><paragraph-text type="body">Therapeutic activity can further be classified in subclass&#160;<class-ref scheme="cpc">A61P</class-ref>, as secondary classification and following the criteria outlined in the definitions of&#160;<class-ref scheme="cpc">A61P</class-ref>.</paragraph-text></section-body></relationship><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing antigens or antibodies </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing blood or cells from blood</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K35/17</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K48/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">T-cell receptor (TcR)-CD3 complex</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K14/7051</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K16/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Fusion polypeptide (containing a transmembrane segment)</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K2319/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Culture or maintenance of cells from the blood or the immune system </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N5/0634</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Screening and/or testing using cells</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12Q1/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">In this group, classification of the cell type and of the antigen specificity is compulsory, provided the document contains credible evidence that the effect has been or can be achieved.</paragraph-text><paragraph-text type="body">Further relevant aspects, like those characterising the structure of the chimeric antigen receptor [CAR], the target(s) and the route of administration, should also be classified.</paragraph-text><paragraph-text type="body">The cell type and the type of immune response is to be classified in subgroups&#160;<class-ref scheme="cpc">A61K40/10</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K40/24</class-ref>.</paragraph-text><paragraph-text type="body">These subgroups relate to immune cells, including antigen-presenting cells or T lymphocytes. Further aspects relate to the type of immune responses, which can be for instance, immunosuppressive or immunostimulatory (<class-ref scheme="cpc">A61K40/20</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K40/24</class-ref>).</paragraph-text><paragraph-text type="body">Aspects relating to the nature of the receptors or molecules expressed recombinantly by the immune cell are to be classified in subgroups&#160;<class-ref scheme="cpc">A61K40/30</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K40/36</class-ref>. CAR receptors are for instance, classified in&#160;<class-ref scheme="cpc">A61K40/31</class-ref>.</paragraph-text><paragraph-text type="body">The former subgroups should all be used in combination with the subgroups relating to the target antigen(s), which are to be found in subgroups&#160;<class-ref scheme="cpc">A61K40/40</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K40/482</class-ref>.</paragraph-text><paragraph-text type="body">The additional subgroups&#160;<class-ref scheme="cpc">A61K2239/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K2239/59</class-ref>&#160;should also be considered for a comprehensive classification of cellular immunotherapy.</paragraph-text><paragraph-text type="body">These subgroups concern the structure of the chimeric antigen receptor [CAR], as well as the mechanisms enabling the control of the function or activity of the CAR or of the CAR-expressing cells in vivo.</paragraph-text><paragraph-text type="body">In case of multiple targets, classification in the subgroups <class-ref scheme="cpc">A61K2239/27</class-ref> - <class-ref scheme="cpc">A61K2239/30</class-ref> can also be considered.</paragraph-text><paragraph-text type="body">The route of administration, the schedule and the adjuvant(s) used can be classified in&#160;<class-ref scheme="cpc">A61K2239/31</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K2239/39</class-ref>.</paragraph-text><paragraph-text type="body">Finally, and in view of the wide use of cellular immunotherapy against cancer, specific subgroups for the cancer organ can be found in subgroups <class-ref scheme="cpc">A61K2239/46</class-ref> - <class-ref scheme="cpc">A61K2239/59</class-ref>. These subgroups can be used in combination with the antigen subgroups to more precisely identify documents relating to some specific cancers.</paragraph-text><paragraph-text type="body">Combination Sets (C-Sets) classification:</paragraph-text><list><list-item><paragraph-text type="body">In groups&#160;<class-ref scheme="cpc">A61K40/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K40/482</class-ref>, the combined use of cellular immunotherapy with other therapeutic elements classified in&#160;<class-ref scheme="cpc">A61K31/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K41/00</class-ref>&#160;are classified in the form of C-Sets.</paragraph-text></list-item><list-item><paragraph-text type="body">While multiple drugs are used in an invention, only the essential components of the invention that differentiate them from the prior art are given C-Sets.</paragraph-text></list-item></list><paragraph-text type="body">C-Sets syntax rules:</paragraph-text><list><list-item><paragraph-text type="body">Each C-Set shall contain exactly two symbols, in which the base symbol represents one therapeutic drug belonging to&#160;<class-ref scheme="cpc">A61K31/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K41/00</class-ref>, and followed by a subsequent symbol of&#160;<class-ref scheme="cpc">A61K2300/00</class-ref>.</paragraph-text></list-item><list-item><paragraph-text type="body">Two or more separate C-Sets are made when two or more drugs are used in combination with cellular immunotherapy. See examples below.</paragraph-text></list-item></list><paragraph-text type="body">C-Sets examples:</paragraph-text><list><list-item><paragraph-text type="body">Example 1: The treatment of blood cancer with anti-CD19 CAR-T cells and venetoclax is classified as (<class-ref scheme="cpc">A61K40/4211</class-ref>, <class-ref scheme="cpc">A61K2300/00</class-ref>).</paragraph-text></list-item><list-item><paragraph-text type="body">Example 2: The treatment of blood cancer with anti-CD19 CAR-T cells and exogenous IL-7 is classified as (<class-ref scheme="cpc">A61K40/4211</class-ref>, <class-ref scheme="cpc">A61K2300/00</class-ref>).</paragraph-text></list-item><list-item><paragraph-text type="body">Example 3: The treatment of cancer with anti-CEA CAR-T cells combined with anti-PD-L1 antibodies is classified as (<class-ref scheme="cpc">A61K40/4266</class-ref>, <class-ref scheme="cpc">A61K2300/00</class-ref>).</paragraph-text></list-item></list></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K41/00</classification-symbol><definition-title>Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><list><list-item><paragraph-text type="body">Medicinal preparations guided in vivo through the body by a magnetic field:&#160;<class-ref scheme="cpc">A61K41/00</class-ref>.</paragraph-text></list-item><list-item><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0004</class-ref>: preparations which are obtained by using homeopathic procedures, procedures for dynamisation, or esoteric preparations; homeopathy; vitalisation; resonance; dynamisation; esoteric applications; oxygenation of blood.</paragraph-text></list-item></list><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0023</class-ref>: preparations for use in therapy during which wave energy or particle radiation is administered, in order to &quot;activate&quot; the agent, e.g. photodynamic therapy, or for releasing a pharmacologically active agent, e.g. thermosensitive liposomes, photolabile linkers are classified in <class-ref scheme="cpc">A61K41/0023</class-ref> - <class-ref scheme="cpc">A61K41/0095</class-ref></paragraph-text><list><list-item><paragraph-text type="body">aggression treatment or altering: of a medicinal preparation prior to administration to the human/animal (e.g. altering a binding specificity of a monoclonal antibody used in a medicinal agent with an oxidizing agent or an electric potential); of a tissue/organ prior to graft (e.g. destroying immunodominant epitopes); the permeability of cell membranes or biological barriers in vivo (e.g. by ultrasound) prior to the administration of a medicinal preparation to the animal/human; for inducing the production of stress response proteins or heat shock proteins in order to reduce subsequent response to injuries.</paragraph-text></list-item></list><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0028</class-ref>: disruption (e.g. by heat or ultrasounds), sonophysical or sonochemical activation; e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0033</class-ref>: sonodynamic cancer therapy with sonochemically active agents/sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds (ultrasound therapy per se is classified in&#160;<class-ref scheme="cpc">A61N7/00</class-ref>).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0038</class-ref>: radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se is classified in&#160;<class-ref scheme="cpc">A61N5/10</class-ref>).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0042</class-ref>: photocleavage of drugs in vivo (e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent); photothrombosis or photoocclusion.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0047</class-ref>: sonopheresis (i.e. ultrasonically-enhanced transdermal delivery), electroporation of a pharmacologically active agent (NB: to be classified in&#160;<class-ref scheme="cpc">A61K9/0009</class-ref> when it is in relation to the galenic form).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0052</class-ref>: thermotherapy; hyperthermia; magnetic induction; induction heating therapy (NB: simple magnetic guidance of drugs in vivo is to be classified in&#160;<class-ref scheme="cpc">A61K41/00</class-ref>, and in&#160;<class-ref scheme="cpc">A61K47/6941</class-ref>).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0057</class-ref>: photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0061</class-ref>: 5-aminolevulinic acid-based PDT (5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0066</class-ref>: psoralene-activated UVA photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens (fucocoumarins).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0071</class-ref>: PDT with porphyrins having 20 carbon atoms and 4 nitrogen atoms forming the ring system (i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin e6, or phthalocyanines).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0076</class-ref>: PDT with expanded (i.e. having more than 20 carbon atoms and/or 4 nitrogen atoms forming the ring system) (metallo)porphyrins, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/008</class-ref>: two-photon or multi-photon PDT, e.g. with two-photon upconverting dyes or photosensitizers.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0085</class-ref>: mossbauer effect therapy based on mossbauer effect of a material (i.e. re-emission of gamma rays after absorption of gamma rays by the material); selective radiation therapy (i.e. involving re-emission of ionizing radiation upon exposure to a first ionizing radiation).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/009</class-ref>: neutron capture therapy, e.g. using uranium or non-boron material.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0095</class-ref>: boron neutron capture therapy (BNCT), e.g. using boronated porphyrins.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/10</class-ref>: preparations which are obtained by treating materials with wave energy, e.g. U.V. light, or particle radiation, prior to administration, for decontamination:</paragraph-text><list><list-item><paragraph-text type="body">inactivation or decontamination of a medicinal preparation prior to administration to the animal/human, e.g. : inactivation of viruses or bacteria for vaccines, sterilisation by electromagnetic radiation (see&#160;<class-ref scheme="cpc">A61K41/17</class-ref>&#160;for the specific method;&#160;<class-ref scheme="cpc">A61L2/0029</class-ref>&#160;if the invention lies in the method of sterilization of the medicinal preparation rather than the sterilized medicinal preparation.</paragraph-text></list-item></list><paragraph-text type="body"><class-ref scheme="cpc">A61K41/13</class-ref>: by ultrasonic waves.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K41/17</class-ref>: by ultraviolet [UV] or infrared [IR], X-rays or gamma rays.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Galenical aspects of pharmaceutical compositions are also classified by giving a combination of classes in <class-ref scheme="cpc">A61K9/00</class-ref> and <class-ref scheme="cpc">A61K47/00</class-ref> to and including <class-ref scheme="cpc">A61K47/50</class-ref>.</paragraph-text><paragraph-text type="body">The active ingredients in pharmaceutical compositions are classified in <class-ref scheme="cpc">A61K31/00</class-ref> - <class-ref scheme="cpc">A61K48/00</class-ref>.</paragraph-text><paragraph-text type="body">Preparations for testing in vivo using radioactive substances, or substances for use in therapy labeled with a radioactive isotope, are classified in <class-ref scheme="cpc">A61K51/00</class-ref>.</paragraph-text><paragraph-text type="body">Preparations for testing in vivo, or for use in an in vivo diagnostic imaging method (e.g., by luminescence, fluorescence, X-ray imaging, ultrasound imaging, echography, MRI) are classified in <class-ref scheme="cpc">A61K49/00</class-ref> and its subgroups.</paragraph-text><paragraph-text type="body">Attention is drawn to <class-ref scheme="cpc">A61L2/0029</class-ref>, <class-ref scheme="cpc">A61L2202/21</class-ref> and/or <class-ref scheme="cpc">A61L2202/22</class-ref> if the invention lies in the method of sterilization of the medicinal preparation rather than the sterilized medicinal preparation.</paragraph-text></section-body></relationship><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Electrotherapy, magnetotherapy, radiation therapy, ultrasound therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Radiotherapy per se</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N5/10</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Therapy by ultrasound</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N7/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Methods or apparatus related to mechanical vibrations</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">B06B</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Polymerisation induced by radiation</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08F</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Electric discharge tubes or discharge lamps</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">H01J</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">In <class-ref scheme="cpc">A61K41/10</class-ref> and its subgroups, pharmaceutical compositions are classified that are decontaminated prior to use, by applying radiation, or of which one of the constituents is thus decontaminated.</paragraph-text><paragraph-text type="body">Photosensitizers used in photodynamic therapy (the photosensitizer being considered as the therapeutically active part) and modified by another compound (e.g. polymer or an antibody) to be classified in <class-ref scheme="cpc">A61K41/0071</class-ref> or <class-ref scheme="cpc">A61K41/0076</class-ref> and according to the <class-ref scheme="cpc">A61K47/50</class-ref> subclass of the modifying agent.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2020-01-01"><classification-symbol scheme="cpc">A61K41/10</classification-symbol><definition-title>Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person</definition-title><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Attention is drawn to <class-ref scheme="cpc">A61L2/0029</class-ref> if the invention lies in the method of sterilization of the medicinal preparation rather than the sterilized medicinal preparation.</paragraph-text><paragraph-text type="body">Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses by radiation are classified in <class-ref scheme="cpc">A61L2/08</class-ref> - <class-ref scheme="cpc">A61L2/12</class-ref>.</paragraph-text></section-body></relationship></definition-item>
<definition-item date-revised="2018-01-01"><classification-symbol scheme="cpc">A61K45/06</classification-symbol><definition-title>Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Pharmaceuticals </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Galenic aspects</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Organic active ingredients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Inorganic active ingredients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K33/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Active ingredients of undetermined constitution (i.e. natural products) </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K35/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Active ingredients from algae, lichens, fungi or plants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K36/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Peptides, proteins</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K38/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Antigens or antibodies, vaccines, adjuvants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Homeopathy, thermotherapy, photodynamic therapy, photoactivable drugs</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Characterized by non-active ingredients e.g. carriers, inert additives, excipients...</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Conjugates; targeted drugs</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/50</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Gene therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K48/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Medicine/pharmacy - mechanical aspects</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F</class-ref>, <class-ref scheme="cpc">A61J</class-ref>, <class-ref scheme="cpc">A61M</class-ref>, <class-ref scheme="cpc">A61N</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Stents</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F2/07</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Contraceptive devices </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F6/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Ophthalmic implants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F9/0017</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Bandages, dressings, absorbent pads </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F13/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Making transdermal patches</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F2013/0296</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Tampons (also medicated)</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61F13/20</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Biomaterials</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Disinfecting or sterilising contact lenses</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L12/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">For bandages, dressings or absorbent pads</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L15/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Surgical sutures</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L17/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Surgical adhesives or cements</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L24/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">For wound dressings, bandages, also liquid, gel, powder</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L26/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">For (coating of) grafts, prostheses, also with active</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L27/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">For other surgical articles, e.g. stents, embolization</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Electrotherapy </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N1/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Iontophoresis</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N1/30</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Magnetotherapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61N2/00</class-ref></paragraph-text></table-column></table-row></table><paragraph-text type="subheading">Diagnosis</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Testing in vivo, e.g. screening, contrast agents, ultrasound</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Radioactive substances</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K51/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">In vitro diagnosis</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G01N</class-ref></paragraph-text></table-column></table-row></table><paragraph-text type="subheading">Other medical</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Dentistry</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K6/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Sterilization methods</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61L2/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body"> Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefore </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N5/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Contact lenses</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G02C7/04</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Healthcare informatics</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G16H</class-ref></paragraph-text></table-column></table-row></table><paragraph-text type="subheading">Other human necessities</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Cosmetics</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K8/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Biocides, pest repellants or attractants</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A01N</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Animal feeding-stuffs</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23K10/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Food or functional food (neutraceuticals)</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A23L</class-ref></paragraph-text></table-column></table-row></table><paragraph-text type="subheading">General chemistry</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Quaternary ammonium compounds</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07C211/62</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Phosphatides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07F9/10</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dendrimers</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08G83/002</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Macromolecular gels</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C08J3/075</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Detergent compositions</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C11D</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">1) No distinction is made between Invention and Additional information.</paragraph-text><paragraph-text type="body">2) Therapeutic use: the <class-ref scheme="cpc">A61K45/06</class-ref> classification symbol should mainly be reserved for mixtures containing at least one active ingredient without chemical characterisation.</paragraph-text><paragraph-text type="body">It is also used in the case that there are too many exemplified combinations.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2022-08-01"><classification-symbol scheme="cpc">A61K47/00</classification-symbol><definition-title>Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K47/00</class-ref> - <class-ref scheme="cpc">A61K47/46</class-ref></paragraph-text><list><list-item><paragraph-text type="body">Pharmaceutical compositions characterised by the excipients, i.e. the non-active ingredients.</paragraph-text></list-item><list-item><paragraph-text type="body">New excipients per se.</paragraph-text></list-item></list><paragraph-text type="body"><class-ref scheme="cpc">A61K47/50</class-ref></paragraph-text><list><list-item><paragraph-text type="body">Conjugates, i.e. compounds comprising a non-active ingredient chemically bound to the pharmaceutically active ingredient.</paragraph-text></list-item></list></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">It should be noted that in <class-ref scheme="cpc">A61K47/00</class-ref> the invention resides in the use of at least one particular compound as a biologically inert additive or excipient, for example to enhance the stability of a pharmaceutical formulation or to enhance the bioavailability of a biologically active ingredient in the body. The invention therefore does not reside in what the active ingredient does but in what at least one of the biologically inert ingredients does. It may be that this inert ingredient is a separate chemical entity from the biologically active ingredient or it may be that the inert ingredient is chemically bound to the biologically active ingredient. Thus any novelty that resides in the said inert compound per se will warrant classification in the appropriate area in class <class-ref scheme="cpc">C01</class-ref> for inorganic compounds or classes <class-ref scheme="cpc">C07</class-ref> or <class-ref scheme="cpc">C08</class-ref> for organic or polymeric compounds respectively.</paragraph-text><paragraph-text type="body">Galenical aspects of pharmaceutical compositions are classified in <class-ref scheme="cpc">A61K9/00</class-ref> and in <class-ref scheme="cpc">A61K47/00</class-ref>. The last place rule does not apply between <class-ref scheme="cpc">A61K9/00</class-ref> and <class-ref scheme="cpc">A61K47/00</class-ref> - <class-ref scheme="cpc">A61K47/46</class-ref>.</paragraph-text><paragraph-text type="body">Excipients can be classified in <class-ref scheme="cpc">A61K47/00</class-ref>- <class-ref scheme="cpc">A61K47/46</class-ref> or in <class-ref scheme="cpc">A61K9/00</class-ref>, depending on the situation: <class-ref scheme="cpc">A61K47/00</class-ref> is used to classify excipients in compositions for which <class-ref scheme="cpc">A61K9/00</class-ref> does not provide information on excipients. No <class-ref scheme="cpc">A61K47/00</class-ref> is given if <class-ref scheme="cpc">A61K9/00</class-ref> already provides information on excipients (e.g. tablet excipients are only classified in <class-ref scheme="cpc">A61K9/20</class-ref>...). New excipients per se are (in addition) classified in <class-ref scheme="cpc">A61K47/00</class-ref>. </paragraph-text><paragraph-text type="body">Conjugates, i.e. compounds comprising a non-active ingredient bound to the active ingredient, are classified in <class-ref scheme="cpc">A61K47/50</class-ref>. Pharmaceutical compositions comprising conjugates may in addition be classified in <class-ref scheme="cpc">A61K9/00</class-ref>.</paragraph-text><paragraph-text type="body">The active ingredients in pharmaceutical compositions are classified in <class-ref scheme="cpc">A61K31/00</class-ref> - <class-ref scheme="cpc">A61K45/00</class-ref>, or <class-ref scheme="cpc">A61K48/00</class-ref> - <class-ref scheme="cpc">A61K51/00</class-ref>.</paragraph-text></section-body></relationship><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/18</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Preparations containing radioactive substances </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K51/12</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Classified are concrete, well-defined pharmaceutical compositions disclosed in the examples. Also classified are independent claims defining galenical aspects of a pharmaceutical composition or a medical use.</paragraph-text><paragraph-text type="body">IIn principle all examples are classified, also &apos;standard&apos; examples in documents describing e.g. a new medical use.</paragraph-text><paragraph-text type="body">However, systematically classifying all excipients in the examples is not necessary, and often undesirable. In any case classified are excipients which are described as being important for the invention, or which the reader can identify as having an important function, e.g. for sustained release. For &apos;standard&apos; compositions the examiner should choose one or a few excipients to classify.</paragraph-text><paragraph-text type="body">Animal tests are not classified, unless it is absolutely clear that they represent the intended mode of administration.</paragraph-text><paragraph-text type="body">The description and dependent claims are not classified. However, if the document as a whole focuses on one clearly preferred embodiment, this embodiment may be classified, even in the absence of relevant examples or independent claims.</paragraph-text><paragraph-text type="body">In general, information relating to the invention is classified using invention information symbols, while additional information is classified using additional information symbols. This is largely up to the discretion of the examiner. Please note however the following special situations:</paragraph-text><list><list-item><paragraph-text type="body">Normally only final compositions are classified, not intermediates. However, it may be useful to classify intermediates as additional information (e.g. a tablet comprising microcapsules; a multicoated microparticle). If the intermediates are claimed separately, they must be classified as invention information. If, in the classification scheme, a group refers out to another group, an additional information symbol may still be given for the first group (e.g. oral mucoadhesive film). </paragraph-text></list-item></list><paragraph-text type="body"><class-ref scheme="cpc">A61K47/02</class-ref> covers inorganic compounds but does not cover polymeric inorganic materials, which are covered by <class-ref scheme="cpc">A61K47/30</class-ref> - macromolecular (organic or inorganic) compounds &#8211; e.g., inorganic polyphosphates.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K47/06</class-ref> covers hydrocarbon materials of both natural and synthetic sources. Natural examples include petrolatum, mineral oil and ozokerite &#8211; i.e., there are no functional groups present in such materials, i.e., ester, ketone, hydroxyl or carboxylic groups. <class-ref scheme="cpc">A61K47/06</class-ref> also covers mixtures of hydrocarbons as well as pure hydrocarbons.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K47/10</class-ref> covers alcohols such as aliphatic alcohols, phenols or salts thereof; polyalkylene glycols [PEG], [PPG]; poloxamers; PEG/POE alkyl ethers. This subgroup does not cover sugar alcohols (<class-ref scheme="cpc">A61K47/26</class-ref>) or copolymers comprising polyalkylene glycols or poloxamers (<class-ref scheme="cpc">A61K47/34</class-ref>).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K47/34</class-ref> does not cover polyalkoxylated compounds, which are classified according to the compounds being derivatised. The following list gives examples of such polyalkoxylated compounds together with the relevant group.</paragraph-text><list><list-item><paragraph-text type="body">POE alkyl ethers - <class-ref scheme="cpc">A61K47/10</class-ref></paragraph-text></list-item><list-item><paragraph-text type="body">PEG fatty acid esters &#8211; <class-ref scheme="cpc">A61K47/14</class-ref></paragraph-text></list-item><list-item><paragraph-text type="body">Poloxamines &#8211; <class-ref scheme="cpc">A61K47/18</class-ref></paragraph-text></list-item><list-item><paragraph-text type="body">Polysorbates &#8211; <class-ref scheme="cpc">A61K47/26</class-ref></paragraph-text></list-item><list-item><paragraph-text type="body">POE castor oil &#8211; <class-ref scheme="cpc">A61K47/44</class-ref></paragraph-text></list-item></list><paragraph-text type="body"><class-ref scheme="cpc">A61K47/44</class-ref> covers materials that comprise mixtures of chemically distinct components, i.e., more than one of the groups <class-ref scheme="cpc">A61K47/02</class-ref>-<class-ref scheme="cpc">A61K47/42</class-ref>, i.e., carboxylic acids and esters. Materials that comprise such mixtures may include natural or modified oils, fats or waxes such as olive oil, castor oil, montan wax, lignite, shellac, lanolin and beeswax. Materials that comprise only a mixture of different carboxylic acids &#8211; i.e., of different carbon chain lengths or a mixture of aromatic and aliphatic carboxylic acids &#8211; will be classified in <class-ref scheme="cpc">A61K47/12</class-ref>.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K47/64</class-ref> covers the situation where peptides, proteins or polyamino acids are chemically bonded directly to drugs or are chemically bonded to the drug via a linker. <class-ref scheme="cpc">A61K47/62</class-ref> is more appropriate where peptides, proteins or polyamino acids are bound or complexed to special galenical forms of a drug, e.g., a liposome or a nanoparticle modified on its surface by a peptidic modifying agent. In these latter situations, classification in <class-ref scheme="cpc">A61K47/69</class-ref> would also be appropriate.</paragraph-text><paragraph-text type="body">If the modifying agent in the conjugate is some kind of inclusion complex, e.g., a cyclodextrin, then classification in <class-ref scheme="cpc">A61K47/69</class-ref> will be appropriate. If cyclodextrin is used as a simple excipient then classification in <class-ref scheme="cpc">A61K47/40</class-ref> will be required.</paragraph-text></section-body></special-rules><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Targeting agent</paragraph-text></table-column><table-column><paragraph-text type="body">Natural or artificial substances that enhance absorption of a biologically active agent in a particular part of the body &#8211; i.e., in a particular organ or to a particular cell type.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Pre-targeting system</paragraph-text></table-column><table-column><paragraph-text type="body">An example of this is an immuno-conjugate that has a part that recognizes a target antigen and a part that recognizes a further substance to which a therapeutic agent is attached. When said conjugate is administered it binds to target cells, furnishing said cells with binding sites for the therapeutic agent.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Modifying agent</paragraph-text></table-column><table-column><paragraph-text type="body">Natural or artificial substances that enhance the physio-chemical properties of a biologically active agent &#8211; i.e., that improve long term storage stability or enhance bioavailability when delivered orally.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Macromolecular</paragraph-text></table-column><table-column><paragraph-text type="body">A chemical moiety (organic or inorganic) that is linked to identical sub-units in numbers of greater than 5. Thus, polysiloxanes are classified in <class-ref scheme="cpc">A61K47/34</class-ref>, polyphosphazines in <class-ref scheme="cpc">A61K47/34</class-ref> and inorganic species such as polyphosphate <class-ref scheme="cpc">A61K47/30</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Chemically bound</paragraph-text></table-column><table-column><paragraph-text type="body">When two distinct chemical entities are linked to one another by co-valent bonds. An alternative situation may arise when both chemical entities are linked using ionic bonds, for example using organic/inorganic ions that complex with one another, e.g., see <class-ref scheme="cpc">A61K47/52</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Codrug</paragraph-text></table-column><table-column><paragraph-text type="body">A dimer, oligomer or polymer of one or more pharmacologically or therapeutically active compounds. e.g. polyaspirin</paragraph-text></table-column></table-row></table></section-body></glossary-of-terms></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/34</classification-symbol><definition-title>Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers  (<class-ref scheme="cpc">A61K47/10</class-ref> takes precedence)</definition-title><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">This group does not cover polyalkoxylated compounds, which are classified according to the derivatized compounds. The following list of references provides examples of such polyalkoxylated compounds together with their relevant group.</paragraph-text></section-body></relationship><references><section-title>References</section-title><limiting-references><section-title>Limiting references</section-title><section-body><paragraph-text type="preamble">This place does not cover:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">POE alkyl ethers</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/10</class-ref></paragraph-text></table-column></table-row></table></section-body></limiting-references><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">PEG fatty acid esters</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/14</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">poloxamines</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/18</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">polysorbates</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/26</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">POE castor oil</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/44</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2023-08-01"><classification-symbol scheme="cpc">A61K47/50</classification-symbol><definition-title>the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Medicinal preparations containing conjugates. A conjugate is meant to define a pharmacologically/therapeutically-active agent or drug chemically bound (by covalent bonds or by complexation) to a modifying agent. The classification in this subgroup is based on this modifying agent. The &quot;pharmacologically/therapeutically-active agent&quot; covers a molecule used as the drug and linked to the modifying agent, or a molecule used as the drug and encapsulated/linked to a special physical/galenical form. The modifying agent is for example used to:</paragraph-text><list><list-item><paragraph-text type="body">modify the physico-chemical properties of the pharmacologically/therapeutically-active agent, for example to increase its solubility in bodily fluids,</paragraph-text></list-item><list-item><paragraph-text type="body">modify the pharmacokinetic properties, for example to increase the time of residence in the blood,</paragraph-text></list-item><list-item><paragraph-text type="body">modify the pharmacological activity (in case of e.g. codrugs or mutual drugs), or</paragraph-text></list-item><list-item><paragraph-text type="body">target specific sites in the body for delivery, i.e. receptors, cells, tissues or organs.</paragraph-text></list-item></list></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing organic active ingredients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Organic chemistry in general</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Labelling of peptides or proteins</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K1/13</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Enzymes or proenzymes</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N9/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">In the subgroups of <class-ref scheme="cpc">A61K47/50</class-ref>, the classification is based on the non-active ingredient, i.e. the modifying agent. </paragraph-text><paragraph-text type="body">However, for the conjugates of an antibody, the pharmacologically/therapeutically-active agent of the conjugate is also classified, in the subgroups of <class-ref scheme="cpc">A61K47/68</class-ref>. The modifying group must be part of a well-defined class of compounds.</paragraph-text><paragraph-text type="body">The last place priority rule does not apply in group <class-ref scheme="cpc">A61K47/50</class-ref>, i.e. all aspects of the invention are classified. For example, a liposome modified on its external surface by a modifying agent, is classified both in <class-ref scheme="cpc">A61K47/6911</class-ref> and in the appropriate subgroup of <class-ref scheme="cpc">A61K47/50</class-ref>, e.g. in <class-ref scheme="cpc">A61K47/62</class-ref> for a peptide/protein, and in the appropriate subgroup of <class-ref scheme="cpc">A61K47/6835</class-ref> for an antibody.</paragraph-text><paragraph-text type="body">Targeted drug delivery systems as defined in <class-ref scheme="cpc">A61K47/555</class-ref>, <class-ref scheme="cpc">A61K47/66</class-ref> and <class-ref scheme="cpc">A61K47/6891</class-ref> comprise more than one component. For example, in antibody-directed enzyme prodrug therapy [ADEPT], one component carries the enzyme to its target, and the other the prodrug. Although less detailed, the classification of conjugates in which the modifying component is a peptide follows a classification similar to that in the field of new peptides or proteins, i.e. <class-ref scheme="cpc">C07K14/00</class-ref> and subgroups. Similarly, the classification of conjugates in which the modifying component is an antibody, the classification of the characterising antibody follows a classification similar to that of new antibodies, <class-ref scheme="cpc">C07K16/00</class-ref> and subgroups, again less detailed. For the specificity of the antibody, the same rules are followed as for the classification in <class-ref scheme="cpc">C07K16/00</class-ref>. For the specificity of the antibody, if the antibody is new, the corresponding class in <class-ref scheme="cpc">C07K16/00</class-ref> and subgroups is also given.</paragraph-text><paragraph-text type="body">The active agent is also classified in <class-ref scheme="cpc">A61K47/50</class-ref> in two situations:</paragraph-text><list><list-item><paragraph-text type="body">if the modifying agent is also active: <class-ref scheme="cpc">A61K47/55</class-ref>, <class-ref scheme="cpc">A61K47/551</class-ref>, <class-ref scheme="cpc">A61K47/552</class-ref>, and in the case of sugars <class-ref scheme="cpc">A61K47/549</class-ref>;</paragraph-text></list-item><list-item><paragraph-text type="body">if the active agent is attached to an antibody as modifying agent: <class-ref scheme="cpc">A61K47/68</class-ref>.</paragraph-text></list-item></list></section-body></special-rules><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">ADEPT</paragraph-text></table-column><table-column><paragraph-text type="body">Antibody-Directed Enzyme-Prodrug Therapy</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">VDEPT</paragraph-text></table-column><table-column><paragraph-text type="body">Virus-Directed Enzyme-Prodrug Therapy</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">PDEPT</paragraph-text></table-column><table-column><paragraph-text type="body">Polymer-Directed Enzyme-Prodrug Therapy</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">ECTA</paragraph-text></table-column><table-column><paragraph-text type="body">Enzyme-Catalyzed Therapeutic Agent</paragraph-text></table-column></table-row></table></section-body></glossary-of-terms></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/52</classification-symbol><definition-title>the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Classic ion pairs of medicinal agents</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/543</classification-symbol><definition-title>{Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Fatty acid conjugates</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/542</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">He Cholesterol conjugates </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/554</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/546</classification-symbol><definition-title>{Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Porphyrins used as photosensitizers in photodynamic therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0071</class-ref>, <class-ref scheme="cpc">A61K41/0076</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Porphyrins used as fluorescent diagnostic optical agents administered in vivo</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0036</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Porphyrins used as photosensitizers in photodynamic therapy, where the photosensitizer is considered as the therapeutically active part, and modified by another compound, e.g. polymer or an antibody, should be classified in <class-ref scheme="cpc">A61K41/0071</class-ref> or <class-ref scheme="cpc">A61K41/0076</class-ref> in addition to the appropriate subgroup <class-ref scheme="cpc">A61K47/50</class-ref> according to the modifying agent.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/547</classification-symbol><definition-title>{Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Paramagnetic chelates used in MRI and conjugated to another compound, e.g. a polymer, a peptide, a protein, an antibody, a small molecule like a sugar</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/06</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Paramagnetic chelates used in MRI and conjugated to another compound not being used as therapeutic agent, according to the nature of the modifying agent</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/085</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Paramagnetic chelates used in MRI and not linked to by further compound, e.g. polymer, peptide, protein, antibody, small molecules like sugars</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/101</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Radiolabelled chelates</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K51/0474</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Radiolabelled chelates being linked to a further molecule, e.g. an organic compound, polymer, peptide, protein or polyamino acid, antibody</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K51/0497</class-ref>, <class-ref scheme="cpc">A61K51/065</class-ref>, <class-ref scheme="cpc">A61K51/088</class-ref>, <class-ref scheme="cpc">A61K51/1093</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/548</classification-symbol><definition-title>{Phosphates or phosphonates, e.g. bone-seeking  (phospholipids <class-ref scheme="cpc">A61K47/544</class-ref>)}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Nucleic acid carriers</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/549</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/549</classification-symbol><definition-title>{Sugars, nucleosides, nucleotides or nucleic acids}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Nucleic acids can be coding, non-coding, nucleic acid which being therapeutically-active or not, e.g. oligonucleotides, DNA, RNA, siRNA, and nucleic acid aptamers.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/55</classification-symbol><definition-title>the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Sugar, nucleoside, nucleotide, nucleic acid </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/549</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/554</classification-symbol><definition-title>{the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Cholesterol</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Codrugs of pharmacologically active/therapeutically-active steroids are classified in this group and also in <class-ref scheme="cpc">A61K47/55</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/555</classification-symbol><definition-title>{pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">A targeting agent able to target specific cells or receptors in the body (T) being an organic compound, not being a peptide, protein or antibody.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">The concept of &quot;pre-targeting&quot; covers the administration of the modifying agent, which is an agent able to target specific cells in the body, and of the pharmacologically or therapeutically active agent, e.g. drug D, in several steps, their &quot;binding&quot; occurring at the in vivo targeted site.</paragraph-text><paragraph-text type="body">It involves administration in at least two steps, for example, (i) a conjugate T-A corresponding to a targeting agent able to target specific cells or receptors in the body (T) linked to a compound A, and (ii) a conjugate D-M corresponding to the drug linked to a modifying agent M able to target the compound A. </paragraph-text><paragraph-text type="body">The sequence involves the administration of T-A and then D-M. Between step (i) and step (ii), a further compound able to bind to A and M may also be administered, e.g. during a clearing step.</paragraph-text><paragraph-text type="body">Classification is made according to the nature of T in the subgroups of <class-ref scheme="cpc">A61K47/555</class-ref>, <class-ref scheme="cpc">A61K47/66</class-ref>, and <class-ref scheme="cpc">A61K47/6891</class-ref>. </paragraph-text><paragraph-text type="body">In <class-ref scheme="cpc">A61K47/555</class-ref> and its subgroups, if T is an organic compound, other than a peptide, protein or antibody, classification is also made according to the nature of organic compound T in the appropriate <class-ref scheme="cpc">A61K47/54</class-ref> subgroup. If T is a peptide, protein or antibody, classification is made in the corresponding <class-ref scheme="cpc">A61K47/66</class-ref> (peptide or protein) or <class-ref scheme="cpc">A61K47/6891</class-ref> (antibody) group.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/556</classification-symbol><definition-title>{enzyme catalyzed therapeutic agent [ECTA]}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Enzymes being used as group A, and being first targeted to specific cells via administration of the conjugate T-A. Then, the conjugate M-D which being a substrate for A being administered. The enzyme A being able to cleave the conjugate M-D, which can be a prodrug. The drug D being thus released through enzymatic cleavage at particular targeted cells.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/558</classification-symbol><definition-title>{the modifying agent being a chemiluminescent acceptor}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Chemical reactions inducing the cleavage of the pharmacologically or therapeutically active agent from the carrier while at the same time producing light.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Conjugates being cleaved through activation by light in vivo in order to release the drug</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0042</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dyes or luminescent agents for photodynamic therapy</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0057</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Dyes or luminescent agents for optical diagnostic imaging</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/001</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2024-08-01"><classification-symbol scheme="cpc">A61K47/56</classification-symbol><definition-title>the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Block copolymers</paragraph-text></table-column><table-column><paragraph-text type="body"> <class-ref scheme="cpc">A61K8/90</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Peptides, proteins, polyamino acids </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/62</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Antibodies</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/68</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/61</classification-symbol><definition-title>the organic macromolecular compound being a polysaccharide or a derivative thereof</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Proteoglycans as modifying agents attached to the pharmacologically or therapeutically active agents</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/62</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Cyclodextrin being used to complex the drug </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/6951</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/62</classification-symbol><definition-title>the modifying agent being a protein, peptide or polyamino acid</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Peptidic linkers used to connect a drug and a modifying agent</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/65</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Antibodies or immunoglobulins </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/68</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Special physical or galenic forms modified by covalent attachment or complexation of a protein, peptide or polyamino acid, are classified in <class-ref scheme="cpc">A61K47/62</class-ref> and additionally in <class-ref scheme="cpc">A61K47/69</class-ref>, if considered relevant. E.g. a liposome modified on its surface by a peptide is classified in <class-ref scheme="cpc">A61K47/6911</class-ref> and in <class-ref scheme="cpc">A61K47/62</class-ref>, a PLGA nanoparticle modified on its surface by a peptide is classified in <class-ref scheme="cpc">A61K47/6937</class-ref> and in <class-ref scheme="cpc">A61K47/62</class-ref>. </paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/64</classification-symbol><definition-title>Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent  (peptidic linkers <class-ref scheme="cpc">A61K47/65</class-ref>)</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Conjugates, wherein a peptide or protein being the pharmacologically or therapeutically active agent is linked to another peptide or protein being the modifying agent via chemical methods.</paragraph-text><paragraph-text type="body">Chemically-produced peptides or protein-peptides or protein conjugates, the peptides or proteins used as modifying agents.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">The connection of the drug to the peptide, protein or polyamino acid can be by a direct covalent linkage or through a linker Fusion/chimeric proteins genetically produced</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K2319/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/646</classification-symbol><definition-title>{the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Haptens, e.g. conjugates of morphine or nicotine and KLH inducing an immune response</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/643</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Haptens, e.g. conjugates of morphine or nicotine and KLH inducing an immune response, are classified both in this group and additionally in <class-ref scheme="cpc">A61K47/643</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/66</classification-symbol><definition-title>the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">The concept of &quot;pre-targeting&quot; covers the administration of the modifying agent, i.e. an agent able to target specific cells in the body, and of the pharmacologically or therapeutically active agent (drug D) in several steps, their &quot;binding&quot; occurring at the in vivo targeted site. </paragraph-text><paragraph-text type="body">It involves administration in at least two steps, for example, (i) a conjugate T-A corresponding to a targeting agent T able to target specific cells or receptors in the body (T) linked to a compound A, and (ii) a conjugate D-M corresponding to the drug D linked to a modifying agent M, able to target the compound A. </paragraph-text><paragraph-text type="body">T being a peptide or protein, not being an antibody.</paragraph-text><paragraph-text type="body">The sequence involves the administration of T-A and then D-M. Between step (i) and step (ii), a further compound able to bind to both A and M may also be administered, e.g. during a clearing step. </paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">M being biotin and A being a (strept)avidin or a derivative thereof</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/665</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Classification is made according to the nature of T in subgroups of <class-ref scheme="cpc">A61K47/555</class-ref>, <class-ref scheme="cpc">A61K47/66</class-ref>, and <class-ref scheme="cpc">A61K47/6891</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/67</classification-symbol><definition-title>{Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT], VDEPT. An enzyme is used as group A in the sense of this group, being first targeted to specific cells via administration of the conjugate T-A. Then, the conjugate M-D, which is a substrate for A, is administered. The enzyme A is able to cleave the conjugate M-D, which can be a prodrug. The drug D is thus released through enzymatic cleavage at particular targeted cells.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6803</classification-symbol><definition-title>{Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates. The modifying part is an antibody or immunoglobulin bearing at least one antigen-binding site.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Antibodies per se are classified in <class-ref scheme="cpc">C07K16/00</class-ref>.</paragraph-text></section-body></relationship><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Conjugates comprising a polymer or a polyamino acid</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/6883</class-ref>, <class-ref scheme="cpc">A61K47/6885</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">In this group, classification is made according to the nature of the drug, i.e. the pharmacologically or therapeutically active agents in the antibody conjugate. If the nature of the antibody in a specific conjugate is known, it is additionally classified in <class-ref scheme="cpc">A61K47/6835</class-ref>. If the conjugate comprises also a polymer or a polyamino acid, then classification is also made in <class-ref scheme="cpc">A61K47/6883</class-ref> or <class-ref scheme="cpc">A61K47/6885</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6835</classification-symbol><definition-title>{the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Modifying agents being a well-defined antibody or immunoglobulin bearing at least one antigen-binding site.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Porphyrins used as photosensitizers in photodynamic therapy, the photosensitizer being considered as the therapeutically active part, and modified by an antibody</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0071</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">According to the nature of the antibody, classification is additionally made in the appropriate groups of <class-ref scheme="cpc">A61K47/6835</class-ref>. The pharmacologically or therapeutically active agent in the antibody conjugate is additionally classified in <class-ref scheme="cpc">A61K47/6803</class-ref>, whenever considered appropriate.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6891</classification-symbol><definition-title>{Pre-targeting systems involving an antibody for targeting specific cells}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Pre-targeting systems involving an antibody for targeting specific cells. The concept of &quot;pre-targeting&quot; covers the administration of the modifying agent, i.e. an agent able to target specific cells in the body, and of the pharmacologically or therapeutically active agent (drug D) in several steps, their &quot;binding&quot; occurring at the in vivo targeted site.</paragraph-text><paragraph-text type="body">It involves administration in at least two steps, for example, (i) a conjugate T-A corresponding to a targeting agent able to target specific cells or receptors in the body (T) linked to a compound A (wherein T is an antibody), and (ii) a conjugate D-M corresponding to the drug linked to a modifying agent M, able to target the compound A.</paragraph-text><paragraph-text type="body">The sequence involves e.g. the administration of T-A and then D-M. Between step (i) and step (ii), a further compound able to bind to A and M may also be administered, e.g. during a clearing step.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Classification is additionally made according to the nature of T in <class-ref scheme="cpc">A61K47/555</class-ref>, <class-ref scheme="cpc">A61K47/66</class-ref>, and <class-ref scheme="cpc">A61K47/6893</class-ref>. Classification is also made according to the nature of the antibody in <class-ref scheme="cpc">A61K47/6835</class-ref>. If M and A form a pair of biotin and (strept)avidin, or derivatives of biotin and (strept)avidin, then classification is also made in <class-ref scheme="cpc">A61K47/6898</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6898</classification-symbol><definition-title>{using avidin- or biotin-conjugated antibodies}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Avidin-biotin systems, wherein at least one avidin- or biotin-conjugated antibody is used in a two- or three-steps pretargeting system, e.g. wherein M and A in form a pair of biotin and (strept)avidin, or derivatives of biotin and (strept)avidin.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6899</classification-symbol><definition-title>{Antibody-Directed Enzyme Prodrug Therapy [ADEPT]}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Antibody Directed Enzyme Prodrug Therapy [ADEPT]. An enzyme is used as group A and is first targeted to specific cells via administration of the conjugate T-A. Then, the conjugate M-D, which is a substrate for A, is administered. The enzyme A is able to cleave the conjugate M-D, which can be a prodrug. The drug D is thus released through enzymatic cleavage at particular targeted cells.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/69</classification-symbol><definition-title>the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Conjugates characterized by a special physical or galenical form.</paragraph-text><paragraph-text type="body">The conjugates correspond either (i) to a pharmacologically or therapeutically active agent complexed/covalently linked to the special physical or galenical form, e.g. on the surface of a polymeric nanoparticle or liposome, or to polymeric chains in the matrix of a polymeric gel, or (ii) to a special physical or galenical form encapsulating the pharmacologically or therapeutically active agent and modified on its surface or matrix by a modifying agent.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">In case of (i) above, classification is made according to the nature of the special physical or galenical form in this group. Additionally the compound, to which the pharmacologically or therapeutically active agent is linked, is classified in the relevant subgroups of <class-ref scheme="cpc">A61K47/50</class-ref> e.g. <class-ref scheme="cpc">A61K47/544</class-ref> in case of a drug linked to a phospholipid and inserted in the bilayer surface of a liposome.</paragraph-text><paragraph-text type="body">In case of (ii) above, classification is made according to the nature of the modifying agent. Physical or galenical forms not modified by a modifying agent and/or wherein the pharmacologically or therapeutically active agent is not complexed/covalently linked to said forms, are not classified in <class-ref scheme="cpc">A61K47/50</class-ref>, but in <class-ref scheme="cpc">A61K9/00</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6901</classification-symbol><definition-title>{Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Encapsulation in cells</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/5068</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Encapsulation in a virus capsid </paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/5184</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6907</classification-symbol><definition-title>{the form being a microemulsion, nanoemulsion or micelle}</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Simple encapsulation of a drug in micelle</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/1075</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Micelles modified by a polymer because they incorporate a polymer-lipid conjugate are only classified in this group, if the polymer modifying the lipid is unusual. Micelles, which are pegylated because they incorporate a pegylated lipid, are not classified in this group, but in <class-ref scheme="cpc">A61K9/1075</class-ref>.</paragraph-text></section-body></special-rules><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Microemulsion </paragraph-text></table-column><table-column><paragraph-text type="body">means that the dispersed phase being in the form of globules having a diameter above or equal to 1 micrometer.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Nanoemulsion</paragraph-text></table-column><table-column><paragraph-text type="body">means that the dispersed phase being in the form of globules having a diameter below 1 micrometer.</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Micelles</paragraph-text></table-column><table-column><paragraph-text type="body">comprise a monolayer of surfactant molecules that are aggregated head-to-head and tail-to-tail, thus forming a small spherical particle; micelles can be normal, i.e. the surfactant heads are hydrophilic, or inverse.</paragraph-text></table-column></table-row></table></section-body></glossary-of-terms></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6911</classification-symbol><definition-title>{the form being a liposome}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Liposomes, i.e. bi-layered vesicles, having its surface modified by covalent attachment or complexation of the pharmacologically or therapeutically active agent and/or modifying agent.</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Encapsulation of a drug, which is not functionalised on its surface by a modifying agent</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/127</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Antibodies</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/6913</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Liposomes, which are modified by a polymer because they incorporate a polymer-lipid conjugate are only classified in this group, if the polymer modifying the lipid is unusual. Liposomes, which are PEGylated because they incorporate a PEGylated lipid, are not classified in this group, but in <class-ref scheme="cpc">A61K9/1271</class-ref>. </paragraph-text><paragraph-text type="body">When the surface of the liposome is functionalised by a modifying agent, classification is also made according to the nature of this modifying agent, e.g. a liposome modified on its surface by a peptide is classified in this group and additionally in <class-ref scheme="cpc">A61K47/605</class-ref>. Liposomes, wherein the pharmacologically or therapeutically active agent is linked to a phospholipid of the liposomal surface, are classified in this group and additionally in <class-ref scheme="cpc">A61K47/544</class-ref>. </paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6913</classification-symbol><definition-title>{the liposome being modified on its surface by an antibody}</definition-title><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Classification is also made according to the nature of the antibody in the appropriate subgroup of <class-ref scheme="cpc">A61K47/6835</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6915</classification-symbol><definition-title>{the form being a liposome with polymerisable or polymerized bilayer-forming substances, e.g. polymersomes}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Polymersomes, i.e. a liposome with polymerisable or polymerized bilayer-forming substances.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Liposomes comprising polymers grafted on their surface are not classified in this group, but in <class-ref scheme="cpc">A61K47/6911</class-ref>, if the polymer is unusual, or in <class-ref scheme="cpc">A61K9/1271</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6923</classification-symbol><definition-title>{the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Inorganic particles, e.g. ceramic particles, silica particles, ferrite, synsorb</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">When the inorganic particle is a magnetic particle, being guided from outside the body with the means of a magnetic field, classification is additionally made in <class-ref scheme="cpc">A61K41/00</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6925</classification-symbol><definition-title>{the form being a microcapsule, nanocapsule, microbubble or nanobubble}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Microcapsules, nanocapsules, microbubbles or nanobubbles, i.e. a hollow or gas-filled microparticle or nanoparticle or sphere, a gas-filled microparticle or nanoparticle for use in therapy</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Micro- or nanobubbles used for ultrasound imaging</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/223</class-ref>, <class-ref scheme="cpc">A61K49/225</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Pharmacologically or therapeutically active agents released from a microcapsule or nanocapsule by acoustic/ultrasound activation are also classified in <class-ref scheme="cpc">A61K41/0028</class-ref> and <class-ref scheme="cpc">A61K9/0009</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6927</classification-symbol><definition-title>{the form being a solid microparticle having no hollow or gas-filled cores}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Solid microparticles having no hollow or gas-filled core, wherein its size or diameter is higher or equal to 1 micrometer.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2017-08-01"><classification-symbol scheme="cpc">A61K47/6929</classification-symbol><definition-title>{the form being a nanoparticle, e.g. an immuno-nanoparticle}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Nanoparticles, e.g. immuno-nanoparticles, wherein its size or diameter is smaller than 1 micrometer.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Classification is also made according to the nature of the antibody with the appropriate subgroup of <class-ref scheme="cpc">A61K47/6835</class-ref>.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2024-01-01"><classification-symbol scheme="cpc">A61K48/00</classification-symbol><definition-title>Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Genetic material encoding proteins, the in vivo expression of which results in an in vivo therapeutic effect being attained. Cells can be used as delivery vehicle following ex vivo transfection with a nucleic acid encoding a therapeutic protein, enzyme or peptide if the therapeutic effect is a consequence of the ex vivo transfection step, i.e. arising as a result of the modification carried out. The protein in question may be expressed directly from the delivered nucleic acid sequence, or may, for example, be involved in a recombination process with a mutant, &apos;defective&apos; gene, protein expression from the &apos;repaired&apos; gene then ensuing at a time thereafter. The expression of the protein may be to replace / complement a &apos;defective protein&apos;, or may be to provide an entity (such as an enzyme) which is therapeutic (for example in the context of cancer therapy).</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Transgenic animals are classified in <class-ref scheme="cpc">A01K67/027</class-ref>.</paragraph-text><paragraph-text type="body">Proteins and peptides per se, encoded by the genetic material, are classified in the appropriate <class-ref scheme="cpc">C07K</class-ref> subgroups, unless the protein is an enzyme. In this case the appropriate subgroup in <class-ref scheme="cpc">C12N9/00</class-ref> should be used. Then classification of the specific enzyme is also made in <class-ref scheme="cpc">C12Y</class-ref> as invention.</paragraph-text><paragraph-text type="body">If therapy arises only as a consequence of the cells per se being delivered, and not due to the manner in which the cells have been modified ex vivo, classification in the subclass for gene therapy should not be made.</paragraph-text></section-body></relationship><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Liposomes</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/127</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations comprising compounds having three or more nucleosides or nucleotides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/7088</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K35/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medical use of proteins</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K38/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medical use of vaccines or antibodies</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K39/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Medicinal preparations characterised by the non-active ingredient</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Specific therapeutic activities</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61P</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Proteins</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K14/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Antibodies</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K16/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Cells</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N5/06</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Viruses</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N7/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Genetic engineering</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N15/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Antisense nucleic acids, siRNA</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N15/113</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Vectors for animal cells</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N15/85</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Viral vectors</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12N15/86</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">An invention classification symbol should be given in <class-ref scheme="cpc">A61K38/00</class-ref> for the protein or peptide if the expression results from the nucleic acid delivered via gene therapy.</paragraph-text><paragraph-text type="body">Enabling subject matter should be classified. More specifically, subject matter that pertains to the technical effect in question which the skilled person would be able to carry out based on the teachings of the application without undue burden, should be classified. Subject matter which is enabling but not clearly a technical contribution over the art should also be classified. Subject matter which is purely hypothetical or theoretical should not be classified. An example is when a particular substance is stated to be suitable for the treatment of a list of diseases but for which no data, even in an in vitro or animal model setting, is made available. On the other hand, subject matter supported by data which may be for example derived only from an in vitro setting but which lends at least partial credibility to an in vivo treatment should be classified.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2023-08-01"><classification-symbol scheme="cpc">A61K49/00</classification-symbol><definition-title>Preparations for testing in vivo</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Contrast agents for use in diagnostic imaging methods performed in vivo, or for detecting in vivo.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">An apparatus used for in vivo imaging is classified in <class-ref scheme="cpc">A61B</class-ref>.</paragraph-text><paragraph-text type="body">In the preparation of new organic compounds and their use in X-ray contrast preparations, classification is only made in the relevant subclasses <class-ref scheme="cpc">C07C</class-ref>&#160;-&#160;<class-ref scheme="cpc">C07J</class-ref> according to the type of compound.</paragraph-text><paragraph-text type="body">Galenical aspects of pharmaceutical compositions: if this is an important aspect of the invention, it may also be classified in <class-ref scheme="cpc">A61K9/00</class-ref> or <class-ref scheme="cpc">A61K47/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K47/46</class-ref>.</paragraph-text></section-body></relationship><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Preparations for testing in vivo using radioactive substances, or substances labeled with a radioactive isotope used for in vivo imaging or detection</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K51/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Preparations for testing in vitro or ex vivo</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G01N</class-ref>, <class-ref scheme="cpc">C12Q</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">In vivo</paragraph-text></table-column><table-column><paragraph-text type="body">in the living animal or performed on/in contact with the living animal</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Ex vivo</paragraph-text></table-column><table-column><paragraph-text type="body">in a sample taken from the living animal</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">In vitro</paragraph-text></table-column><table-column><paragraph-text type="body">means literally: in glass. Tests in vitro are performed outside the living or dead body, e.g. in a test tube or a Petri dish.</paragraph-text></table-column></table-row></table></section-body></glossary-of-terms></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K49/0002</classification-symbol><definition-title>{General or multifunctional contrast agents, e.g. chelated agents}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">General contrast agents are e.g. chelating agents for which several imaging methods are exemplified and/or claimed, e.g., an antibody labeled with a chelating group, where the chelating group is used to complex either gadolinium (for MRI) or a heavy metal (for X-ray imaging). This subgroup also includes conjugates of a targeting agent, linked to a chelating group, wherein the application mentions several imaging techniques, without an actual example.</paragraph-text><paragraph-text type="body">Multifunctional or multimodal agents are preparations, in which the contrast agent is suitable for more than one imaging technique, e.g. agents for dual mode imaging, e.g., containing a moiety for MRI and a fluorescent moiety.</paragraph-text><paragraph-text type="body">The classification codes of the individual imaging techniques are also given.</paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2023-08-01"><classification-symbol scheme="cpc">A61K49/0004</classification-symbol><definition-title>{Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><list><list-item><paragraph-text type="body">compositions used for assessing biological conditions or parameters of a patient or mammal.</paragraph-text></list-item><list-item><paragraph-text type="body">skin tests.</paragraph-text></list-item><list-item><paragraph-text type="body">screening methods performed in vivo using non-human animal models wherein the animal model is especially adapted for this screening, in order to find new agents for treating a disorder or disease.</paragraph-text></list-item></list></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body"> Medicinal preparations containing organic active ingredients</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">New breeds of vertebrates, e.g. animal models</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A01K67/027</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Non-human animal models (e.g. transgenic model for heart failure, Alzheimer disease animal model) are only classified in subgroup&#160;<class-ref scheme="cpc">A61K49/0008</class-ref>&#160;if they are used in a method for testing/screening agent in vivo and if this testing/screening for therapeutic usefulness in vivo is the invention or part of the invention.</paragraph-text><paragraph-text type="body">This subgroup is not used for those documents in which the examples are using a well-known animal model to verify if an agent does indeed exert the effect it is supposed to, where the actual invention is the compound or its use.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2023-08-01"><classification-symbol scheme="cpc">A61K49/001</classification-symbol><definition-title>{Preparation for luminescence or biological staining}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Diagnostic compositions containing an agent detected in vivo using fluorescence, phosphorescence, (chemo)luminescence or dying/colouring/staining.</paragraph-text></section-body></definition-statement><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">If a fluorescent group is complexed or covalently linked to a carrier, classification is also made according to the nature of the carrier in the appropriate <class-ref scheme="cpc">A61K49/005</class-ref> subgroup.</paragraph-text><paragraph-text type="body">If the physical or galenical form containing a fluorescent agent is modified by a particular agent, classification is also made according to the nature of this agent in the appropriate <class-ref scheme="cpc">A61K49/005</class-ref> subgroup.</paragraph-text><paragraph-text type="body">Classification is also made according to the nature of the fluorescent group in the appropriate subgroup of <class-ref scheme="cpc">A61K49/0019</class-ref>.</paragraph-text><paragraph-text type="body">If the dye used for staining is fluorescent, classification is also given for the appropriate subgroup of <class-ref scheme="cpc">A61K49/0019</class-ref>.</paragraph-text><paragraph-text type="body">Quantum dots modified on their surface by an antibody are also classified in <class-ref scheme="cpc">A61K49/0058</class-ref>.</paragraph-text><paragraph-text type="body">When the formulation aspect is the invention or part of the invention (e.g. liposomal formulations), or when the physical form is the fluorescence-active part (e.g. quantum dots), classification is also made according to the appropriate&#160;<class-ref scheme="cpc">A61K49/0063</class-ref>&#160;group.</paragraph-text><paragraph-text type="body">In the fluorescence subgroups, the compound can be characterised by the fluorescing group, by the carrier/targeting group and/or the physical/galenical form. If the three aspects are present, the three groups must be allocated.</paragraph-text><paragraph-text type="body">Microemulsion means that the dispersed phase is in the form of globules having a diameter above or equal to 1 micrometer. Nanoemulsion means that the dispersed phase is in the form of globules having a diameter below 1 micrometer.</paragraph-text><paragraph-text type="body">Micelles comprise a monolayer of surfactant molecules that are aggregated head-to-head and tail-to-tail, thus forming a small spherical particle; micelles can be normal, i.e. the surfactant heads are hydrophilic, or inverse.</paragraph-text><paragraph-text type="body">When the surface of the liposome encapsulating a fluorescent agent and used in vivo is functionalised by a modifying agent, classification is also made according to the nature of this modifying agent: e.g. a liposome modified on its surface by a peptide is classified in <class-ref scheme="cpc">A61K49/0084</class-ref> and <class-ref scheme="cpc">A61K49/0056</class-ref>. Liposomes encapsulating a fluorescent agent, used in vivo and modified on their surface by a polymer because they incorporate a polymer-lipid conjugate, are only additionally classified in <class-ref scheme="cpc">A61K49/0054</class-ref> if the polymer modifying the lipid is unusual. Liposomes encapsulating a fluorescent agent which are pegylated because they incorporate a pegylated lipid are only classified in <class-ref scheme="cpc">A61K49/0084</class-ref>, not in <class-ref scheme="cpc">A61K49/0054</class-ref>.</paragraph-text><paragraph-text type="body">When the surface of the microparticle encapsulating a fluorescent agent and used in vivo is functionalised by a modifying agent, classification is also made according to the nature of this modifying agent, e.g. a microparticle modified on its surface by a peptide is classified in <class-ref scheme="cpc">A61K49/0091</class-ref> and <class-ref scheme="cpc">A61K49/0056</class-ref>.</paragraph-text></section-body></special-rules><glossary-of-terms><section-title>Glossary of terms</section-title><section-body><paragraph-text type="preamble">In this place, the following terms or expressions are used with the meaning indicated:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Luminescence</paragraph-text></table-column><table-column><paragraph-text type="body">light emanating from the compound or composition when used in vivo</paragraph-text></table-column></table-row></table></section-body></glossary-of-terms></definition-item>
<definition-item><classification-symbol scheme="cpc">A61K49/04</classification-symbol><definition-title>X-ray contrast preparations</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">compositions used for enhancing the contrast of an X-ray image taken in vivo or in contact with the living animal/patient.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0404</class-ref> (2 dots): containing barium sulphate.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0409</class-ref> (2 dots): physical forms, mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound. </paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0414</class-ref> (3 dots): particles, beads, capsules, spheres. </paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0419</class-ref> (4 dots): microparticles, microbeads, microcapsules, microspheres (i.e. having a size or diameter higher or equal to 1 micrometer). </paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0423</class-ref> (4 dots): nanoparticles, nanobeads, nanospheres, nanocapsules (i.e. having a size or diameter smaller than 1 micrometer). </paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0428</class-ref> (5 dots): surface-modified nanoparticles, e.g. immuno-nanoparticles. </paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0433</class-ref> (2 dots): containing an organic halogenated X-ray contrast-enhancing agent.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0438</class-ref> (3 dots): organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0442</class-ref> (3 dots): polymeric X-ray contrast-enhancing agent comprising a halogenated group.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0447</class-ref> (3 dots): physical forms, mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0452</class-ref> (4 dots): solutions, e.g. for injection.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0457</class-ref> (4 dots): semi-solid forms, ointments, gels, hydrogels. </paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0461</class-ref> (4 dots): dispersions,colloids, emulsions, suspensions.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0466</class-ref> (5 dots): liposomes, lipoprotein vesicles (e.g. HDL and LDL lipoproteins), phospholipidic or polymeric micelles. </paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0471</class-ref> (5 dots): perflubron (i.e. perfluoroctylbromide, C<sub>8</sub>F<sub>17</sub>Br) emulsions </paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0476</class-ref> (4 dots): particles, beads, capsules, spheres.</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/048</class-ref> (5 dots): microparticles, microbeads, microcapsules, microspheres (i.e. having a size or diameter higher or equal to 1 micrometer).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0485</class-ref> (5 dots): nanoparticles, nanobeads, nanospheres, nanocapsules (i.e. having a size or diameter smaller than 1 micrometer).</paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/049</class-ref> (6 dots): surface-modified nanoparticles, e.g. immune-nanoparticles. </paragraph-text><paragraph-text type="body"><class-ref scheme="cpc">A61K49/0495</class-ref> (4 dots): intended for oral administration </paragraph-text></section-body></definition-statement></definition-item>
<definition-item date-revised="2023-08-01"><classification-symbol scheme="cpc">A61K49/06</classification-symbol><definition-title>Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Contrast agents used for enhancing the (diagnostic) imaging or detection in vivo, i.e., in the living animal or patient. Such contrast agents are active in MRI because they bear an NMR-active nucleus (e.g. 1H, 13C, 31P, 19F), or because they have a magnetisable group (e.g. iron oxide).</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K9/5094</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Magnetic targeting of therapeutic agents</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Magnetic compositions used for therapeutic heating of a living body part</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0052</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Pharmaceutical compositions in which the active agent is chemically bound to inorganic nanoparticles</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K47/6923</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Detecting, measuring or recording for diagnosis involving electronic or nuclear magnetic resonance</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61B5/055</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Introduction of isotopes of elements into organic compounds (e.g. deuterium, 13C)</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07B59/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">The classification is made according to the carrier which is covalently linked/complexed to the MRI-active nucleus that is responsible for the NMR/MRI signal (e.g. Gd<sup>3+</sup>), and according to the galenical aspect or physical form (in&#160;<class-ref scheme="cpc">A61K49/18</class-ref>&#160;subgroups).</paragraph-text><paragraph-text type="body">The complex-forming compound (e.g. chelating group) of an NMR/MRI-active metal ion is classified only if it is an uncommon agent that is the real contribution to the claimed invention, or if it is the only carrier (i.e. no targeting part like e.g. a peptide further linked to the chelating group). In the <class-ref scheme="cpc">A61K49/101</class-ref> subgroups, the MRI-active nucleus being complexed to a complex-forming compound, e.g. chelating group. Classification being made according to the nature of this complex-forming agent, if it being either an uncommon or new complexing agent (not the usual DTPA, DOTA, DOTP, etc. groups) that forms the real contribution to the claimed MRI invention, or if it being not conjugated to any further molecule, e.g. which being not conjugated to a polymer, peptide, protein or antibody. In that latter case, the MRI probe being e.g. a paramagnetic metal chelate.</paragraph-text><paragraph-text type="body"> Chelates (e.g. Gd-DOTA) conjugated to a further molecule are classified in&#160;<class-ref scheme="cpc">A61K49/085</class-ref>&#160;and, additionally, according to the nature of this further molecule, e.g. an MRI contrast agent being Gd-DOTA conjugated to glucose is classified in&#160;<class-ref scheme="cpc">A61K49/085</class-ref>&#160;and&#160;<class-ref scheme="cpc">A61K49/10</class-ref>, a MRI contrast agent comprising a plurality of Gd-DOTA appending to a linear polymer backbone is classified in&#160;<class-ref scheme="cpc">A61K49/085</class-ref>&#160;and&#160;<class-ref scheme="cpc">A61K49/128</class-ref>. MRI contrast agents which are based on MRI-active nanoparticles (e.g. iron oxide nanoparticles, MRI nanoparticles) are classified in the appropriate&#160;<class-ref scheme="cpc">A61K49/1818</class-ref>&#160;subgroups. If the nanoparticles have a super/para/magnetic core which is coated or functionalised with different compounds, classification is made according to the nature of all these different compounds (e.g. a nanoparticle having a super/para/magnetic core which is coated with an organic silane linked to a peptide is classified in&#160;<class-ref scheme="cpc">A61K49/1848</class-ref>&#160;and&#160;<class-ref scheme="cpc">A61K49/1866</class-ref>). MRI contrast agents containing free radicals are classified in&#160;<class-ref scheme="cpc">A61K49/20</class-ref>.</paragraph-text><paragraph-text type="body">When the carrier is a peptide or protein, it is classified in <class-ref scheme="cpc">A61K49/14</class-ref> and subgroups, e.g. a carrier being a polyamino acid is classified in <class-ref scheme="cpc">A61K49/146</class-ref> and not in <class-ref scheme="cpc">A61K49/16</class-ref> that concern antibodies. If the MRI-active nucleus being linked to the peptide or protein or polyamino acid via a complexing or chelating group, the subgroup <class-ref scheme="cpc">A61K49/085</class-ref> should also be given. If the peptide or protein or polyamino acid being a dendrimer, a dendron, or hyperbranched, then the <class-ref scheme="cpc">A61K49/124</class-ref> is also given.</paragraph-text><paragraph-text type="body">When the carrier is an organic macromolecular compound, it concerns an oligomeric, polymeric, dendrimeric molecule, not a peptide, protein, polyamino acid (see <class-ref scheme="cpc">A61K49/00</class-ref>) or an antibody (see <class-ref scheme="cpc">A61K49/00</class-ref> or <class-ref scheme="cpc">A61K49/16</class-ref>).</paragraph-text><paragraph-text type="body">Dendrimeric, dendronised or hyperbranched polyamino acids used as carriers are also classified in <class-ref scheme="cpc">A61K49/146</class-ref>.</paragraph-text><paragraph-text type="body">If the MRI-active nucleus is linked to the peptide or protein or polyamino acid via a complexing or chelating group, the subgroup <class-ref scheme="cpc">A61K49/085</class-ref> should also be allocated. If the peptide or protein or polyamino acid is a dendrimer, a dendron, or hyperbranched, then the <class-ref scheme="cpc">A61K49/124</class-ref> is also allocated.</paragraph-text><paragraph-text type="body">If the MRI-active nucleus is linked to the antibody via a complexing or chelating group, the subgroup <class-ref scheme="cpc">A61K49/085</class-ref> should also be allocated.</paragraph-text><paragraph-text type="body">If the paramagnetic metal complexes are covalently linked to the bilayered membrane, then the <class-ref scheme="cpc">A61K49/085</class-ref> subgroup is also allocated. Liposomes modified on their external surface by a targeting agent, e.g. an antibody are classified in <class-ref scheme="cpc">A61K49/1812</class-ref> without further indication for the targeting agent.</paragraph-text><paragraph-text type="body">For nanoparticles, i.e. having a size or diameter smaller than 1 micrometer, the subgroups <class-ref scheme="cpc">B82Y5/00</class-ref> and <class-ref scheme="cpc">B82Y15/00</class-ref> are also allocated.</paragraph-text></section-body></special-rules></definition-item>
<definition-item date-revised="2023-08-01"><classification-symbol scheme="cpc">A61K49/22</classification-symbol><definition-title>Echographic preparations; Ultrasound imaging preparations {; Optoacoustic imaging preparations}</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Compositions used for the in vivo diagnosis using ultrasound activation, or wherein the detected signal is an acoustic signal (e.g. optoacoustic imaging).</paragraph-text></section-body></definition-statement><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Preparations liberating a therapeutically active compound by applying ultrasound</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0028</class-ref>, <class-ref scheme="cpc">A61K9/00</class-ref>, <class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Preparations containing sonosensitizers for use in therapy, sonoferese or ultrasonically enhanced transdermal delivery</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K41/0047</class-ref>, <class-ref scheme="cpc">A61K9/00</class-ref>, <class-ref scheme="cpc">A61K47/00</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2023-08-01"><classification-symbol scheme="cpc">A61K51/00</classification-symbol><definition-title>Preparations containing radioactive substances for use in therapy or testing in vivo</definition-title><definition-statement><section-title>Definition statement</section-title><section-body><paragraph-text type="preamble">This place covers:</paragraph-text><paragraph-text type="body">Preparations containing radioactive substances or substances that bear a radioactive label, used for therapy in humans or animals, or used for testing in vivo, diagnosis in vivo or diagnostic imaging in vivo.</paragraph-text><paragraph-text type="body">Liposomes encapsulating the radioactive probe and/or having no radiolabelled phospholipids are classified in&#160;<class-ref scheme="cpc">A61K51/1234</class-ref>.</paragraph-text></section-body></definition-statement><relationship><section-title>Relationships with other classification places</section-title><section-body><paragraph-text type="body">Galenical aspects of pharmaceutical compositions: if this is an important aspect of the invention, it may also be classified in <class-ref scheme="cpc">A61K9/00</class-ref> or <class-ref scheme="cpc">A61K47/00</class-ref>&#160;-&#160;<class-ref scheme="cpc">A61K47/46</class-ref>.</paragraph-text><paragraph-text type="body">Preparations for testing in vitro or ex vivo are classified in <class-ref scheme="cpc">G01N</class-ref> or <class-ref scheme="cpc">C12Q</class-ref>, depending on the techniques used.</paragraph-text><paragraph-text type="body">Radioactive compounds that are new are also classified in <class-ref scheme="cpc">C07B59/00</class-ref>.</paragraph-text></section-body></relationship><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">The use in vivo of substances containing a non-radioactive isotope, such as deuterium or 13C.</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K31/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Preparations for testing in vivo using non-radioactive substances</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K49/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Introduction of isotopes of elements into organic compounds</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07B59/00</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">Labelling of peptides</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C07K1/13</class-ref></paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">The use of preparations containing a radioactive substance or a substance that bears a radioactive label, used for diagnosis ex vivo or used for diagnosis or testing in vitro. Therefore, the use in testing in bacteria on, e.g. a Petri dish is excluded.</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">G01N33/60</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references><special-rules><section-title>Special rules of classification</section-title><section-body><paragraph-text type="body">Compositions that are well defined and disclosed in the examples or in the claims are classified in this group. Thus, radioactive isotopes mentioned only in the description as being possibly linked to an active agent are not classified here.</paragraph-text><paragraph-text type="body">The classification is made according to the carrier which is covalently linked, or complexed to the radionuclide, and according to the galenical aspect(s) or physical form(s).</paragraph-text><paragraph-text type="body">The classification of conjugates in which the carrier is an antibody, the classification of the characterising antibody follows a classification similar to that of new antibodies, <class-ref scheme="cpc">C07K16/00</class-ref> and subgroups, although less detailed. For the specificity of the antibody, the same rules are followed as for the classification in <class-ref scheme="cpc">C07K16/00</class-ref>.</paragraph-text><paragraph-text type="body">If the radionuclide is complexed using a chelating group, the classification according to this chelating group is only made in two situations:</paragraph-text><list><list-item><paragraph-text type="body">if the chelating group is an uncommon agent, that is the real contribution of the claimed invention, or</paragraph-text></list-item><list-item><paragraph-text type="body">if it is the carrier per se.</paragraph-text></list-item></list><paragraph-text type="body">If a common chelating group is linked/conjugated to another carrier (e.g. a targeting group, a peptide, or an active agent), classification takes place according to this other carrier, and not according to the common chelating group.</paragraph-text><paragraph-text type="body">Under <class-ref scheme="cpc">A61K51/041</class-ref> the last place priority rule is followed.</paragraph-text><paragraph-text type="body">Porphyrins or texaphyrins used as complex-forming compounds, i.e. wherein the nitrogen atoms forming the central ring system complex the radioactive metal, are classified in <class-ref scheme="cpc">A61K51/0485</class-ref>.</paragraph-text><paragraph-text type="body">Liposomes encapsulating the radioactive probe or having no radiolabelled phospholipids are classified in&#160;<class-ref scheme="cpc">A61K51/1234</class-ref>.</paragraph-text><paragraph-text type="body">Liposomes modified on their external surface by a targeting agent, e.g. an antibody, are not additionally classified with the symbol of the targeting agent.</paragraph-text><paragraph-text type="body">Pretargeting is the administration of an agent X bearing the radioisotope or radioactive nucleus and of an agent Y capable of binding X and a cell Y in several steps, e.g. the radiolabelled agent is a radiolabelled biotin and the agent Y is a (strept)avidin molecule targeting specific cells. Classification is also made according to the nature of the carrier bearing/linked to the radioactive nucleus, e.g. an antibody.</paragraph-text><paragraph-text type="body">In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (organic compound in <class-ref scheme="cpc">A61K51/0497</class-ref>), the nature of this complex-forming compound is not classified except if the complexing/chelating group is the subject of the invention and is uncommon, e.g. 111In-DTPA-glucose is classified in <class-ref scheme="cpc">A61K51/0497</class-ref> (not in <class-ref scheme="cpc">A61K51/048</class-ref>) and in <class-ref scheme="cpc">A61K51/0491</class-ref>.</paragraph-text><paragraph-text type="body">In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (organic macromolecular compound in <class-ref scheme="cpc">A61K51/065</class-ref>), the nature of this complex-forming compound is not classified except if it is the real contribution of the claimed invention and it is an uncommon complexing/chelating group, e.g. 111In-DTPA-PEG is classified in <class-ref scheme="cpc">A61K51/065</class-ref> and new DTPA-like derivatives conjugated to PEG and complexing 111In for use in vivo is classified in <class-ref scheme="cpc">A61K51/0478</class-ref> and <class-ref scheme="cpc">A61K51/065</class-ref>.</paragraph-text><paragraph-text type="body">In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (peptide, protein or polyamino acid in <class-ref scheme="cpc">A61K51/088</class-ref>), the nature of this complex-forming compound is not classified except if it is the real contribution of the claimed invention and it is an uncommon complexing or chelating group, e.g. 111In-DTPA-interleukin 2 is classified in <class-ref scheme="cpc">A61K51/088</class-ref>; new DTPA-like derivatives conjugated to interleukin 2 and complexing 111In for use in vivo is classified in <class-ref scheme="cpc">A61K51/0478</class-ref> and <class-ref scheme="cpc">A61K51/088</class-ref>.</paragraph-text><paragraph-text type="body">In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (antibody in <class-ref scheme="cpc">A61K51/1093</class-ref>), the nature of this complex-forming compound being not classified except if it being the real contribution of the claimed invention and it being an uncommon complexing/chelating group, e.g. 111In-DTPA-herceptin being classified in <class-ref scheme="cpc">A61K51/1093</class-ref> and <class-ref scheme="cpc">A61K51/1051</class-ref>, new DTPA-like derivatives conjugated to herceptin and complexing 111In for use in vivo being classified in <class-ref scheme="cpc">A61K51/0478</class-ref>, <class-ref scheme="cpc">A61K51/1093</class-ref> and <class-ref scheme="cpc">A61K51/1051</class-ref>.</paragraph-text><paragraph-text type="body">If the disclosed compound/composition is used for therapy classification is also given in <class-ref scheme="cpc">A61K2121/00</class-ref>.</paragraph-text><paragraph-text type="body">If the disclosed compound/composition is used for testing in vivo classification is also given in <class-ref scheme="cpc">A61K2123/00</class-ref>.</paragraph-text></section-body></special-rules><synonyms-keywords><section-title>Synonyms and Keywords</section-title><abbreviations>
<paragraph-text type="preamble">In patent documents, the following abbreviations are often used:</paragraph-text>
<table>
<table-row><table-column><paragraph-text type="body">PET</paragraph-text></table-column><table-column><paragraph-text type="body">Positron Emission Tomography</paragraph-text></table-column></table-row>
<table-row><table-column><paragraph-text type="body">SPECT</paragraph-text></table-column><table-column><paragraph-text type="body">Single Photon Emission Computed Tomography</paragraph-text></table-column></table-row></table>
</abbreviations></synonyms-keywords></definition-item>
<definition-item date-revised="2024-08-01"><classification-symbol scheme="cpc">A61K2236/19</classification-symbol><definition-title>involving fermentation using yeast, bacteria or both; enzymatic treatment</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Fermentation or enzyme-using processes in general</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">C12P</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item>
<definition-item date-revised="2024-08-01"><classification-symbol scheme="cpc">A61K2236/331</classification-symbol><definition-title>using water, e.g. cold water, infusion, tea, steam distillation or decoction</definition-title><references><section-title>References</section-title><informative-references><section-title>Informative references</section-title><section-body><paragraph-text type="preamble">Attention is drawn to the following places, which may be of interest for search:</paragraph-text><table>
<table-row><table-column><paragraph-text type="body">Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction</paragraph-text></table-column><table-column><paragraph-text type="body"><class-ref scheme="cpc">A61K2236/37</class-ref></paragraph-text></table-column></table-row></table></section-body></informative-references></references></definition-item></definitions>